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1 SUMMARY 
 
The cellular prion protein termed PrPC is an extracellular GPI-linked protein expressed by 
cells in many organs, including those of the nervous and immune system. It has attracted 
broad scientific interest due to its crucial role in the pathogenesis of prion diseases, 
which are transmissible and fatal neurodegenerative conditions occurring in humans and 
animals. Overwhelming evidence indicates that the infectious prion agent consists solely 
of a misfolded and aggregated isoform of PrPC, as formulated in the protein-only 
hypothesis. One of the main pillars of this hypothesis is that mice lacking PrPC fail to 
succumb to prion diseases. These Prnp-/- mice have been the subject of extensive 
investigations to search for the physiological role of PrPC, which to date remains 
enigmatic. Various subtle phenotypes have been reported in Prnp-/- mice, many of which 
are not reproducible in different laboratories, suggesting the influence of confounding 
genetic elements. Most of these studies with discordant results were conducted using 
knockout animals on a specific genetic background that contained residual ESC-derived 
genetic material surrounding Prnp. These flanking regions may contain polymorphic 
genes that may be responsible for misinterpretation of phenotypes attributed to the 
ablated gene. The goal of the first project described in this thesis was to identify any 
potential confounding genes in Prnp-/- mice and to revisit two immune phenotypes 
attributed to PrPC based on observations in Prnp-/- mice that lacked mechanistic 
explanation: modulation of phagocytosis of apoptotic cells and regulation of 
neuroinflammation. Applying formal genetics with genomic and transcriptomic 
approaches as well as functional studies, we provide evidence that the polymorphic 
immunoregulatory signal regulatory protein alpha (SIRPα), and not PrPC, regulate the 
uptake of apoptotic cells, thus disproving the proposed function of PrPC as an inhibitor of 
phagocytosis. However, the development of the experimentally induced 
neuroinflammation seems to be regulated neither by SIRPα polymorphisms nor by PrPC. 
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Hence, these results conflict with previously published findings that the absence of PrPC 
exacerbates neuroinflammation, and also suggest that other polymorphic genes flanking 
Prnp exert a stronger effect on the EAE disease course than Prnp and/or Sirpa. In 
conclusion, our study not only questions many previously reported phenotypes attributed 
to the prion protein, but also provides an approach to identify possibly confounding 
genes in knockout mice. 
In the second part of my thesis, I describe the experiments that enabled us to prove that 
FDC derive from perivascular PDGFRβ+ precursors. FDC are stromal cells located in 
SLO, where they provide a crucial scaffold for lymphoid follicles and facilitate the 
encounter between immune cells and antigens to generate high-affinity antibodies. In 
chronic inflammatory states such as rheumatoid arthritis and persistent infections, 
ectopic lymphoid structures containing FDC can arise almost anywhere in the body, 
suggesting that radiation-resistant stromal FDC precursors must develop in situ from 
unknown local precursors. Previous work in our lab identified perivascular PDGFRβ+ 
cells as the earliest cells co-expressing the FDC marker Mfge8. We lineage-traced FDC 
and confirmed that mature PDGFRβ- FDC expressed PDGFRβ during their development. 
When isolated from the stromal-vascular fraction of perigonadal fat, pure PDGFRβ+ cells 
fractions respond to FDC maturation factors by expressing FDC differentiation markers 
in vitro. To test their identity as bona fide FDC precursors, we soaked collagen sponges 
with purified stromal-vascular PDGFRβ+ cells and transplanted them under the renal 
capsule of FDC-deficient Ltbr-/- hosts. After four weeks we detected networks of cells 
expressing mature FDC markers and capable of trapping IC and recruiting B cells. 
Because Ltbr-/- animals cannot generate FDC, these experiments demonstrate that 
stromal-vascular PDGFRβ+ cells can give rise to mature and functional FDC. The 
identification of the perivascular origin of FDC explains their ability to arise rapidly in 
almost every region of the body under conditions of continuous inflammatory stimulation 
and may contribute to understanding the pathogenesis of autoimmune and other chronic 
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inflammatory disorders. Also, mature FDC are used as Trojan horses by various 
pathogens, such as HIV, and participate in the accumulation and replication of prions. 
Our findings provide the basis for future experiments to assess whether FDC precursors 
can participate in these destructive processes. 
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2 ZUSAMMENFASSUNG 
 
Das zelluläre Prion Protein, genannt PrPC, ist ein extrazelluläres Protein, welches durch 
einen GPI-Anker mit der Zellmembran verbunden ist. Viele Zellen exprimieren PrPC, 
darunter auch Zellen des Nervensystems und des Immunsystems. Dieses Protein hat 
grosse Aufmerksamkeit der Forschung auf sich gezogen, da es entscheidend an der 
Entstehung von Prionenerkrankungen beteiligt ist. Diese Gruppe von übertragbaren und 
unheilbaren neurodegenerativen Erkrankungen findet sich sowohl beim Menschen als 
auch beim Tier. Gemäss der sogenannten „Prionhypothese“ besteht das infektiöse 
Agens nur aus PrPSc Protein, welches einer falsch gefalteten und aggregierten Isoform 
von PrPC entspricht. Einer der wichtigsten Grundpfeiler dieser Hypothese ist die 
Tatsache, dass genetisch manipulierte Mäuse, welche kein PrPC herstellen, resistent für 
Prionenerkrankungen sind. Diese Prnp-/- Tiere wurden auch in zahlreichen Studien 
untersucht, die sich der Ergründung der physiologischen Funktion des Prion Proteins 
widmeten. Bis heute gibt es jedoch keine mechanistisch geklärte Funktion, die man dem 
Prion Protein zuschreiben kann. Prnp-/- Mäuse weisen verschiedene sehr subtile 
Auffälligkeiten auf, die Hinweise auf die Funktion von PrPC geben könnten. Viele dieser 
Auffälligkeiten konnten jedoch von verschiedenen Forschergruppen nicht bestätigt 
werden, was auf möglicherweise vorhandene genetische Störfaktoren hinweist. Die 
meisten dieser kontroversen Studien wurden mit auf einen bestimmten genetischen 
Hintergrund gekreuzten Knockout-Mäusen durchgeführt, die jedoch residuelles 
genetisches Material rund um den manipulierten Prnp-Locus enthalten, welches von der 
genetisch manipulierten embryonalen Stammzelle stammt. Diese benachbarten 
genetischen Anteile können Gene mit Polymorphismen enthalten, die beim Zuschreiben 
eines beobachteten Phänotyps zum manipulierten Gen zu falschen Interpretationen 
führen können. Das Ziel des Projektes, welches ich im ersten Teil meiner Dissertation 
beschreibe, war einerseits die Identifikation solcher möglicherweise vorhandenen Gene 
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um den Prnp-Locus. Andererseits wollten wir zwei Immunfunktionen reevaluieren, 
welche dem Prion Protein basierend auf Studien in Prnp-/- Mäusen zugeschrieben 
wurden: Modulation der Phagozytose von apoptotischen Zellen und Regulierung der 
Entstehung von Neuroinflammation. Mit Hilfe von genetischen, genomischen und 
transkriptomischen Untersuchungen, sowie mit funktionellen Studien konnten wir zeigen, 
dass das polymorphe immunregulierende Protein SIRPα, und nicht PrPC, die 
Phagozytose von apoptotischen Zellen reguliert. Bei der Untersuchung von 
experimenteller autoimmunen Enzephalomyelitis (EAE) sahen wir jedoch, dass weder 
SIRPα Polymorphismen, noch PrPC deren Entstehung beeinflussten. Diese Resultate 
widersprechen demnach publizierten Studien, in denen Prnp-/- Mäusen einen 
schlimmeren Verlauf der Entzündung aufwiesen, und weisen auch darauf hin, dass 
zusätzliche polymorphe Gene, die Prnp benachbart sind, den EAE Verlauf stärker als 
Prnp und/oder Sirpa beeinflussen könnten. Unsere Studie stellt deshalb nicht nur 
zahlreiche vorgeschlagene Funktionen des Prion Proteins in Frage, sondern kann als 
Beispiel dienen, wie Gene, die dem manipulierten Locus benachbart sind und 
möglicherweise als Störfaktoren fungieren, untersucht werden können. 
Im zweiten Teil meiner Arbeit beschreibe ich die Experimente, mit denen wir zeigen 
konnten, dass follikuläre dendritische Zellen (FDC) von perivaskulären PDGFRβ+  
Vorläuferzellen abstammen. FDC sind stromale Zellen, welche in sekundären 
lymphoiden Organen entscheidend am Aufbau von Lymphfollikeln und an der Interaktion 
zwischen Immunzellen und Antigenen beteiligt sind. Während chronischer 
Entzündungen, wie zum Beispiel der Rheumatoiden Arthritis, oder bei chronischen 
Infektionen, können ektope Entzündungsherde mit FDC fast überall im Körper neu 
entstehen. Dies weist darauf hin, dass die strahlenresistenten und stromalen FDC 
Vorläufer lokal von dort ansässigen, bisher unbekannten Vorläuferzellen abstammen 
müssen. Frühere in unserem Institut durchgeführte Arbeiten haben perivaskuläre 
PDGFRβ+ Zellen mit Hilfe des FDC Markermoleküls Mfge8 als früheste FDC 
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Vorläuferzellen identifiziert. Wir führten weitere Experimente durch, welche zeigen, dass 
reife FDC, bei denen PDGFRβ nicht nachweisbar ist, dieses Molekül während ihrer 
Entwicklung exprimiert haben. Wir isolierten stromal-vaskuläre PDGFRβ+ Zellen aus 
perigonadalem Fettgewebe und sahen, dass diese Zellen in vitro auf Gabe von FDC 
Differenzierungsfaktoren mit der Expression von FDC-Molekülen reagierten. Um zu 
ergründen, ob diese Zellen wirkliche FDC Vorläufer sind, transplantierten wir einen 
Schwamm mit reinen stromal-vaskulären PDGFRβ+ Zellen unter die Nierenkapsel von 
FDC-freien Ltbr-/- Mäusen. Nach vier Wochen fanden wir in diesen Transplantaten 
Zellnetzwerke, die reife FDC Marker aufwiesen und fähig waren Immunkomplexe 
zurückzuhalten und B Zellen zu rekrutieren. Da sich in Ltbr-/- Mäusen keine reifen FDC 
entwickeln können, konnten diese neu entstandenen reifen FDC nur von den 
transplantierten stromal-vaskulären PDGFRβ+ Zellen abstammen. Die Erkenntnis, dass 
FDC von perivaskulären Zellen abstammen, erklärt die rasche und fast ubiquitäre 
Entstehung von FDC unter chronischen Entzündungszuständen. Diese Resultate 
werden hoffentlich dazu beitragen, neue Erkenntnisse über die Pathogenese von 
Autoimmunkrankheiten und anderen chronisch entzündlichen Erkrankungen zu 
erlangen. Auch werden reife FDC von verschiedenen Erregern, wie dem HIV, als 
Versteck, oder von Prionen als Akkumulations-, und Replikationsorte missbraucht. Die 
Identifizierung von FDC Vorläuferzellen wird es ermöglichen die Frage zu beantworten 
ob diese auch schon an solch heimtückischen Prozessen beteiligt sind.  
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3 ABBREVIATIONS 
 
129  129 mouse strain (including substrains, e.g. 129/Sv) 
AA  amino acid 
α-SMA smooth muscle alpha-actin 
B6  C57BL/6 mouse strain 
BEC  blood endothelial cell 
BMDM  bone-marrow derived macrophages 
C  BALB/c mouse strains 
CD  cluster of differentiation 
cDNA  complementary desoxyribonucleic acid 
CFA  complete Freund's adjuvant  
Chr2  chromosome 2 of the laboratory mouse 
CJD  Creutzfeldt–Jakob disease 
CNS  central nervous system 
CR  complement receptor 
CXCL   CXC-chemokine ligand  
DNA    desoxyribonucleic acid 
EAE  experimental autoimmune encephalomyelitis 
ESC  embryonic stem cell 
FDC  follicular dendritic cell 
FGCZ  functional genomic center Zürich 
FRC  fibroblastic reticular cell 
GC  germinal center 
gDNA  genomic DNA 
GPI  glycosyl phosphatidyl inositol 
HEV  high endothelial venule 
IAP  integrin alpha 7 expressing pericyte  
IC  immune complex 
ICAM   intercellular adhesion molecule  
Ig  immunoglobulin 
i.p.  intraperitoneal 
HE  hematoxylin and eosin 
LEC  lymphatic endothelial cell 
LN  lymph node 
LT  lymphotoxin 
LTβR  lymphotoxin β receptor 
LTi  lymphoid tissue inducer cell  
LTo  lymphoid tissue organizer cell 
Madcam mucosal vascular addressin cell adhesion molecule  
MALT  mucosa-associated lymphoid tissue 
Mertk  gene encoding c-mer proto-oncogene tyrosine kinase MER 
Mfge8  milk fat globule-EGF factor 8 protein 
MGG  May-Grünwald-Giemsa 
MRC  marginal reticular cell 
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MS  multiple sclerosis 
M:T  macrophage : thymocytes (ratio) 
NGS  next generation sequencing 
ORF  open reading frame 
PAP  peroxidase-anti-peroxidase 
PCR  polymerase chain reaction 
PDGFRβ platelet-derived growth factor receptor beta 
PE  phycoerythrin  
p.i.  post immunization 
pMΦ  peritoneal macrophages 
Prnp  gene encoding the prion protein 
PrP  prion protein 
PrPC  normal cellular isoform of the prion protein 
PrPSc   pathological misfolded (scrapie) isoform of the prion protein 
qPCR  quantitative PCR 
RFLP  restriction fragment length polymorphism 
ROI  region of interest 
RNA  ribonucleic acid 
RNAi  RNA interference 
RNA-Seq RNA sequencing 
RT-PCR reverse transcription PCR 
s.c.  subcutaneous 
SD  standard deviation 
SEM  standard error of the mean 
Sirpa  gene encoding signal regulatory protein alpha 
SIRPα  signal regulatory protein alpha 
SLO  secondary lymphoid organs 
SNP  single nucleotide polymorphism 
SPF  specific pathogen free 
sRBC  sheep red blood cells 
STR  short tandem repeat 
TBM  tingible body macrophage 
Thbs1  gene encoding thrombospondin 1 protein 
TLO  tertiary lymphoid organs 
TNF  tumor necrosis factor 
TNFR  tumor necrosis factor receptor 
TSE  transmissible spongiform encephalopathies 
TSP-1  thrombospondin 1 protein 
Tyro3  gene encoding tyrosine-protein kinase receptor 3 
VCAM  vascular cell adhesion molecule 
vSMC  vascular smooth muscle cell 
WAT  white adipose tissue   
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4 THE ROLE OF THE PRION PROTEIN IN THE IMMUNE SYSTEM 
 
Parts of this chapter of my thesis are reproduced or adapted from the following 
manuscript in preparation: 
 
The SIRPα receptor, but not the prion protein, controls phagocytosis of 
apoptotic cells 
 
Mario Nuvolone1,2+, Veronika Kana1,+, Gregor Hutter1,+, Daiji Sakata1, Steven M. Mortin-
Toth3, Giancarlo Russo4, Jayne S. Danska3,# and Adriano Aguzzi1, # 
 
1 Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland 
2 Amyloidosis Research and Treatment Centre, Foundation IRCCS San Matteo Hospital and 
Department of Molecular Medicine, University of Pavia, Institute for Advanced Studies, Pavia 
3 Hospital for Sick Children, Programme in Genetics and Genome Biology, University of Toronto, 
Faculty of Medicine, Departments of Immunology and Medical Biophysics MaRS East Tower 14-
313, 101 College Street, Toronto, ON, Canada M5G 1L7 
4 Functional Genomic Center Zurich, University of Zurich, Zurich, Switzerland 
+ Equal contribution 
 
# Correspondence:  
Adriano Aguzzi, Institute of Neuropathology, University Hospital of Zurich, Schmelzbergstrasse 
12, CH-8091 Zurich, Switzerland, Phone: +41 (44) 255-2107, Fax: +41 (44) 255-4402, email: 
adriano.aguzzi@usz.ch 
 
Jayne S. Danska, Hospital for Sick Children, Programme in Genetics and Genome Biology, 
MaRS East Tower 14-313, 101 College Street, Toronto, ON, Canada M5G 1L7, Phone: +1 416 
813 8810, Fax: +1 416 813 8823, email: jayne.danska@sickkids.ca 
 
 
 
 
Parts of the introduction of this chapter of my thesis are reproduced or adapted with the 
permission from John Wiley and Sons, Rightslink license number: 3127170502680, from 
the following book chapter: 
 
Aguzzi, A. and Kana, V. (2011) Introduction to Prion Disorders, in Neurodegeneration: The 
Molecular Pathology of Dementia and Movement Disorders, Second Edition (eds D. W. Dickson 
and R. O. Weller), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444341256.ch31 
  
12 |  
 
 
 
4.1 INTRODUCTION 
 
4.1.1 Prion diseases – the inglorious reason for the prion protein’s fame 
 
Prion diseases, also called TSE, are deadly neurodegenerative diseases occurring in 
humans and animals (Aguzzi and Calella, 2009). A defining trait of TSE is their infectious 
nature. The infectious agent causing TSE, the prion, consists solely of ordered 
aggregates of PrPSc, the abnormally folded, protease-resistant, beta-sheet rich isoform of 
the normal PrPC, the main statement of the “protein-only”-hypothesis (Fig. 1) (Aguzzi and 
Polymenidou, 2004). The provocative concept, that protein alone, without genetic 
material, could act as an infectious agent was proposed by Griffith (Griffith, 1967), who 
found that the unknown infectious material in brains from Scrapie-affected sheep was 
resistant to ultraviolet irradiation, high temperatures and various aggressive chemicals, 
hence devoid of nucleic acids. Later, Prusiner purified and characterized PrPSc (Bolton et 
al., 1982), and called this infectious protein “prion”, a portmanteau word fusing 
Proteinaceous Infectious particle with virion. More specifically, he defined prion as “a 
small proteinaceous infectious particle that is resistant to inactivation by most procedures 
that modify nucleic acids” (Prusiner, 1982). Since then, the “protein-only”-hypothesis was 
endorsed by many findings, among them the crucial identification of the Prnp gene, 
which encodes PrPSc and also the normal cellular prion protein PrPC (Chesebro et al., 
1985; Oesch et al., 1985), followed by the generation of Prnp knockout mice lacking 
PrPC (Büeler et al., 1992). The striking resistance of these mice to prion infectivity 
provided strong evidence for the protein-only hypothesis (Büeler et al., 1993). The 
generation of de novo infectivity from defined compounds would ultimately prove that 
PrPSc is the sole infectious agent (Colby and Prusiner, 2011). Yet, prions produced by 
genetically engineered bacteria and converted into aggregates that contained 
recombinant PrPC alone, yielded only low infectivity (Kim et al., 2010; Legname et al., 
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2004; Makarava et al., 2010). Interestingly, by adding “cofactors” such as lipids or RNA, 
the de-novo generated prions reached equal infectivity similar to brain homogenates 
from terminally ill prion infected mice (Deleault et al., 2007; Supattapone, 2010; Wang et 
al., 2010). The role of these cofactors is not well defined. While the association of these 
cofactors with misfolded PrPSc is a possible explanation for the prion strain phenomenon 
(Aguzzi et al., 2007; Li et al., 2010), their precise role in the promotion of prion replication 
and generation of infectivity is unclear (Colby and Prusiner, 2011).  
 
Figure 1. Characteristics 
of prion diseases. (a) 
Schematic representation of 
normal (PrPC) and disease-
associated (PrPSc) isoforms 
of the prion protein, which 
have identical amino-acid 
sequences, but differ in 
their secondary structure. 
The high amount of beta-
sheets in PrPSc increases 
its propensity to form higher 
ordered aggregates and 
elongate into fibrils 
(Goldschmidt et al., 2010). 
(b) PrPSc aggregates are 
partially resistant to proteinase K (PK) digestion as shown in a PrPC-immunoblot of brain 
homogenates from prion-infected (left) and uninfected (right) mice. (c) Formation of large 
vacuoles in the cerebral cortex of a patient affected by sCJD. This observed “status spongiosus” 
is a pathological hallmark of TSE, along with extensive neuronal cell loss and astrogliosis. (d) 
Another cardinal feature of prion diseases is the widespread deposition of amyloid plaques or 
amorphous PrP aggregates (Glatzel et al., 2005). The cortex of a sCJD patient stained with PrP-
specific antibodies shows accumulation of insoluble PrPSc deposits. Panel (a) reused and adapted 
from (Wilson and Nixon, 2009), and panels (b-d) reused and adapted from (Aguzzi and O'Connor, 
2010), with the permission of Nature Publishing Group, Rightslink license numbers: 
3127540974267 and 3127541294550.  
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In humans, prion diseases present with rapidly progressive dementia, akinetic mutism, 
myoclonus, ataxia, visual and cerebellar impairments. Based on clinical, 
neuropathological and genetic findings, human prion diseases are classified as sporadic, 
inherited, or infectious (Glatzel et al., 2005). In most cases, patients are affected with the 
sporadic form of CJD (sCJD), whose cause is unknown. Less than 10% of reported 
human prion cases are familial forms such as familial CJD, Gerstmann–Sträussler–
Scheinker syndrome or fatal familial insomnia, where mutations in the human PRNP 
gene have been identified as the causative primary pathogenic event (Glatzel et al., 
2005; Hsiao and Prusiner, 1990). Yet the best-known, most threatening forms of prion 
diseases are those caused by transmission between individuals due to iatrogenic 
infection (Brown et al., 2012), or even from animals to humans, as seen in the bovine 
spongiform encephalopathy (BSE) crisis in the late 20th century, where the ingestion of 
contaminated animal products is believed to have led the outbreak of variant CJD 
(Ironside, 2012).  
How do peripherally acquired prions reach the CNS? The immune system has been 
shown to be the major player in this process called neuroinvasion, since the peripheral 
immune system is indispensable for extraneural prion replication and subsequent spread 
of the infectious agent to the CNS (Fig. 2) (Aguzzi and Heikenwalder, 2006). 
Experiments in mice lacking various components of the immune system have pointed to 
the crucial role of FDC in the process of prion accumulation and replication. FDC depend 
on signaling through LTβR, thus interfering with this pathway at various levels inhibits 
peripheral prion replication (Klein et al., 1997; Mabbott et al., 2000; Montrasio et al., 
2000; Prinz et al., 2003; Prinz et al., 2002). However, ectopic inflammatory foci without 
mature FDC and mice, whose FDC differentiation is stopped at a premature level, still 
show prion replication competence, suggesting that stromal cells other than mature FDC, 
possibly FDC precursors, can participate in prion propagation (Heikenwalder et al., 2008; 
Krautler et al., 2012; Oldstone et al., 2002; Prinz et al., 2002). Accordingly, generic 
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stimulation of the immune system and induction of chronic inflammatory conditions, 
which favor the generation of tertiary lymphoid organs (TLO), enhance the susceptibility 
to prion infection and lead to an increased peripheral prion deposition – even in organs 
previously deemed prion free – and accelerate the disease process (Bremer et al., 2009; 
Heikenwalder et al., 2005; Klein et al., 2001; Ligios et al., 2005; Seeger et al., 2005). 
Since replication-competent cells of the secondary lymphoid organs have been shown to 
be in direct contact with dendrites from peripheral neurons, the spread via axons of 
peripheral nerves might explain how prions finally find their way into the CNS (Glatzel et 
al., 2001; Heikenwalder et al., 2007).  
 
Figure 2. Propagation of prions 
in the organism. Orally acquired 
prions are taken up by M cells in 
the intestine (Donaldson et al., 
2012) and reach SLO either 
directly or via blood and lymphoid 
fluids. After peripheral replication 
in SLO, prions are transported to 
the brain primarily by peripheral 
nerves. Apart from SLO, prions 
can be detected in other 
extraneural tissues, such as 
skeletal muscle (Glatzel et al., 
2003). Figure reprinted from (Aguzzi and Heikenwalder, 2006) with permission from Nature 
Publishing Group; Rightslink license number: 3127721289952. 
 
The role of the immune system in CNS prion propagation is less clear. Mice whose 
peripheral immune system was genetically or pharmacologically modulated show equal 
susceptibility to prion diseases after intracerebral inoculation. On the other hand, prion 
diseases lead to a dramatic activation of CNS-resident microglia, which can phagocytose 
PrPSc in vitro, and – less efficiently – in vivo (Aguzzi et al., 2013). Moreover, experiments 
with organotypic tissue slice cultures show that the removal of microglia leads to a 15-
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fold increase of prion titers, suggesting that microglia play an important role in the 
clearance of PrPSc (Falsig and Aguzzi, 2008; Heppner et al., 2005), even though they 
eventually lose the battle against the rapidly replicating infectious agent.  
 
4.1.2 A function for PrPC in the immune system 
 
The cellular isoform of the prion protein, PrPC, is a GPI-anchored extracellular protein 
containing two N-terminal glycosylation sites and is associated to lipid rafts (Taylor and 
Hooper, 2006). NMR studies of mouse prion protein (Hornemann et al., 1997; Riek et al., 
1996; Riek et al., 1997) have revealed a long, flexible, unstructured amino-terminal part 
(AA 23–120) with several octapeptide repeats (termed OR) and two charged clusters 
(CC1: AA 23-37; CC2: AA 95-110) and a structured carboxy-terminal globular domain (AA 
121-231) containing three α-helices, and two β-sheets. The carboxy-terminal globular 
domain and the amino-terminal flexible part are connected by a hydrophobic part (AA 
111-134, termed hydrophobic core (HC)). The prion protein is highly conserved across 
species, suggesting a broad and important function (Aguzzi et al., 2008). This notion is 
strengthened by its virtually ubiquitous expression: PrPC is not only highly expressed in 
the developing and adult CNS, but is also found in the peripheral nervous system, 
kidney, heart, skeletal muscle, in various hematopoietic cells (monocytes, dendritic cells, 
megakaryocytes, lymphocytes, hematopoietic progenitors), pericytes, and in secondary 
lymphoid organs, particularly in FDC (Aguzzi and Heikenwalder, 2006; Ford et al., 2002; 
Linden et al., 2008).  
The dramatic phenotype of prion diseases, the threatening BSE crisis and the 
fascinating, yet highly controversial protein-only hypothesis has led to an enormous 
scientific interest in prion biology and the normal function of the cellular prion protein. 
Although among the most studied proteins, the function of PrPC has not been explained 
at a mechanistic level to date (Aguzzi et al., 2008). Most searches for the physiological 
                                                                                                                                                    17 | 
 
 
 
role of PrPC are based on experiments in Prnp knockout mice. These mice have a clear 
and irrefutable phenotype characterized by resistance to the infectivity of the prion agent 
(Büeler et al., 1993; Büeler et al., 1992). In addition, studies in Prnp knockout mice have 
revealed numerous subtle phenotypes, which affect a large variety of physiological 
functions of an organism. These include neuronal signal transduction, various 
behavioral, metabolic and immunological functions, myelin maintenance, copper binding, 
amyloid capture, and both pro- and anti-apoptotic functions (Aguzzi et al., 2008; Biasini 
et al., 2012; Bremer et al., 2010; Calella et al., 2010; Laurén et al., 2009; Linden et al., 
2008; Steele et al., 2007). Some of these proposed functions have been confirmed, but 
equally many have been refuted by subsequent studies from other laboratories, 
questioning their validity. In the following paragraphs, I will introduce two functions, which 
were attributed to PrPC: and include the inhibition of phagocytosis and modulation of 
neuroinflammation. 
 
PrPC as an inhibitor of phagocytosis of apoptotic cells 
Phagocytosis of apoptotic cells is a basic process of the organism crucial for 
development, tissue homeostasis, innate and adaptive immunity. Defects in its function 
or regulation can lead to autoimmunity, developmental defects, organ dysfunction and 
cancer (Gregory and Devitt, 2004; Lemke and Rothlin, 2008; Ravichandran and Lorenz, 
2007). Removal of apoptotic cells is carried out by special, so-called “professional” 
mononuclear phagocytes, which are dendritic cells, and include circulating monocytes in 
the blood and tissue-resident macrophages (Kindt et al., 2007). But also “non-
professional” phagocytes, such as retinal pigment epithelial cells, kidney mesangial cells, 
or Sertoli cells in the testis, take up dying cells and their debris, and thereby contribute to 
the function of their resident organ (Gregory and Devitt, 2004). In contrast to the 
phagocytic uptake of pathogens, where pathogens recognition patterns lead to the direct 
recognition of the target and opsonization activates Fc receptor-mediated uptake (Poon 
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et al., 2010), the removal of apoptotic cells involves a multistep signal exchange between 
the dying cell and the phagocyte. After having sent out “find-me” signals, which help the 
phagocyte to sense the dying cell, the engulfment process itself is initiated by “eat-me” 
signals, which are displayed by the dying cell and recognized by various engulfment 
receptors on the phagocyte (Fig. 3) (Lauber et al., 2012; Nagata et al., 2010). The 
process of apoptosis involves also the downregulation of “don’t-eat-me” signals, which 
are expressed on cells to avoid phagocytosis and thereby regulate and balance the 
phagocytic uptake of cognate cells (Fig. 3) (Lauber et al., 2012). One of the best-
described molecule pairs mediating a “don’t eat me” signal are the ubiquitously 
expressed CD47 and SIRPα found on the phagocyte. The ligation of CD47 on the target 
cell and SIRPα on the phagocyte negatively regulates the phagocytic process and hence 
the CD47 expressing cell evades engulfment (Matozaki et al., 2009). Accordingly, cells 
from CD47 deficient mice are rapidly cleared from wild type phagocytes (Oldenborg et 
al., 2000).  
 
Figure 3. Phagocytosis of apoptotic cells: 
examples of "eat-me" and “don’t-eat-me” signals”. 
Apoptotic cells downregulate “don’t-eat-me” signals, 
such as CD31 and CD47, hence the inhibitory signal of 
CD31 and SIRPα on phagocytes is abolished. The 
exposure of PS, normally found inside the plasma 
membrane, is the major “eat-me” signal. PS alone or in 
combination with attached molecules (e.g. Gas6, 
Mfge8) is recognized by engulfment receptors on the 
phagocyte (Ravichandran and Lorenz, 2007). Other eat 
me signals bind complement or TSP1, and mediate binding to SR, CR and integrins. BAI-1, brain 
angiogenesis inhibitor 1; PS, phosphatidylserine; TIM, T cell Ig and mucin; SR, scavenger 
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receptor. Figure adapted from (Lauber et al., 2012), © 2012 Lauber, Ernst, Orth, Herrmann and 
Belka, Creative Commons Attribution License. 
 
PrPC was reported to be an additional phagocyte receptor that would sense and mediate 
“don’t-eat-me” signals, and hence act as an inhibitor of phagocytosis (de Almeida and 
Linden, 2005). Peritoneal macrophages and retinal Müller glial cells from Prnp-/- mice 
were shown to be more active in engulfing apoptotic cells than phagocytes expressing 
wildtype PrPC (de Almeida et al., 2005). The molecular mechanisms by which PrPC could 
act as inhibitor of phagocytosis are unclear. It was proposed that the GPI-anchored PrPC 
might influence the ligand-binding of other engulfment receptors or regulate their 
relocation to lipid rafts (de Almeida et al., 2005; de Almeida and Linden, 2005; Peyron et 
al., 2000). 
 
PrPC as a modulator of neuroinflammation 
While expression of PrPC in mature quiescent T cells was shown to be low (Liu et al., 
2001), T cell activation leads to PrPC upregulation (Cashman et al., 1990; Isaacs et al., 
2006). In addition, PrPC was found to be part of the immunological synapse (Ballerini et 
al., 2006; Paar et al., 2007) and to co-precipitate with the TCR (Mattei et al., 2004), 
suggesting that PrPC might actively modulate T cell activation and function.  
This hypothesis can be tested in an in vivo model of CD4+ T cell-mediated autoimmune 
disease, EAE, which is widely used to study neuroinflammation and has led to the 
elucidation of important aspects of MS pathogenesis (Baxter, 2007; Schreiner et al., 
2009). EAE is characterized by perivascular inflammation, primary demyelination and 
subsequent axonal damage leading to ascending paralysis. These events are induced by 
peripheral immunization with CNS tissue or an emulsion of myelin peptide, such as 
myelin basic protein or proteolipid protein in complete Freud’s adjuvants, together with 
pertussis toxin (Miller et al., 2010). This leads to the peripheral priming of myelin-specific 
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CD4+ T cells, which transmigrate through the choroid plexus and enter the subarachnoid 
space, where they are re-stimulated by local antigen-presenting cells to finally enter the 
brain parenchyma (Greter et al., 2005). Activated T cells produce chemokines and 
cytokines, which activate local microglia, further, disrupt the blood-brain barrier and 
induce a massive influx of effector T cells and monocytes (Ajami et al., 2011; Ransohoff 
and Engelhardt, 2012). The demyelination of axonal tracts is a result of inflammatory and 
cytotoxic effector molecules released by activated T and mononuclear cells, and the 
subsequent phagocytosis by activated microglia and monocytes (Miller et al., 2010). 
Several groups have studied the effect of removal of the Prnp gene (henceforth termed 
Prnp-/-) on the development of mouse EAE (Table 1). In the first study, the authors 
Tsuitsui et al reported that the lack of PrPC led to an earlier onset and a more severe 
EAE disease course during the chronic phase (Tsutsui et al., 2008). This was 
accompanied by increased infiltration of inflammatory cells and higher activity of myelin-
primed T cells, suggesting a T-cell dependent attenuation of neuroinflammation (Tsutsui 
et al., 2008). A subsequent study reported a slight exacerbation of EAE during the onset 
of disease with increased T cell infiltrates in the brain, yet lower amounts of IL-17 
responses, again suggesting an involvement of PrPC in T cell activation (Ingram et al., 
2009). In another study, Prnp-/- mice and mice treated with small interfering RNA (siRNA) 
blocking Prnp developed a more severe EAE and a higher antigen-specific T cell 
activation (Hu et al., 2010). In addition, PrPC-overexpressing tga20 mice (Fischer et al., 
1996) showed only mild EAE symptoms, suggesting a PrPC-dependent rescue of EAE 
exacerbation (Hu et al., 2010). In contrast, PrPC-overexpressing tga35 mice (Fischer et 
al., 1996) showed a similar exacerbation as Prnp-/- mice, both in the development of EAE 
and optic neuritis, yet PrPC-overexpression had a neuroprotective effect on retinal 
ganglion cells in tga35 mice as compared to Prnp-/- and the respective wild type mice 
(Williams et al., 2011). The authors of this study point to the reported insertional artifact 
reported in tga20 mice, which perturbs T cell development (Zabel et al., 2008), and might 
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explain less sever  EAE in tga20 versus tga35 mice. However, they do not comment on 
the exacerbation of EAE in presence of 4-5 times more PrPC, which was comparable to 
the disease seen in Prnp-/- animals. Finally, a recent report again confirmed the 
exacerbation of EAE in mice lacking Prnp, but reciprocal bone-marrow reconstitution 
experiments demonstrated that the effect was caused by the lack of PrPC function in the 
central nervous system, rather than the result of altered T cell function in Prnp-/- mice 
(Gourdain et al., 2012). Taken together, these studies consistently report a worsening of 
the EAE development in the absence of PrPC – with considerable variation in the onset 
and severity of the effect. This might be the result of different immunization protocols, the 
heterogeneity of the mouse strains, or reflect the intrinsic variability of the EAE model 
(Gold et al., 2006; Gourdain et al., 2012). Yet the studies in PrPC-overexpressing mouse 
strains yielded conflicting results and there are unresolved discrepancies concerning the 
underlying mechanisms of the observed phenotype. 
 
Prnp-/- strain Prnp+/+ strain Prnp-/- phenotype Rescue/other 
experiments 
Reference 
FVB129-PrnpZrchI/ZrchI 
littermates (F1) 
 
B6129-PrnpZrchI/ZrchI 
backcrossed for 7-8 
generations 
FVB129-Prnp+/+ 
littermates (F1)  
 
C57BL/6 wild 
type 
Exacerbation of 
EAE, at onset and 
during chronic 
phase 
T-cell mediated (Tsutsui et 
al., 2008) 
FVB/N.129-
PrnpZrchI/ZrchI 
backcrossed for 10 
generations 
FVB/N wild type Exacerbation of 
EAE, at onset 
T-cell mediated (Ingram et 
al., 2009) 
Sv129/Ola-PrnpEdbg/Edbg  
 
Sv129/Ola-
Prnpwt/wt  
Exacerbation of 
EAE, at onset 
-Prnp-siRNA 
-tga20: EAE 
suppression 
-T cell mediated 
(Hu et al., 
2010) 
B6129-PrnpZrchI/ZrchI C57BL/6 wild 
type 
Exacerbation of 
EAE, optic neuritis 
tga35: EAE 
exacerbation 
(Williams 
et al., 
2011) 
B6.129-PrnpZrchI/ZrchI 
backcrossed for > 12 
generations 
C57BL/6 wild 
type 
Exacerbation of 
EAE, during 
chronic phase 
-non T-cell 
mediated 
-dependent on 
PrPC in CNS 
(Gourdain 
et al., 
2012) 
 
Table 1. Studies investigating the role of PrPC in EAE development.  
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4.1.3 The Prnp knockout mouse and the flanking gene problem  
 
Since the generation of the first Zürich I-Prnp-/- line (PrnpZrchI/ZrchI) (Büeler et al., 1992), a 
remarkable number of other laboratories have engineered independent Prnp-/- mouse 
strains using homologous recombination. Similarly to the Zürich I line, the genetic 
modification in Edinburgh-Prnp-/- (PrnpEdbg/Edbg) (Manson et al., 1994) is restricted to the 
open reading frame of exon 3 in the mouse Prnp gene. These two mouse lines showed 
normal development and no severe pathologies in adulthood. Yet they have been 
fundamental in supporting the protein-only hypothesis, since these mice were resistant to 
prion infection (Büeler et al., 1993; Weissmann and Flechsig, 2003). In contrast to the 
normal development of these two lines, the subsequently generated Nagasaki-Prnp-/- line 
(PrnpNgsk/Ngsk) (Sakaguchi et al., 1995), as well as the Rcm0-Prnp-/- line (PrnpRcm0/Rcm0) 
(Moore et al., 1995), and the Zürich II-Prnp-/- line (PrnpZrchII/ZrchII) (Rossi et al., 2001) 
developed severe neurological abnormalities with ataxia and Purkinje cell loss (Fig. 4).  
 
Figure 4. Mouse lines with disrupted Prnp 
locus. Different strategies used to knock out 
Prnp. Dotted line: segment of deleted Prnp 
DNA. Yellow, inserted sequence; red, open 
reading frame; blue, noncoding region; neo, 
neomycin phosphotransferase; HPRT, 
hypoxanthine phosphoribosyltransferase; lox, a 
34-bp recombination site from phage P1. Figure 
adapted from (Weissmann and Aguzzi, 1999) 
with the permission of Science. 
 
 
Since the reintroduction of a Prnp transgene reversed the, this effect was originally 
thought to relate to Prnp deletion (Nishida et al., 1999). However, the lack of phenotype 
observed in the Zürich I and Edinburgh lines did not support this hypothesis. These 
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divergent results could only be resolved when a new gene, Prnd, located 16 kb 
downstream of Prnp and coding for the Doppel (Dpl) protein, was discovered. A careful 
examination of the Prnp deletion strategies revealed that the deletion in Nagasaki, 
Rcm0, and Zürich II-lines involved also a splice acceptor site for Prnp exon 3. As a 
result, Prnd was expressed under the control of the Prnp promoter, which led to the 
formation of chimeric RNA and a Dpl-overexpression in the brain, causing ataxia and 
Purkinje cell loss (Moore et al., 1999; Weissmann and Aguzzi, 1999). 
All available Prnp-/- lines were generated using ESC derived from the inbred 129 strain of 
the laboratory mouse (Silver, 2008; Wade and Daly, 2005). The Edinburgh-Prnp-/- and 
the Rcm0 lines represent the only lines that were generated and maintained on the same 
genetic background, thus representing coisogenic mouse strains (Fig. 5; Manson et al., 
1994; personal communication D. Melton). Coisogenic knockout and wild type animals 
are genetically identical, with the exception of the targeted locus, which in this example is 
Prnp.  Furthermore, they represent the most clean genetic experimental setting when 
searching for a knockout phenotype (Silver, 2008).  
 
 
Figure 5. Main steps in the generation of coisogenic and B6.129 congenic mouse strains. 
129-derived ESC carrying the targeted mutation are injected into blastocysts from variable strains 
(most frequently B6, C, FVB), which are injected in pseudopregnant females (not shown). To 
generate a coisogenic strain (right), chimeric mice are bred with mating partners form the same 
strain as the ESC, thereby creating coisogenic 129-knockout mice, which differ only in the 
targeted locus from their wild type counterparts. To generate a congenic mouse strain (left), the 
chimeric mice are bred with mating partners from another strain, here B6. Backcrossing to B6 for 
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at least 10 generations creates a congenic B6.129 knockout strain. In B6.129 congenic mice, 
residual 129 genomic material derived from the ESC (in brown) is present, particularly in the 
region flanking the targeted locus.  
 
However, the 129 mouse strain has certain disadvantages, such as poor breeding 
performance, and behavioral and immunological abnormalities, and therefore researches 
traditionally preferred to backcross the knockout lines to more robust strains, such as the 
B6 strain (Fig. 5) (Seong et al., 2004). Hence, in all other Prnp-/- lines, the chimeric 
Prnpwt/- mice were crossed with wild type mice of a strain other than 129, most frequently 
the B6 strain. The resulting mice carrying the targeted allele were then maintained either 
on a mixed background (mainly B6 and 129, B6.129) or repeatedly backcrossed for a 
minimum of 10 generation to a specific inbred strain to create a so-called congenic strain 
(Fig. 5) (Silver, 2008). Every backcrossing event progressively reduces the 129-derived 
genetic material. However, despite extensive backcrossing to a non-129 strain, a 
significant fragment of 129-derived genomic material will cosegregate with the Prnp 
locus (Sparkes et al., 1986), due to the low probability of recombination between closely 
linked genes. Thus, any polymorphism located within these flanking fragments will 
contaminate all congenic Prnp-/- strains. As a result of this, in most of the studies 
comparing Prnpwt/wt and Prnp-/- mice, the two experimental groups differed not only at the 
targeted locus, Prnp, but also for an undetermined number of polymorphic loci between 
the 129 and the non-129 strain used for backcrossing. 
This phenomenon, which is commonly observed in knock out animal studies, is referred 
to as the “flanking gene problem” (Eisener-Dorman et al., 2009; Gerlai, 1996; Smithies 
and Maeda, 1995). It creates a fundamental confounder when attributing specific 
functions to a gene based on observations made in knockout animals. This observation 
also holds true for the functions reported for PrPC, since most of the subtle phenotypes 
reported in Prnp-/- mice were studied in congenic animals (Steele et al., 2007). In order to 
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validate subtle phenotypes as seen in Prnp-/- mice, it becomes crucial to exclude the 
contribution of linked polymorphic genes cosegregating with Prnp. 
 
4.1.4 Scientific aims 
 
Prnp-/- mice are resistant to prion diseases (Büeler et al., 1993; Büeler et al., 1992) and 
show many subtle phenotypes, which however have not been reproduced in different 
laboratories (Steele et al., 2007), suggesting the presence of interfering genetic 
confounders. All currently available Prnp-/- mice have been generated using 129-derived 
ESC, and with two exceptions, were kept in a mixed background, or backcrossed for > 
10 generations, thereby creating congenic mice (Crusio et al., 2009). Whilst this 
approach progressively reduces the content of the 129-derived genomic material, 129-
derived regions flanking Prnp co-segregate with it and persist. These regions may 
contain many polymorphic genes, which may confound the attribution of phenotypes to 
PrPC based on studies in Prnp-/- mice (Steele et al., 2007; Wolfer et al., 2002).  
We have selected two phenotypes, which were previously reported in Prnp-/- mice and 
lack mechanistic explanation - first, a simple, cell-autonomous function, modulation of 
phagocytosis (de Almeida et al., 2005), and second, a complex phenotype involving the 
interplay of many different immune cells, the regulation of EAE development (Gourdain 
et al., 2012; Ingram et al., 2009; Tsutsui et al., 2008). 
Here I will describe the genetic, genomic and transcriptomic approaches we used to 
validate the influence of Prnp and its linked genes on phagocytosis of apoptotic cells and 
EAE development. 
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4.2 RESULTS 
 
4.2.1 Higher phagocytic activity in congenic – but not in coisogenic – Prnp 
knockout mice  
 
To determine the potential contribution of PrPC in regulating phagocytosis of apoptotic 
cells, we compared the phagocytic activity of primary macrophages isolated from 
Prnpwt/wt and three independent strains of Prnp-/- mice. As assessed by a microscopy-
based in vitro phagocytosis assay (Fig. 6a), pMΦ from congenic B6.129-PrnpZrchI/ZrchI 
mice (Büeler et al., 1992) phagocytosed more apoptotic thymocytes than macrophages 
from heterozygous B6.129-Prnpwt/ZrchI and wildtype congenic B6.129-Prnpwt/wI littermates 
(Fig. 5, Fig. 6b, Fig. 7), in agreement with the previously reported hyperphagocytic 
phenotype of B6.129-PrnpZrchI/ZrchI mice (de Almeida et al., 2005). We observed the same 
hyperphagocytosis also seen in BMDM of B6.129-PrnpZrchI/ZrchI mice, as well as in BMDM 
of another Prnp-/- mouse strain, the congenic B6.129-PrnpNgsk/Ngsk mice (Sakaguchi et al., 
1995) (Fig. 8). However, when assessing the phagocytosis activity of pMΦ isolated from 
coisogenic 129-PrnpEdbg/Edbg mice (Manson et al., 1994), we could not detect any 
significant difference compared to 129-Prnpwt/wt littermate pMΦ (Fig. 9). 129-PrnpEdbg/Edbg 
mice were generated from 129 ESC and kept as a strictly coisogenic line (Fig. 5). 
Therefore, coisogenic 129-PrnpEdbg/Edbg and 129-Prnpwt/wt are thought to differ only in their 
Prnp status, and are considered free of potentially confounding polymorphic flanking 
genes. Thus, the lack of increased phagocytic activity in 129-PrnpEdbg/Edbg macrophages 
indicated that ablation of Prnp was insufficient to drive hyperphagocytosis, and 
suggested the presence and influence of additional non-identical genetic elements in the 
congenic Zrchl-, and Ngsk-lines. 
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Figure 6. Microscopy-based phagocytosis assay. (a) Workflow for assessing phagocytic 
activity of pMΦ using microscopy and software-based image analysis. After interaction of cultured 
pMΦ with apoptotic thymocytes, the wall of the one-well chamber slide was removed and the slide 
was stained with MGG. 50 randomly selected fields were scanned using an automated slide-
scanning device. The obtained images were then analyzed by software developed by Monika 
Bieri and Norbert Wey for an automated detection and classification of cells. The software was 
trained to recognize macrophages according to their shape and size using a classification 
algorithm. An additional algorithm is applied to classify the detected cells into macrophages 
having engulfed thymycytes (yellow border) and macrophages not having engulfed thymocytes 
(red border). The analyzed images are then sent to a blinded operator, who validates at least 800 
cells. (b) Representative light microscopy images of B6.129-PrnpZrchI/ZrchI , B6.129-Prnpwt/ZrchI  and 
B6.129-Prnpwt/wt pMΦ. Yellow arrows indicate pMΦ having engulfed apoptotic thymocytes. 
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Figure 7. Phagocytic activity of pMΦ from 
congenic B6.129-PrnpZrchI/ZrchI, B6.129-Prnpwt/ZrchI 
and B6.129-Prnpwt/wt mice. pMΦ from congenic 
B6.129-PrnpZrchI/ZrchI mice showed higher 
phagocytic activity that those of B6.129-Prnpwt/ZrchI 
and B6.129-Prnpwt/wt mice. Two independent 
experiments (shown as blue and black dots) were 
performed; mean phagocytic activities of B6.129-
Prnpwt/wt (44.4% and 33.0% respectively) were set 
as 100%. 
 
 
 
 
Figure 8. Phagocytic activity of BMDM from congenic B6.129-PrnpZrchI/ZrchI , congenic 
B6.129-PrnpNgsk/Ngsk and B6-Prnpwt/wt mice. (a) Flow cytometry gating strategy for assessing 
phagocytic activity of BMDM. Gating of live nucleated cells (left panel) and quantification of 
CD11b+ pHrodo+ cells (macrophages having engulfed pHrodo-labelled apoptotic thymocytes, 
right panel). (b) BMDM from congenic B6.129-PrnpZrchI/ZrchI and congenic B6.129-PrnpNgsk/Ngsk 
show higher phagocytic activity than B6-Prnpwt/wt BMDM. Two independent experiments were 
performed (shown as blue and black dots); mean phagocytic activites of B6-Prnpwt/wt BMDM 
(11.9% and 18.4% respectively) were set as 100%  
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Figure 9. Phagocytic activity of 
coisogenic 129-PrnpEdbg/Edbg and 
129-Prnpwt/wt pMΦ. The phagocytic 
activity of 129-PrnpEdbg/Edbg and 129-
Prnpwt/wt macrophages was similar, 
both at higher (1:10) and lower (1:1) 
M:T ratios. Data are from three 
individual experiments (shown as 
blue, grey and black dots) and mean 
phagocytic activities of 129-Prnpwt/wt 
pMΦ at 1:10 (31.3%, 26.7% and 
19.4% respectively) were set as 100%.  
 
 
Having determined that Prnp-/- mice generated and maintained on the same genetic 
background as their Prnpwt/wt counterparts did not display the reported phagocytic 
phenotype, we hypothesized that the phenotype observed in backcrossed, congenic 
Prnp-/- mouse lines might be due to polymorphic flanking genes derived from the original 
ESC 129-strain (Fig. 5). 
To control the genetic background of the three investigated Prnp-/- lines and to 
investigate the extend of the 129-derived region flanking the targeted Prnp locus that 
possibly contained polymorphic flanking genes, we performed low density microsatellite-
assisted analysis of the whole genome (Fig. 10) and a medium density microsatellite 
analysis of the region on Chr2 containing the Prnp locus (Fig. 11). Whole-genome STR 
analysis confirmed that congenic B6.129-PrnpZrchI/ZrchI and B6.129-PrnpNgsk/Ngsk mice 
contained mostly B6 strain-specific STRs, comparable to the B6-reference (Fig. 10). On 
the other hand, 129-PrnpEdbg/Edbg mice and their 129-Prnpwt/wt littermates contained a 
homogeneous 129 strain genetic background (Fig. 10). As expected, the 129-
PrnpEdbg/Edbg and 129-Prnpwt/wt strains also showed no differences in Chr2 around Prnp as 
assessed by a more dense STR analysis (Fig. 11), documenting their coisogenic 
generation.  
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Figure 11. STR analysis of Chr2 of B6.129-PrnpZrchI/ZrchI, B6.129-PrnpNgsk/Ngsk, 129-
PrnpEdbg/Edbg and 129-Prnpwt/wt mice. For each STR marker (colored box), name and position on 
Chr2 are indicated on the left. Blue dashed line indicates the position of Prnp. B6.129-
PrnpZrchI/ZrchI, B6.129-PrnpNgsk/Ngsk contain 129-derived genetic material flanking the Prnp locus. 
Conversely, the markers flanking the Prnp locus in129-PrnpEdbg/Edbg were identical to 129-Prnpwt/wt 
mice. 
 
In congenic B6.129-PrnpNgsk/Ngsk mice most markers were B6-derived, except the two 
markers D2Mit308 and D2Mit447, which were homozygous for 129. D2Mit447 is located 
3.3 Mbp upstream of Prnp (Fig. 11), suggesting that the recombination breakpoint might 
be located between Chr2:128,607,202-131,909,927 bp in B6.129-PrnpNgsk/Ngsk mice. 
However, when analyzing Chr2 of congenic B6.129-PrnpZrchI/ZrchI mice, we found that 
these mice harbored 129-derived genomic material in a region of ≥ 47 Mbp flanking Prnp 
on Chr2, despite having been backcrossed for >12 generations (Fig. 11). This region 
was delimited by the microsatellite markers D2Mit100 (Chr2:106,537,368-106,537,479 
bp) and D2Mit493 (Chr2:153,972,906-153,973,015 bp, MGI database) and contained 
689 genes derived from the 129 genome (NCBI map viewer resource, mouse genome 
build 37.2). In order to narrow down the list of potential candidate genes explaining the 
observed phagocytic phenotype of B6.129-PrnpZrchI/ZrchI macrophages, we systematically 
interrogated public databases for genes that were in linkage disequilibrium with the Prnp 
locus. We applied the following restrictions: a. mapped between Chr2: 106,537,479-
153,972,906 bp; b. expressed in macrophages (MGI gene expression database); c. 
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involved in phagocytosis (if retrievable records on pubmed.gov using the search terms: 
“gene xy phagocytosis”, and/or associated terms on geneontology.org, using unfiltered 
search parameters and considering all recorded species); d. polymorphic between B6 
and 129 strains (containing coding-non-synonymous SNPs, using MGI Strains, SNPs & 
Polymorphisms database). Out of the 698 genes mapped in this region, we found 8 
genes that fulfilled all the criteria (Table 2), and thereby qualified as candidate 
confounder genes in studies comparing congenic Prnp-/- mice vs. Prnpwt/wt mice.  
 
Region on Chr2 (bp) Gene name Protein 
117,937,658-117,952,869 Thbs1 thrombospondin 1 
119,625,250-119,643,840 Tyro3 TYRO3 protein tyrosine kinase 3 
128,524,733-128,627,923 Mertk c-mer proto-oncogene tyrosine kinase 
129,418,575-129,457,964 Sirpa signal-regulatory protein alpha 
131,735,664- 131,764,167 Prnp prion protein 
148,262,387-148,269,271 Cd93 CD93 antigen 
150,506,438-150,514,873 Vsx1 visual system homeobox 1 homolog 
152,934,204-152,977,177 Hck hemopoietic cell kinase 
152,987,037-153,036,199 Tm9sf4 transmembrane 9 superfamily protein 
member 4 
 
Table 2. Public database search identifies candidate confounder genes in the B6.129-
PrnpZrchI/ZrchI mouse on Chr2 in the Prnp flanking region delimited by D2Mit 100 and 
D2Mit493. All genes were shown to be expressed in macrophages and to be involved in 
phagocytosis and contain coding-non-synonymous SNPs between B6 and 129. In blue is the 
location of Prnp.  
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4.2.2 RNA sequencing identifies candidate confounder genes linked to 
Prnp on mouse Chr2 
 
We were able to identify possible confounder genes using STR-markers and database 
searches (Table 2). To determine the allelic status of these eight candidates and to 
possibly identify other candidate confounder genes in our mice, we applied a NGS 
technology, RNA-Seq (Majewski and Pastinen, 2011; Wang et al., 2009). In order to find 
genes that are linked to Prnp, polymorphic between B6 and 129, and expressed only in 
macrophages, we performed RNA-Seq on B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt pMΦ 
(n = 3 per group) at the FGCZ. The use of RNA-Seq permitted us to a) find genes 
differentially expressed between B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt pMΦ, and b) to 
analyze the gene-coding sequences for the presence of single nucleotide variants 
between B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt pMΦ. Technical quality parameters of 
the RNA-Seq experiment are indicated in Table 3. 
 
Mouse Total number of reads Mapped reads Average coverage 
WT 1 58,838,924 56,801,099 (96.5%) 58.604 
WT 2 56,971,575 55,447,441 (97.3%) 60.104 
WT 3 77,632,102 75,325,378 (97.0%) 67.430 
KO 1 71,507,393 69,906,771 (97.8%) 64.637 
KO 2 70,456,814 68,728,168 (97.6%) 62.745 
KO 3 75,295,650 73,039,778 (97.0%) 65.377 
Table 3 Technical quality parameters RNA-Seq: sequencing depth, mapping of reads, 
average coverage. WT: B6.129-Prnpwt/wt; KO: B6.129-PrnpZrchI/ZrchI. 
 
Detection of differentially expressed genes 
Out of 11,586 transcribed genes, 304 were differentially expressed between the two 
groups (Fig. 12). The full list of genes is shown in Supplementary Table 1. 55 of the 304 
differentially regulated genes were located on Chr2, significantly more than on any other 
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chromosome (p based on z-score (z > 44) = 0.0011, corrected for chromosome size). 
This clustering was even more pronounced, when considering the highly differentially 
expressed genes (absolute Log2-fold change > 1) and correcting for chromosome size (p 
based on z-score (z > 29) = 0.00039). 
 
 
 
Figure 12. Heatmap of mRNA 
of 304 differentially 
expressed genes between 
B6.129-PrnpZrchI/ZrchI and 
B6.129-Prnpwt/wt pMΦ. Genes 
are listed according to their 
chromosomal location. Columns 
represent data of individual 
mice, sorted by hierarchical 
clustering, as indicated by the 
dendrogram in the legend. 
Yellow: Chr2. All genes are 
listed in Supplementary Table 
2. 
 
 
 
 
 
 
Detection of single nucleotide variants  
The reads were then analyzed for the presence of variants from the B6 transcriptome. 
Compared to B6 reference, B6.129-PrnpZrchI/ZrchI pMΦ RNA contained more overall 
numbers of SNPs and more insertion/deletion mutations (indels) than did B6.129-
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Prnpwt/wt pMΦ RNA (Table 4). To determine the distribution of variants among the 
transcriptome, we plotted the density of sequence variation of genes expressed in 
B6.129-PrnpZrchI/ZrchI pMΦ against the chromosomal map and detected the highest SNP 
density on Chr2 (Fig. 13), located around Prnp at 128-156 Mbp (Fig. 14). 
 
Mouse # SNPs # Het. 
SNPs 
# Hom. 
SNPs 
# Indels # Nonsyn. 
variants 
# Nonsyn. 
variants genes 
WT 1 102,465 14,249 88,216 6,860 2,902 284 
WT 2 102,756 12,591 90,165 7,451 2,874 280 
WT 3 117,354 15,501 101,853 8,356 3,360 329 
common 
for all WT 
84,205 9,535 74,670 5,644 2,277 197 
KO 1 117,979 15,146 102,833 8,164 3,517 365 
KO 2 114,906 14,943 99,963 8,185 3,391 367 
KO 3 117,592 15,539 102,053 8,405 3,515 379 
common 
for all KO 
92,176 9,569 82,607 6,397 2,682 264 
Table 4 Summary of variants of the B6.129-Prnpwt/wt and B6.129-PrnpZrchI/ZrchI transcriptomes 
as detected by RNA-Seq. WT: B6.129-Prnpwt/wt; KO: B6.129-PrnpZrchI/ZrchI; #, number; SNPs: 
single nucleotide polymorphisms; Het.: heterozygous; Hom.: homozygous; Nonsyn.: 
nonsynonymous; Indels: insertions/deletions. 
 
 
Figure 13. Manhattan plot showing the chromosomal distribution of SNPs found in the 
transcriptome of B6.129-PrnpZrchI/ZrchI, but not of B6.129-Prnpwt/wt, pMΦ by RNA-Seq. Variants 
unique to B6.129-PrnpZrchI/ZrchI pMΦ clustered on Chr 2 (in yellow, t-test, two tailed, p=0.019). 
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Figure 14. Clustering of SNPs on Chr2 around Prnp in B6.129-PrnpZrchI/ZrchI vs. B6.129-
Prnpwt/wt. To identify the minimal region containing excess SNPs in the B6.129-PrnpZrchI/ZrchI vs. 
B6.129-Prnpwt/wt peritoneal macrophage transcriptome, we determined the p value of SNP density 
comparison between these two groups when different regions of Chr 2 comprising Prnp where 
excluded from the analysis. In detail, we calculated p-values (two tailed t-test, z-axis) for every 
possible window spanning 2-100 Mbp around Prnp (set to position Chr 2: 130 Mbp) in steps of 1 
Mbp. We compared the average SNP density between the two groups in the region 129-131 Mbp, 
then moved telomerically (y axis) or centromerically (x-axis) in 1-Mbp steps. Red area: p ≥ 0.05. 
Blue line: boundaries of the minimal significantly SNP-enriched region comprising Prnp between 
B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt peritoneal macrophages, located at 128-156 Mbp on Chr 
2. 
 
Both differentially expressed genes and genes with high SNP density cluster on Chr2  
Studies analyzing the effect of regulatory SNPs on gene expression have reported 
robust allele-specific differences in gene expression among different inbred mouse 
strains (Cowles et al., 2002). Consequently, when comparing congenic B6.129-
PrnpZrchI/ZrchI pMΦ vs. B6.129-Prnpwt/wt pMΦ RNA, where we found the largest density of 
SNPs around Prnp, we expected to find the majority of differentially expressed genes in 
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the same region, suggesting a 129-mouse strain-specific expression pattern. Indeed, we 
observed that genes that contained a high SNP density and were also differentially 
expressed, clustered on Chr2 around Prnp (Table 5). Apart from 1 gene (Chd3), all 
genes that were polymorphic between B6 and 129 and also differentially expressed 
between the two groups are located on Chr2. Thereof, 8 genes are located < 12 Mbp 
from Prnp. 
 
Gene Locus Log2 - fold change q-value 
Dnm1 chr2:32308470-32353304 0.814 3.927e-02 
Eif2ak4 chr2:118388616-118475234 -0.864 8.504e-05 
Plcb2 chr2:118707516-118728438 0.790 1.755e-04 
Zfyve19 chr2:119172499-119217050 -0.941 8.040e-04 
Chac1 chr2:119351241-119354327 0.995 7.664e-04 
Exd1 chr2:119519403-119547627 3.252 8.384e-06 
Mtap1a chr2:121289601-121351013 1.443 9.860e-03 
Spg11 chr2:122053526-122118386 -1.104 4.966e-06 
Slc28a2 chr2:122426476-122461130 0.735 2.236e-02 
Chd3 chr11:69344350-69369391 -0.505 1.848e-02 
Table 5. Genes containing a high density of SNPs and being differentially regulated in 
B6.129-PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt mice. Display of top 10 genes according to their 
absolute log2-fold change. 9 of 10 genes are located on chromosome 2. 
 
 
Identification of candidate confounder genes linked to Prnp controlling phagocytosis in 
PrnpZrchI/ZrchI vs. Prnpwt/wt mice 
To identify genes that possibly act as a confounder in the phagocytic phenotype in 
congenic Prnp-/- mouse strains, we introduced a filtering strategy to narrow down the list 
of candidates (Fig. 15). We analyzed all 22,981 SNPs not shared between B6.129-
Prnpwt/wt and B6.129-PrnpZrchI/ZrchI pMΦ for the presence of variants affecting the amino 
acid sequence of the transcribed protein (non-synonymous coding SNPs). We found 132 
transcribed genes harboring non-synonymous coding variants between B6.129-Prnpwt/wt 
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and B6.129-PrnpZrchI/ZrchI pMΦ (Supplementary Table 2). Of these, 62 genes mapped on 
Chr2 (47%) between 34,943,257 and 175,061,548 bp, and 56 of these were located in 
the region previously identified using STR analysis as being 129-derived in congenic 
B6.129-PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt mice (delimited by the microsatellite markers 
D2Mit100 (Chr2:106,537,368-106,537,479 bp) and D2Mit493 (Chr2:153,972,906-
153,973,015 bp), Fig. 11). We then searched public databases for prior evidence 
demonstrating an involvement in phagocytosis (Fig. 15). Four of the 62 genes located on 
chromosome 2 matched this criterion: Sirpa, Mertk, Tyro3 and Thbs  (Box 1) and 
therefore qualified as potential confounder genes when comparing the phagocytic activity 
of macrophages isolated from congenic Prnp-/- vs. Prnp+/+ mice 
 
 
Figure 15. Filtering strategy to prioritize genes 
controlling phagocytosis in PrnpZrchI/ZrchI vs. Prnpwt/wt 
mice. Single nucleotide polymorphisms (SNPs), including 
insertions/deletions (or genes with SNPs) not shared 
between the transcriptomes of B6.129-PrnpZrchI/ZrchI and 
B6.129-Prnpwt/wt peritoneal macrophages were subjected to 
sequential filters (yellow boxes). SNPs affecting protein 
structure refers to non-synonymous SNPs or 
insertions/deletions. * based on Gene Ontology 
annotations and PubMed search. § based on PubMed 
search. Sirpa, Mertk, Thbs1 and Tyro3 have non-
synonymous SNPs between B6.129-PrnpZrchI/ZrchI and 
B6.129-Prnpwt/wt mice, reside on chromosome 2 and are 
involved in phagocytosis. Of these genes, we prioritized 
Sirpa, since only Sirpa polymorphisms have been shown to 
modulate phagocytosis (Takenaka et al., 2007; Yamauchi 
et al., 2013) 
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Sirpa 
The transmembrane glycoprotein SIRPα encoded by Sirpa belongs to the group of SIRP 
receptors, which are part of the immunoglobulin (Ig) superfamily (Barclay and Brown, 2006). It 
consists of an extracellular region with three highly variable Ig-like loops and a cytoplasmatic tail 
containing two tyrosine phosphorylation sites and mostly expressed in neurons and myeloid cells, 
especially on macrophages, dendritic cells and neutrophils (Matozaki et al., 2009). SIRPα is 
mostly known as a negative regulator of phagocytosis (Okazawa et al., 2005; Tada et al., 2003) 
Via binding of its main binding partner, the ubiquitously expressed CD47 on cognate cells, SIRPα 
transmits “don’t eat me” signals that protect the targets from phagocytosis. In contrast, 
downregulation of CD47 leads to phagocytosis (Oldenborg et al., 2000; Tada et al., 2003). As a 
consequence, tumor cells upregulate CD47 expression to evade phagocytosis (Jaiswal et al., 
2009) and molecules targeting CD47 are considered promising immunotherapeutics (Chao et al., 
2012). SIRPα was also shown to be part of the immunological synapse between dendritic cells 
and T cells (Brooke et al., 2004), and is required for T and NK cell homeostasis (Legrand et al., 
2011b). Sirpa is highly polymorphic in mice (Nakaishi et al., 2008) and humans (Barclay, 2009; 
Hatherley et al., 2007) and its polymorphisms have been shown to have a profound impact on its 
function (Takenaka et al., 2007; Yamauchi et al., 2013) 
 
Mertk and Tyro3 
Mertk and Tyro3 encode two of the three members of the TAM receptor protein tyrosine kinases, 
which are TYRO3, AXL and MER. MER and TYRO3 largely share their expression patterns with 
differences in the abundance of expression. Both receptors are found in monocytes/macrophages 
and other immune cells, platelets, ovary, testis, lung, retina and nervous system (Linger et al., 
2008). TAM receptors and their ligands Gas6 and Protein S are crucial in the process of 
recognition and engulfment of apoptotic cells and membranes (Halliday, 1997; Scott et al., 2001), 
they regulate innate immunity, and are fundamental for tissue homeostatis in organs with a high 
cellular turnover, such as the retina and reproductive system (Lemke and Rothlin, 2008; Rothlin 
and Lemke, 2010). Consequently, alterations in expression and function of TAM receptors are 
implicated in a variety of dysfunctions, such as autoimmune diseases (Rothlin and Lemke, 2010), 
malignancies (Linger et al., 2008; Verma et al., 2011) and mutations in Mertk can cause 
retinopathies (Gal et al., 2000; Ksantini et al., 2012; Li et al., 2011). 
 
Thbs1 
Thbs1 encodes the large secreted matricellular glycoprotein TPS-1, which is expressed in most 
adult tissues, especially in fibroblasts and endothelial cells (Adams and Lawler, 2004; Carlson et 
al., 2008a). It binds to a multitude of adhesion-molecules (Roberts and Lau, 2011), among others 
CD47 (Gao et al., 1996) and is involved in the regulation of various cellular processes, such as 
angiogenesis, cell motility, platelet activation and immunomodulation (Adams and Lawler, 2004). 
Interestingly, TSP-1 and CD47-SIRPα interact in erythrophagocytosis: CD47 on aged 
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erythrocytes seems to undergo conformational changes, thereby exposing a TSP-1 binding site, 
which inhibits CD47- SIRPα binding, thereby permitting the phagocytosis of the aged erythrocyte 
(Burger et al., 2012). TSP-1 has been implicated in various cancers, where its downregulation 
leads to cancer progression and metastasis (Chong et al., 2012). Thbs1 is highly polymorphic and 
several functional polymorphisms have been reported, for instance the human N700S Thbs1 
polymorphism, which alters the function of the protein and is associated with premature coronary 
heart disease (Carlson et al., 2008b). 
 
 
Box 1. Characteristics of the four candidate confounder genes Sirpa, Mertk, Tyro3 and 
Thbs1. 
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4.2.3 Analysis of candidate confounder genes Sirpa, Mertk, Tyro3 and 
Thbs1 
 
We determined the allelotypes of the four candidate confounder genes in Prnp-/- mouse 
lines previously used for assessing the phagocytic activity of pMΦ and BMDM (Fig. 7, 
Fig. 8, Fig. 9). Coisogenic 129-PrnpEdbg/Edbg were Sirpa129/129 Mertk129/129 Tyro3129/129 
Thbs1129/129, reflecting their generation using 129-derived ESC and their coisogenic 
maintenance (Table 6). Also congenic B6.129-PrnpZrchI/ZrchI were Sirpa129/129 Mertk129/129 
Tyro3129/129 Thbs1129/129, despite having been backcrossed to B6 for 12 generations 
(Table 6). Therefore, in experiments comparing congenic B6.129-PrnpZrchI/ZrchI and 
B6.129-Prnpwt/wt mice, all four genes (Sirpa, Mertk, Tyro3 and Thbs1) can act as genetic 
confounder. On the other hand, congenic B6.129-PrnpNgsk/Ngsk mice were Sirpa129/129 
Mertk129/129 Tyro3B6/B6 Thbs1B6/B6 (Table 6), most likely reflecting a recombination event 
between Prnp-Sirpa-Mertk and Tyro3-Thbs1 during backcrossing to B6 and in 
accordance to the results obtained by microsatellite analysis, where B6.129-PrnpNgsk/Ngsk 
mice had less 129-derived material (Fig. 11). Since congenic B6.129-PrnpNgsk/Ngsk mice 
had retained the hyperphagocytic phenotype (Fig. 8), allelic variation in Tyro3 or Thbs1 
is not necessary to explain the different phagocytic activity of Prnpwt/wt and Prnp-/- mice. 
As a consequence, we excluded Tyro3 and Thbs1 (but not Sirpa and Mertk) as 
candidate genes.  
 
 Prnp Sirpa Mertk Tyro3 Thbs1 
 chr2:131,909,927
-131,938,431 
chr2:129,592,838
-129,632,228 
chr2:128,698,996
-128,802,188 
chr2:119,799,513
-119,818,103 
chr2:118,111,921
-118,127,133 
PrnpEdbg/Edbg -/- 129/129 129/129 129/129 129/129 
PrnpZrchI/ZrchI -/- 129/129 129/129 129/129 129/129 
PrnpNgsk/Ngsk -/- 129/129 129/129 B6/B6 B6/B6 
Table 6 Allelotypes of the four candidate genes on chromosome 2 linked to Prnp (Sirpa, 
Mertk, Tyro3, Thbs1) in the three Prnp-/- mouse lines used for assessing phagocytic activity 
of pMΦ and BMDM. Second row designates the location on Chr2. 
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Having Sirpa and Mertk as remaining two candidate genes, we searched the databases 
for reports on functional polymorphisms, i.e., polymorphisms altering the function of a 
gene (Albert, 2011). Sirpa (Box 1) is highly polymorphic in laboratory mice (Sano et al., 
1999) and polymorphisms of the immunoglobulin-like variable domain of SIRPα affect 
the binding to CD47, thereby modulating phagocytosis (Takenaka et al., 2007; 
Theocharides et al., 2012; Yamauchi et al., 2013). Therefore, we considered Sirpa as a 
plausible candidate in our paradigm. 
Functional polymorphisms have also been reported for Mertk (Box 1) For instance, 
sequence variations in Mertk have been identified in patients suffering from autosomal 
retinitis pigmentosa (Gal et al., 2000). Some of these polymorphisms in Mertk were 
predicted to lead to truncated protein lacking the intracellular region and thereby possibly 
altering the phagocytic capacity of the retinal pigment epithelial cells (McHenry et al., 
2004). 
In our mice, RNA-Seq identified only a single non-synonymous SNP in Mertk129 vs. 
MertkB6 alleles (chr2:128776396, Att/Gtt), which has been reported in the CD-1 strain 
(Dowds et al., 1996) and predicted to result in a isoleucine to valine substitution (I516V). 
Both AA have side chains with similar properties, and therefore, this AA substitution is 
considered conservative. We used the SIFT algorithm to predict the impact of this non-
synonymous SNP on Mertk function (Kumar et al., 2009; Ng and Henikoff, 2001). 
Applying default parameter settings (Kumar et al., 2009), the SIFT algorithm predicted 
the I516V AA substitution to be tolerated and not impacting on Mertk function. Also, 
since this conservative AA substitution was located within the transmembrane region of 
the protein, we reasoned that it was unlikely to significantly impact the function of the 
protein. One natural non-disease-causing variant in the transmembrane region has been 
reported in humans (I518V) (Gal et al., 2000; Li et al., 2011), which corresponds to the 
(I516V) variant in our mice. Moreover, all disease-causing MERTK mutations identified 
so far in patients suffering from retinitis pigmentosa (Gal et al., 2000), Leber congenital 
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amaurosis (Li et al., 2011), or cancer (Greenman et al., 2007) were located in the 
extracellular or cytoplasmic, but not in the transmembrane region, again suggesting that 
the variant identified in our mice is unlikely to impact Mertk function. For these reasons, 
we excluded Mertk as a plausible candidate in our paradigm and we prioritized Sirpa 
over Mertk as the candidate confounder gene for the phagocytic phenotype described in 
B6.129-PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt mice. 
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4.2.4 Sirpa129 is linked to Prnp-/- allele in all analysed Prnp knockout strains 
 
Using RNA-Seq and a subsequent filtering strategy, we had identified the highly 
polymorphic macrophage-expressed gene Sirpa as potentially controlling phagocytosis 
in PrnpZrchI/ZrchI vs. Prnpwt/wt mice. Despite extensive backcrossing, congenic B6.129-
PrnpZrchI/ZrchI and B6.129-PrnpNgsk/Ngsk mice still carried two Sirpa129 alleles (Table 6). We 
analyzed additional five Prnp-/- strains: two congenic, one coisogenic and one on a mixed 
B6129 background. Table 7 summarizes the parental and congenic strains of all 
analyzed Prnp-/- animals and Fig. 16 shows the whole genome STR analysis of the 
additionally analyzed Prnp-/- strains.  
 
Mouse line ESC Origin of ESC Strain of partner 
of chimeric 
mouse 
Reference 
PrnpZrchI/ZrchI AB1 129S7/SvEvBrd C57BL/6 (Büeler et al., 1992) 
PrnpNgsk/Ngsk J1 129S4/SvJae C57BL/6 (Sakaguchi et al., 1995) 
PrnpEdbg/Edbg E14 129/Ola 129/Ola (Manson et al., 1994) 
PrnpGFP/GFP HM-1 129/Ola C57BL/6 (Heikenwalder et al., 2008) 
PrnpRkn/Rkn E14 129P2/OlaHsd C57BL/6 (Yokoyama et al., 2001) 
PrnpZrchII/ZrchII E14.1 129/OlaHsd C57BL/6 (Rossi et al., 2001) 
PrnpRcm0/Rcm0 HM-1 129/Ola 129/Ola (Moore et al., 1995) 
Table 7. Parental and congenic strains of analyzed Prnp-/- mice. 
 
 
 
 
Figure 16. Whole genome STR analysis of additional 5 Prnp-/- strains. The red boarder marks 
the region on Chr2 containing Prnp and Sirpa. For each line a representative mouse is shown. 
For heterozygous markers, the strain-defining color is arbitrary and does not define a specific 
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haplotype. Reference B6, 129 and C samples are the same as in all shown whole genome STR 
analyses.  
We found that in all seven analyzed independently generated Prnp-/- strains the Prnp- 
allele segregated with the 129-allele of Sirpa (Fig. 17). 
 
 
 
Figure 17. Sirpa129 segregates with Prnp-. (a) RFLP analysis of Sirpa allelotypes. The Sirpa129 
allele segregates with Prnp- allele in Prnp-/- mouse lines from 7 independent targeting events 
(Table 7). Sample names in bold font are reference strain DNA. (b) Red box: protein sequence 
alignment of mouse SIRPα immunoglobulin-like variable domain (IgV) confirming the 129 Sirpa 
allelotype in all of the 7 Prnp-/- lines showing in panel (a). Blue box: SIRPα protein reference 
sequences for the B6, 129/Sv, and 129/Ola strains. Polymorphisms are highlighted in yellow. 
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4.2.5 Sirpa129 enhances phagocytosis in the absence of Prnp 
 
PrPC-overexpressing tga20 transgenic mice had been generated by introducing a 
transgene encoding wild type murine PrP into PrnpZrchI/ZrchI blastocysts on a mixed B6129 
background (Fischer et al., 1996), and are therefore expected to carry two Sirpa129 
alleles. However, we incidentally observed that some animals in our PrPC-
overexpressing tga20 colony segregated SirpaB6 and Sirpa129 alleles, perhaps due to an 
unintentional cross with B6-Prnpwt/wt breeders in the early days of this colony (M. Fischer, 
personal communication). We took advantage of this serendipitous discovery to generate 
B6129-PrnpZrchI/ZrchI littermates with all three combinations of SirpaB6 and Sirpa129 alleles. 
We backcrossed B6129-PrnpZrchI/ZrchI SirpaB6/B6 tga20tg/tg mice to B6129-PrnpZrchI/ZrchI 
Sirpa129/129 mice (Fig. 18, Fig. 19) and tested the phagocytic activity of their pMΦ. 
 
 
 
Figure 18. Generation of B6129-PrnpZrchI/ZrchI mice with all three combinations of Sirpa B6-, 
and 129-alleles. (a) Breeding scheme applied to generate B6129-PrnpZrchI/ZrchI mice containing 
SirpaB6 and Sirpa129 alleles. B6129-PrnpZrchI/ZrchI SirpaB6/B6 tga20tg/tg mice (F0) were backcrossed to 
B6129-PrnpZrchI/ZrchI Sirpa129/129 mice for two generations to produce B6129-PrnpZrchI/ZrchI littermates 
with all three combinations of SirpaB6 and Sirpa129 alleles (F3, indicated with red arrows and used 
to assess the phagocytic activity of pMΦ as in Fig. 20. (b) RFLP analysis of Sirpa allelotypes (B6 
vs 129). tga20 mice (lanes 1-3) contained combinations of SirpaB6 and Sirpa129 allelotypes. Lanes 
4-6 represent B6129-PrnpZrchI/ZrchI mice indicated with red arrows in panel b. Controls: reference 
DNA. 
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Figure 19. Genetic background of B6129-PrnpZrchI/ZrchI mice with different combinations of 
Sirpa B6/129. (a) Whole-genome STR analysis of B6129-PrnpZrchI/ZrchI with different combinations 
of Sirpa alleles (B6 vs. 129). The red border marks the region on Chr2 containing Prnp and Sirpa. 
For each line, a representative mouse is shown. For heterozygous markers, the strain-defining 
color is arbitrary and not intended to designate a specific haplotype. Reference B6, 129 and C 
samples are the same as in all shown whole genome STR analyses. (b) STR analysis 
documenting the boundaries of B6 vs. 129-derived genome in Chr 2 of B6129-PrnpZrchI/ZrchI with 
different combinations of Sirpa alleles (B6 vs. 129). Blue dashed line indicates the location of 
Prnp and Sirpa. For each STR marker (colored box) name and position on Chr 2 are indicated on 
the left. 
 
 
pMΦ from B6129-PrnpZrchI/ZrchI Sirpa129/129 mice showed higher rates of phagocytosis than 
B6129-PrnpZrchI/ZrchI SirpaB6/129 and B6129-PrnpZrchI/ZrchI SirpaB6/B6 pMΦ (Fig. 20). Hence, 
compared to Sirpa129/129, a single SirpaB6 allele reduced phagocytosis in the absence of 
Prnp. These results supported the hypothesis that homozygosity for Sirpa129, rather than 
Prnp deficiency was responsible for the hyperphagocytic phenotype of PrnpZrchI/ZrchI mice. 
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Figure 20. SirpaB6 allele segregates with enhanced inhibition of phagocytosis in the 
absence of Prnp. Phagocytic hyperactivity of B6129-PrnpZrchI/ZrchI pMΦ was associated with the 
Sirpa129/129 allelotype. Data are from three independent experiments (in blue, black and grey), 
mean B6129-PrnpZrchI/ZrchI SirpaB6/B6 phagocytic rates at 1:5 (23.6%, 44.4% and 35,0%, 
respectively) were set as 100%. One-way ANOVA, Bonferroni's multiple comparisons test: 
*p<0.05; ***p<0.001, error bars: s.d. 
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4.2.6 Sirpa regulates phagocytosis irrespective of Prnp status 
 
In mice lacking Prnp, we observed that the Sirpa B6/129 polymorphism was associated 
with modulation of the phagocytic activity of pMΦ (Fig. 20). Alternatively, we reasoned 
that Prnp might influence phagocytosis independently of Sirpa. To study whether 
different Sirpa alleles could modify phagocytosis also in Prnpwt/wt mice, we generated 
mice with recombination between Prnp and Sirpa in two different backgrounds (B6 and 
C). The genetic distance between Sirpa (chr2:129,592,838-129,632,228) and Prnp 
(chr2:131,909,927-131,938,431) is approximately 2.4 Mbp, corresponding to 
approximately 2 cM and an estimated recombination frequency of 2%. 
On the B6 background, we screened 103 pups from B6.129-Prnpwt/ZrchI SirpaB6/129 
intercrosses for meiotic transallelic recombination between Prnp and Sirpa and observed 
two events producing a Prnpwt-Sirpa129 and a PrnpZrchI-SirpaB6 haplotype (recombination 
frequency 1.9%) (Fig. 21). Mice carrying the original and novel recombinant haplotypes 
were bred to generate congenic mice with the following Prnp-Sirpa haplotypes (Fig. 21): 
B6.129-PrnpZrchI/ZrchI Sirpa129/129 (original), B6.129-Prnpwt/wt SirpaB6/B6 (recombinant), 
B6.129-Prnpwt/wt SirpaB6/B6 (original), and B6.129-Prnpwt/wt Sirpa129/129 (recombinant). Mice 
form the four groups exhibited a highly similar genetic background (Fig. 22), apart from 
the region flanking Prnp on Chr2. In collaboration with Prof. J. Danska and S. Mortin-
Toth (Hospital for Sick Children, University of Toronto), we performed high density STR 
analysis of the region flanking Sirpa and Prnp, and documented the recombination 
breakpoint between Sirpa and Prnp in B6.129-Prnpwt/wt SirpaB6/B6 mice between the 
markers D2Ngul1888 (Chr2:129,913,603-129,914,407) and D2Ngul1937 (Chr2: 
130,287,604-130,288,020). Sequencing of the Sirpa ORF confirmed the presence of the 
four different Sirpa-Prnp haplotypes (Fig. 22) 
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Figure 21. Recombinant congenic B6.129 mice with different combinations of Prnp (wt and 
ZrchI) and Sirpa (B6 and 129) alleles. (a) Breeding scheme to generate recombinant congenic 
B6.129 mice with different combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) alleles. 
B6.129-Prnpwt/ZrchI mice (F1) were intercrossed and the occurrence of meiotic recombination 
between Prnp and Sirpa was assessed in the F2-offspring. 103 F2 mice with different 
combinations of Prnp genotypes and Sirpa allelotypes were obtained. Two mice (red frame) were 
obligate carriers for a recombinant haplotype, Prnpwt-Sirpa129 and PrnpZrchI-SirpaB6, respectively. 
Obligate carriers of the recombinant Prnp-Sirpa haplotype were interbred to generate B6.129-
PrnpZrchI/ZrchI and B6.129-Prnpwt/wt mice homozygous for SirpaB6 or Sirpa129 alleles. (b) RFLP 
analysis to discriminate Sirpa129 from SirpaB6. B6.129-Prnpwt/wt (lanes 1, 3 and 5) and B6.129-
PrnpZrchI/ZrchI (lanes 2, 4 and 6) mice with different combinations of Sirpa129 and SirpaB6 alleles. 
Controls are reference DNA. Mice in lanes 1 to 4 were used to assess the phagocytic activity of 
pMΦ. 
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Figure 22. STR analysis and SIRPα alleles of recombinant congenic B6.129 mice with 
different combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) alleles. (a) Whole-
genome STR analysis of congenic B6.129 mice with different combinations of Sirpa-Prnp 
haplotypes. The red border marks the region on Chr2 containing Prnp and Sirpa. For each line, a 
representative mouse is shown. For heterozygous markers, the strain-defining color is arbitrary 
and not intended to designate a specific haplotype. Reference B6, 129 and C samples are the 
same as in all shown whole genome STR analyses. (b) STR analysis documents the result of 
transallelic meiotic recombination between Prnp and Sirpa. Blue dashed line indicates the location 
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of Prnp and Sirpa. For each STR marker (colored box) name and position on Chr2 are indicated 
on the left. (c) Protein sequence variants (yellow) in SIRPα immunoglobulin-like variable domain 
(IgV). Homozygous recombinant congenic B6.129 mice displayed four combinations of Prnp-Sirpa 
haplotypes (black boxes). Blue boxes: SIRPα sequence of reference B6 and 129/Sv strains. 
 
Next we wanted to exclude that different Sirpa-Prnp haplytypes could influence the 
abundance of pMΦ in these different strains, or that different Sirpa-Prnp haplytypes 
could mutually influence its protein expression. We did not observe any effect of the 
Prnp-Sirpa haplotype on the prevalence of F4/80+ cells in peritoneal lavages (Fig. 23a-b).  
 
 
Figure 23. Sirpa allelotype does not influence peritoneal macrophage abundance. (a) 
Peritoneal lavages were gated for nucleated cells (left panel), and the percentage of F4/80+ cells 
was assessed (middle panel, right peak). Right panel: overlay of histograms of F4/80 (dark blue), 
isotype antibody (light blue) and unstained peritoneal cells (grey) confirming the specificity of the 
staining. (b) Percentage of F4/80+ macrophages in peritoneal lavage cells of experimental mice. 
The dotted lines delimit individual experiments in which groups of mice (n=3-10 for each 
haplotype) were analyzed. 
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Also, Sirpa allelotype did not impact on PrPC expression (Fig. 24a). RNA-Seq showed no 
differences in Sirpa mRNA levels between pMΦ from B6.129-PrnpZrchI/ZrchI and B6.129-
Prnpwt/wt mice (375.60 vs 356.34 fragments per kilobase of transcript per million mapped 
reads, FPKM, respectively, p=0.73), and immunoblotting of pMΦ lysates failed to detect 
different SIRPα protein levels in congenic mice with different Prnp-Sirpa haplotypes (Fig. 
24b). This excluded a mutual influence of Prnp and Sirpa, which could complicate the 
interpretation of phagocytic activity in mice with different Prnp-Sirpa haplotypes. 
 
 
 
Figure 24. Sirpa allelotype does not influence PrPC and SIRPα expression. (a) PrPC ELISA 
analysis of pMΦ lysates showed no difference (n.s.) in PrPC levels between B6.129-Prnpwt/wt mice 
with different Sirpa allelotypes. Two-tailed unpaired t-test, p=0.241, n=3. N.d. not detectable. 
(b) Unchanged expression of the SIRPα cytoplasmic tail (CT) in cultured pMΦ lysates as 
quantified to actin levels. SHPS-1 KO macrophage lysates lacking the cytosolic tail of SIRPα were 
used as negative control. One-way ANOVA, n.s.: not significant, p=0.27, n=3-4. 
 
Next, we tested the phagocytic activity of pMΦ isolated from congenic B6.129 mice with 
different combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) alleles using 
apoptotic thymocytes as prey. As with B6129-PrnpZrchI/ZrchI pMΦ, where Sirpa-129 
homozygosity led to a higher rate of phagocytosis (Fig. 20), we observed that B6.129-
PrnpZrchI/ZrchI Sirpa129/129 pMΦ phagocytosed more apoptotic thymocytes than B6.129-
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PrnpZrchI/ZrchI SirpaB6/B6 pMΦ. Importantly, this effect held true also in the presence of 
PrPC: pMΦ from congenic B6.129-Prnpwt/wt Sirpa129/129 mice showed a higher phagocytic 
activity than B6.129-Prnpwt/wt SirpaB6/B6 pMΦ. In summary, in congenic B6.129 mice with 
different combinations of Prnp and Sirpa alleles (wt and ZrchI, B6 and 129, respectively), 
hyperphagocytosis segregated with Sirpa129/129 irrespective of the Prnp status (Fig. 25).  
 
 
 
Figure 25. Sirpa129/129, but not Prnp-/-, was associated with hyperphagocytosis in congenic 
B6.129 mice. Data show two independent experiments (in blue and black), mean phagocytosis 
rates of B6.129 Prnpwt/wt SirpaB6/B6 were set as 100%.  One-way ANOVA, Bonferroni’s multiple 
comparisons post-test: *p<0.05; ****p<0.0001. 
 
In the next step, we asked whether homozygosity for Sirpa129 - and not the presence or 
absence of Prnp - could also modulate the phagocytic activity of macrophages on a 
strain background other than B6. We therefore crossed congenic C.129-PrnpZrchI/ZrchI 
mice backcrossed for > 18 generations with C-Prnpwt/wt mice. We intercrossed the 
resulting C.129-Prnpwt/ZrchI mice (F1) and screened their F2-offspring for the occurrence 
of a meiotic recombination event between Sirpa and Prnp (Fig. 26a). Out of 243 pups, 
we found four animals, where a recombination between Sirpa and Prnp had occurred 
(recombination frequency 1.65%): one animal with a Prnpwt/ZrchI SirpaC/C haplotype, a 
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single  animal carrying a Prnpwt/wt SirpaC/129 haplotype, and two animals with a 
PrnpZrchI/ZrchI SirpaC/129 haplotype (Fig. 26a). Following the analogous breeding strategy as 
on the B6-background (Fig. 21), we bred the mice carrying the original and the novel 
recombinant haplotypes to generate congenic mice with the following Prnp-Sirpa 
haplotypes: C.129-PrnpZrchI/ZrchI Sirpa129/129 (original), C.129-PrnpZrchI/ZrchI SirpaC/C 
(recombinant), C.129-Prnpwt/wt SirpaC/C (original), and C.129-Prnpwt/wt Sirpa129/129 
(recombinant) (Fig. 26a-b). Again, we performed a whole genome low density STR 
analysis of representative animals of all four groups and found a highly similar genetic 
background (Fig. 27a), with the exception of the region on Chr2 flanking Prnp (Fig. 27b), 
where mice carrying PrnpZrchI/ZrchI alleles contained 129-derived chromosomal material, 
as assessed by a high density STR analysis of the region flanking Sirpa and Prnp. 
Again, sequencing of the Sirpa ORF confirmed the presence of the four different Sirpa-
Prnp haplotypes (Fig. 27c). 
 
56 |  
 
 
 
 
Figure 26. Recombinant congenic C.129 mice with different combinations of Prnp (wt and 
ZrchI) and Sirpa (C and 129) alleles. (a) Breeding scheme to generate recombinant congenic 
C.129 mice with different combination of Prnp (wt and ZrchI) and Sirpa (C and 129) alleles. 
C.129-Prnpwt/ZrchI mice (F1) were intercrossed and the occurrence of meiotic recombination 
between Prnp and Sirpa was assessed in the F2-offspring. 243 F2 mice with different 
combinations of Prnp genotypes and Sirpa allelotypes were obtained. Three mice (red frame) 
were obligate carriers for a recombinant haplotype. Obligate carriers were bred to generate 
C.129-PrnpZrchI/ZrchI and C.129-Prnpwt/wt mice homozygous for SirpaC or Sirpa129 alleles. 
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Figure 27. STR analysis and SIRPα alleles of recombinant congenic C.129 mice with 
different combinations of Prnp (wt and ZrchI) and Sirpa (C and 129) alleles. (a) Whole-
genome STR analysis of congenic B6.129 mice with different combinations of Sirpa-Prnp 
haplotypes. The red border marks the region on Chr2 containing Prnp and Sirpa. For each line, a 
representative mouse is shown. For heterozygous markers, the strain-defining color is arbitrary 
and not intended to designate a specific haplotype. Reference B6, 129 and C samples are the 
same as in all shown whole genome STR analyses. (b) Short tandem repeat (STR) analysis 
documents the result of transallelic meiotic recombination between Prnp and Sirpa Blue dashed 
line indicates the location of Prnp and Sirpa. For each STR marker (colored box) name and 
position on Chr 2 are indicated on the left. (c) Protein sequence alignment of mouse SIRPα 
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immunoglobulin-like variable domain (IgV) illustrates recombinant congenic C.129 mice with 
different combination of Prnp and Sirpa129 vs. SirpaC (grey border). Blue box: SIRPα protein 
reference sequences for the B6, 129/Sv, and C strains (yellow: polymorphisms).  
 
To assess the influence of Prnp and the Sirpa C/129 polymorphism on the modulation of 
phagocytic activity, we isolated BMDMs from congenic C.129-PrnpZrchI/ZrchI mice with 
different combinations of Prnp and Sirpa alleles (Fig. 26Fig. 27) and performed 
phagocytosis assays using apoptotic thymocytes as prey (Fig. 8a). Again, we observed 
that a higher phagocytosis rate correlated with Sirpa129/129, independently of the presence 
or absence of Prnp (Fig. 28). The comparison of BMDM derived from C.129-PrnpZrchI/ZrchI 
Sirpa129/129 vs. C.129-PrnpZrchI/ZrchI SirpaC/C mice yielded only a borderline significance (p 
= 0.075), most likely due to the high variability in the C.129-PrnpZrchI/ZrchI Sirpa129/129 
group. 
 
 
Figure 28. Sirpa129/129 allelotype, but not the absence of Prnp, was associated with 
hyperphagocytosis of BMDMs in congenic C.129 mice. Data are from three independent 
experiments (blue, black and grey). Average phagocytosis rates of C.129 PrnpZrchI/ZrchI SirpaB6/B6 
were set as 100%. One-way ANOVA, Bonferroni’s multiple comparison post-test,****p<0.0001. 
 
Together, these results eliminate a role for PrPC as an inhibitor of phagocytosis and 
instead support Sirpa polymorphisms as major regulators of phagocytosis in mouse 
strains carrying both wildtype and deleted Prnp alleles.  
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4.2.7 Sirpa129 exacerbates mouse EAE in the absence of Prnp 
 
We have determined that a function previously ascribed to PrPC on the basis of studies 
in congenic Prnp-/- mice, regulation of phagocytosis, was not influenced by Prnp gene 
expression. Instead, our results suggest that the polymorphic Sirpa gene, which flanks 
Prnp, regulates this cell-autonomous phenotype. The process of phagocytosis does also 
play a role in a complex model of neuroinflammation, EAE (Baxter, 2007; Schreiner et 
al., 2009). Both CNS-resident phagocytes (microglia) as well as infiltrating phagocytic 
cells (monocytes) contribute to the development and progression of EAE, both by 
inducing neurotoxicity and exerting a protective role by the clearance of apoptotic bodies 
(Aguzzi et al., 2013; Ajami et al., 2011; Napoli and Neumann, 2010). Several studies 
have reported that Prnp removal leads to exacerbation of the EAE phenotype at various 
time points of EAE induction and/or progression (Gourdain et al., 2012; Ingram et al., 
2009; Tsutsui et al., 2008), using not only congenic Prnp-/- mice, but also coisogenic 
Prnp-/- mice and gene silencing approaches, such as RNAi (Hu et al., 2010). On the 
other hand, mice carrying a dominant-negative knock-in for Sirpa were shown to be 
resistant to EAE development (Tomizawa et al., 2007), suggesting that SIRPα is needed 
for EAE development. In light of these studies and our findings, we asked whether we 
could reproduce the reported effect of Prnp gene on EAE development and whether the 
B6/129 Sirpa polymorphism would additionally influence/modify the clinical course of 
EAE development. 
All EAE experiments were performed in collaboration with Sabine Spath (laboratory of 
Prof. Burkhard Becher, Institute of Experimental Immunology, University of Zurich). We 
MOG35-55-immunized B6129-PrnpZrchI/ZrchI mice carrying SirpaB6/B6, SirpaB6/129 or 
Sirpa129/129 alleles (Fig. 18, Fig. 19), and used B6 (henceforth termed B6-Prnpwt/wt 
SirpaB6/B6) and B6x129 (F1; henceforth termed B6129-Prnpwt/wt SirpaB6/129) mice as wild 
type controls. In two independent experiments, we scored the mice for 93 days and 79 
60 |  
 
 
 
days, respectively. Fig. 29 and Table 8 summarize the EAE clinical course and the 
detailed clinical development of all five experimental groups.  
 
 
Figure 29. Overview of EAE development in B6129-PrnpZrchI/ZrchI mice with all three 
combinations of Sirpa B6-, and 129-alleles and Prnpwt/wt controls on a B6-, or B6129-
background. Data are pooled from two independent experiments. Here and henceforth, graphs 
present mean disease scores, error bars are SEM. Detailed EAE disease course is summarized 
in Table 8. 
 
Mice Number 
of mice 
Incidence° 
(%) 
Mortality* 
(%) 
Mean day 
of onset 
(±SD) 
Mean maximal 
disease score 
(±SD) 
Mean cumulative 
disease score 
(±SD) 
B6129-PrnpZrchI/ZrchI 
Sirpa129/129 
16 10/16  
(62.5) 
4/16  
(25) 
16.70±10.14 3.5±0.5 96.0±40.7 
 
B6129-PrnpZrchI/ZrchI 
SirpaB6/129 
16 13/16 
(81.25) 
3/16 
(18.75) 
20.31±16.41 3.1±1.0 70.0±41.7 
B6129-PrnpZrchI/ZrchI 
SirpaB6/B6 
16 13/16 
(81.25) 
4/16  
(25) 
26.38±29.43 3.2±0.8 89.0±61.1 
B6129-Prnpwt/wt 
SirpaB6/129 
10 9/10  
(90) 
0/10  
(0) 
16.89±10.52 3.0±0.4 67.0±8.7 
B6-Prnpwt/wt 
SirpaB6/B6 
16 12/16  
(75) 
1/16 
(6.25) 
12.75±5.85 2.9±0.7 70.0±36.9 
 
Table 8. Detailed clinical EAE development in B6129-PrnpZrchI/ZrchI mice with all three 
combinations of Sirpa B6-, and 129-alleles, B6129-Prnpwt/wt SirpaB6/129 and B6- Prnpwt/wt 
SirpaB6/B6 mice.  Data are from two pooled experiments. B6129-Prnpwt/wt SirpaB6/B6 mice were 
included only in one experiment. The five groups did not significantly differ in mean day of onset 
(Kruskal-Wallis test, p=0.0695), mean maximal disease score (Kruskal-Wallis test, p=0.1268), or 
the mean cumulative disease score (Kruskal-Wallis test, p=0.5494). ° represents mice with a 
clinical score of at least one. * represents mice that died or were euthanized due to termination 
criteria.  
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We first assessed the effect of different Sirpa alleles (B6 vs. 129) on the clinical 
development of EAE in the absence of Prnp. We did not observe a difference in disease 
onset or disease severity between the 3 groups in the acute (day 11-22 p.i.), or 
remission phase (day 22-42 p.i.; Fig. 30). At day 14 p.i. (peak disease), all 3 groups 
showed comparable amounts of inflammatory infiltrates (CD3-positive T-cells and Iba-1-
positive microglia or monocyte-derived Iba-1-positive macrophages) in spinal cord (Fig. 
31) and brain sections. 
 
Figure 30. In the absence of Prnp, the B6/129 Sirpa polymorphism modulates the clinical 
severity of MOG-induced EAE. B6129-PrnpZrchI/ZrchI Sirpa129/129 mice show a more severe 
relapse phase than B6129-PrnpZrchI/ZrchI SirpaB6/129 mice (a) and than B6129-PrnpZrchI/ZrchI SirpaB6/B6 
mice (b). Data are pooled from two independent experiments (n=16 for each group); see Fig. 29 
for overview of all five experimental groups and Table 8 for detailed clinical development. *, 
p<0.05, two-tailed unpaired Student’s t-test. 
However, after day 43 p.i., B6129-PrnpZrchI/ZrchI homozygous for Sirpa129 had a 
significantly stronger relapse than B6129-PrnpZrchI/ZrchI SirpaB6/129 (Fig. 30a) and B6129-
PrnpZrchI/ZrchI SirpaB6/B6 (Fig. 30b) mice. In representative spinal cord sections at 92 day 
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p.i. (Fig. 32) B6129-PrnpZrchI/ZrchI Sirpa129/129 and B6129-PrnpZrchI/ZrchI SirpaB6/129 mice 
showed predominantly acute inflammatory infiltrates containing CD3-positive 
lymphocytes and Iba1-positive phagocytes, whereas B6129-PrnpZrchI/ZrchI SirpaB6/B6 mainly 
showed chronic, non-florid lesions with a more pronounced loss of myelin (LN) and 
larger NF-negative areas (Fig. 32). 
 
 
Figure 31. Similar amount of inflammatory infiltrates in B6129-PrnpZrchI/ZrchI mice with all 
three combinations of Sirpa B6-, and 129-alleles at day 14 post MOG-immunization (peak 
disease). Representative spinal cord sections of mice with disease score 3.0 (complete bilateral 
hind limb paralysis) - 3.25 (complete bilateral hind limb paralysis and unilateral partial fore limb 
paralysis). All three mice show a comparable amount of inflammatory cells mainly located in the 
spinal cord perivascular space (HE), consisting mostly of CD3-positive T cells and Iba1-positive 
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activated resident microglia or differentiated monocyte-derived Iba-1-positive macrophages. Scale 
bar 100 µm, except for upper panel: 500 µm. 
 
 
Figure 32. Sirpa129 promotes acute inflammatory lesions in B6129-PrnpZrchI/ZrchI mice. 
Representative spinal cords 92 days p.i.. B6129-PrnpZrchI/ZrchI Sirpa129/129 and SirpaB6/129 mice 
predominantly show acute inflammatory infiltrates. B6129-PrnpZrchI/ZrchI SirpaB6/B6 mice show 
mainly chronic, non-florid lesions with evidence of demyelination and concomitant axonal loss. 
Scale bar 100 µm, except for upper panel: 500 µm.  
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In summary, when inducing EAE in B6129-PrnpZrchI/ZrchI mice carrying different Sirpa 
allelotypes, homozygosity for Sirpa129 was associated with a more severe clinical disease 
course corresponding to a strong relapse phase associated with florid inflammatory 
lesions in the spinal cord. These data suggest that different Sirpa allelotypes (B6 and 
129) modulate the disease course of EAE in a B6129-Prnp-/- background. 
Next, we compared the EAE development of B6129-PrnpZrchI/ZrchI mice with different 
Sirpa-B6/129 alleles with the two Prnpwt/wt groups (B6-Prnpwt/wt SirpaB6/B6 and B6129-
Prnpwt/wt SirpaB6/129). Notably, B6129-PrnpZrchI/ZrchI Sirpa129/129 animals showed significantly 
higher disease score during the relapse phase than B6-Prnpwt/wt SirpaB6/B6 animals (Fig. 
33a). The presence of one or two SirpaB6 alleles abolished this difference: the clinical 
course of B6129-PrnpZrchI/ZrchI SirpaB6/129 and B6129-PrnpZrchI/ZrchI SirpaB6/B6 animals largely 
overlapped with the one of B6 wt animals (Fig. 33b). This finding suggests that the 
presence of at least one SirpaB6 allele can rescue the B6129-Prnp-/- phenotype.  
However, since the B6129-PrnpZrchI/ZrchI animals used in these experiments were on a 
mixed B6129 background (Fig. 19), we considered B6-Prnpwt/wt SirpaB6/B6 mice as a 
suboptimal control group. We therefore induced EAE also in F1-offsprings of a B6x129 
cross. To compare their genetic background to B6129-PrnpZrchI/ZrchI mice, we performed 
whole genome STR analysis. As expected, the genetic background of the B6x129 (F1) 
offsprings was similar but not identical to the B6129-PrnpZrchI/ZrchI mice (Fig. 34). We then 
compared the EAE development of B6129-Prnpwt/wt SirpaB6/129 and B6129-PrnpZrchI/ZrchI 
SirpaB6/129. Again, B6129-PrnpZrchI/ZrchI SirpaB6/129 mice showed a similar disease course 
as B6129-Prnpwt/wt SirpaB6/129 on a comparable mixed background (Fig. 35). These 
findings confirmed the observation that the lack of Prnp is not sufficient to aggravate the 
EAE disease course, when the mice do not differ in their Sirpa allelotypes.  
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Figure 33. EAE development in B6129-PrnpZrchI/ZrchI mice with Sirpa129/129, SirpaB6/129 or 
SirpaB6/B6 compared to B6-Prnpwt/wt SirpaB6/B6 mice. (a) B6129-PrnpZrchI/ZrchI Sirpa129/129 animal 
show a strong and continuous relapse phase after day 42 p.i., whereas disease scores B6-
Prnpwt/wt SirpaB6/B6 remain stable. (b) EAE disease scores of B6129-PrnpZrchI/ZrchI with SirpaB6/129 or 
SirpaB6/B6 and of B6-Prnpwt/wt SirpaB6/B6 overlap. The exacerbation during the relapse phase in 
B6129-PrnpZrchI/ZrchI mice is rescued by the presence of one or two SirpaB6 alleles. Data are 
pooled from two independent experiments (n=16 per group); see Fig. 29 for overview of all five 
experimental groups and Table 8 for detailed clinical development. * p<0.05, ** p<0.01, two-tailed 
unpaired Student’s t-test. 
 
 
Figure 34. Genetic background of B6129-PrnpZrchI/ZrchI SirpaB6/129 vs. B6129-Prnpwt/wt 
SirpaB6/129 is similar, but not equal. Box plots show percentages of 192 polymorphic STR 
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markers distributed across the whole genome in B6129-PrnpZrchI/ZrchI SirpaB6/129 (n=9) vs. B6129-
Prnpwt/wt SirpaB6/129 (n=8) mice. B6129-Prnpwt/wt SirpaB6/129 mice are F1-offsprings from a B6x129 
cross. Two-tailed Mann Whitney test (alpha level 0.05) revealed significant differences in the 
amount of B6 markers (****, p<0.0001), 129 markers (****, p<0.0001) and 129/C markers (**, 
p=0.0021). No difference was found for B6/129, C and B6/C markers. 
 
 
 
Figure 35. No difference of EAE development between SirpaB6/129 mice on a mixed B6129-
background differing in their Prnp (wt vs. ZrchI) status. Data are pooled from two 
independent experiments (n=16 for B6129-PrnpZrchI/ZrchI SirpaB6/129 and n=10 for B6129-Prnpwt/wt 
SirpaB6/129); see Fig. 29 for overview of all five experimental groups and Table 8 for detailed 
clinical development. Two-tailed unpaired Student’s t-test revealed no significant difference 
between the two groups. 
 
So far, we have found that i) in absence of Prnp, the B6/129 Sirpa polymorphism is 
sufficient to modulate EAE disease course, and ii) when comparing mice with and 
without Prnp on a similar (but not equal) mixed genetic background and having the same 
Sirpa allelotype, lack of Prnp did not lead to exacerbation of EAE. These results suggest 
that homozygosity for Sirpa129, rather than Prnp deficiency is responsible for the 
exacerbation of EAE in PrnpZrchI/ZrchI mice. 
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4.2.8 EAE development in congenic B6.129 mice with different 
combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) alleles 
 
Our studies in mice with a mixed background suggested that the B6/129 Sirpa 
polymorphism can modulate EAE disease course in the absence of Prnp, and that 
absence of Prnp is not sufficient for EAE exacerbation in groups of mice with a 
comparable genetic background and the same Sirpa allelotype. So far we could not 
exclude that the differences in background (Fig. 34) could complicate the interpretation 
of these results. In addition, we wanted to test whether the B6/129-Sirpa polymorphism 
could modulate EAE disease course also in the presence of Prnp. We therefore used 
congenic B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt mice, where we had screened for 
transallelic meiotic recombinations between the Prnp and Sirpa loci, thereby having 
created recombinant congenic B6.129 mice with different combinations of Prnp (wt and 
ZrchI) and Sirpa (B6 and 129) alleles on a highly homogeneous genetic background (Fig. 
21 and Fig. 22). We used these mice in experiments testing the reported inhibitory 
function of PrP on phagocytosis of apoptotic cells (de Almeida et al., 2005), and could 
show that not the lack of Prnp, but homozygosity for Sirpa129 leads to hyperphagocytosis 
of apoptotic cells. 
We MOG35-55-immunized four groups of congenic B6.129 mice with different 
combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) in two independent 
experiments and followed the clinical score for 52 and 61 days, respectively. Fig. 36 and 
Table 9 summarize the EAE clinical course and the detailed clinical development of all 
four experimental groups. In contrast to the results obtained in B6129-PrnpZrchI/ZrchI mice, 
the Sirpa B6/129-polymorphism did not modulate EAE disease course in B6.129-
PrnpZrchI/ZrchI with different Sirpa allelotypes: B6.129-PrnpZrchI/ZrchI Sirpa129/129 and B6.129-
PrnpZrchI/ZrchI SirpaB6/B6 showed overlapping disease scores (Fig. 36). We observed a 
different picture in the presence of Prnp: here, the Sirpa B6/129 polymorphism seemed 
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to influence EAE disease progression. But unexpectedly, and in contrast to the results 
obtained in B6129-PrnpZrchI/ZrchI animals, mice homozygous for SirpaB6 showed a more 
severe disease course than Sirpa129/129 animals (Fig. 36).  
 
 
Figure 36. EAE development in recombinant congenic B6.129 mice with different 
combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) alleles. Overview of the clinical 
evolution of the four experimental groups (n=16 per group, pooled two independent experiments). 
B6.129-Prnpwt/wt SirpaB6/B6 mice show a more severe clinical development than B6.129-Prnpwt/wt 
Sirpa129/129, B6.129-PrnpZrchI/ZrchI Sirpa129/129 and B6.129-PrnpZrchI/ZrchI SirpaB6/B6 mice. * p<0.05, ** 
p<0.01, two-tailed unpaired Student’s t-test. 
 
Mice Number 
of mice 
Incidence° 
(%) 
Mortality* 
(%) 
Mean day 
of onset 
(±SD) 
Mean maximal 
disease score 
(±SD) 
Mean cumulative 
disease score 
(±SD) 
B6.129-PrnpZrchI/ZrchI 
Sirpa129/129 
16 12/16 
(75) 
3/16 
(18.8) 
14.3±2.6 3.0±1.1 68.5±45.5 
B6.129-PrnpZrchI/ZrchI 
SirpaB6/B6 
16 13/16 
(81.3) 
1/16 
(6.3) 
13.2±1.2 3.1±0.5 
 
62.3±23.6 
B6.129-Prnpwt/wt 
Sirpa129/129 
16 14/16 
(87.5) 
1/16   
(6.25) 
15.2±4.4 3.0±0.7 63.0±29.3 
B6.129-Prnpwt/wt 
SirpaB6/B6 
13 13/13 
(100) 
5/13 
(38.5) 
14.5±2.1 3.6±0.6 83.3±27.1 
 
Table 9. Detailed clinical EAE development in recombinant congenic B6.129 mice with 
different combinations of Prnp (wt and ZrchI) and Sirpa (B6 and 129) alleles. Data are from 
two pooled experiments. The four groups did not significantly differ in mean day of onset (Kruskal-
Wallis test, p=0.4314), mean maximal disease score (Kruskal-Wallis test, p=0.2417), or mean 
cumulative disease score (Kruskal-Wallis test, p=0.3272). ° mice with a clinical score of at least 
one. * mice that died or were euthanized due to termination criteria. 
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We wondered, whether we could still observe different EAE disease scores between the 
groups when ignoring either the Prnp status or the Sirpa allelotype. When mice were 
pooled according to their Prnp genotype and irrespective of their Sirpa allelotype, 
B6.129-Prnpwt/wt mice showed a more severe disease course than B6.129-PrnpZrchI/ZrchI 
mice  (Fig. 37a). In contrast, when pooling the groups according to Sirpa allelotype and 
irrespective of their Prnp genotype, the difference between the groups was abolished 
(Fig. 37b), suggesting that the Sirpa B6/129 polymorphism does not modulate EAE 
development.  
 
 
Figure 37. Exacerbated EAE development in B6.129-Prnpwt/wt mice and no influence of the 
Sirpa B6/129 polymorphism. (a). Pooling of groups shown in Fig. 36 according to their Prnp 
genotype and irrespective of the Sirpa polymorphism (n=32 per group, two independent 
experiments). (c) Pooling of groups shown in Fig. 36 according to their Sirpa allelotype and 
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irrespective of the Prnp genotype (n=32 per group, two independent experiments). The B6/129 
polymorphism did not significantly influence EAE disease course. * p<0.05, ** p<0.01, two-tailed 
unpaired Student’s t-test. 
 
Taken together, these results do not support the hypothesis that Sirpa polymorphisms – 
rather than Prnp deficiency – modulate EAE disease course. On the other hand, we 
could not reproduce previously reported findings that the lack of Prnp exacerbates EAE 
(Gourdain et al., 2012; Hu et al., 2010; Ingram et al., 2009; Tsutsui et al., 2008; Williams 
et al., 2011). In contrary, in our hands, B6.129-Prnpwt/wt showed a more severe EAE 
development than B6.129-PrnpZrchI/ZrchI mice. These results suggest the influence of other 
polymorphic genes flanking Prnp and Sirpa, which exert a stronger effect on EAE 
disease course than Prnp and/or Sirpa. 
 
  
                                                                                                                                                    71 | 
 
 
 
4.3 DISCUSSION 
 
4.3.1 Mouse genetics excludes PrPC as inhibitor of phagocytosis  
One of the various functions attributed to PrPC based on studies in Prnp-/- mice kept on a 
mixed or congenic background is the inhibition of phagocytosis of apoptotic cells (de 
Almeida et al., 2005). Since studies using knockout animals generated as chimeras with 
different strains are subject to the confounding effect of polymorphic genes flanking the 
targeted locus, we sought to revisit the impact of PrPC gene dosage on phagocytosis of 
apoptotic cells. When using coisogenic Prnp-/- mice, which differ from their wild type 
counterpart only at the mutated site, but are otherwise are genetically identical, the 
inhibitory effect of PrPC on phagocytosis was no longer present. In addition, we analyzed 
the regions flanking Prnp in B6129-PrnpZrchI/ZrchI, and found a 129-derived segment, 
which, when homozygous, correlated with higher rate of phagocytosis independent of 
Prnp. Taken together, these data showed that Prnp does not impact phagocytosis, and 
suggests that the conclusion of previous studies resulted from unrecognized effects of 
polymorphic flanking genes, which were the in truth responsible for the observed effect. 
A detailed genomic, transcriptomic and functional analysis of candidate genes in the 
129-derived region flanking Prnp supports a focus on the well-characterized inhibitor of 
phagocytosis Sirpa, whose polymorphisms alter this phenotype (Legrand et al., 2011a; 
Strowig et al., 2011; Takenaka et al., 2007). Indeed, Sirpa129, rather than Prnp-, 
segregates with increased phagocytosis.  
The search for polymorphic candidate confounder genes was based on the detection of 
genetic variants in the transcriptome of pMΦ isolated from B6.129-PrnpZrchI/ZrchI and 
B6.129-Prnpwt/wt mice using RNA-Seq. We chose this approach because it permitted us 
to focus on (i) genes expressed only in our cells of interest, macrophages, and (ii) 
genetic variants only in protein-coding regions of genes possibly relevant for the function 
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of the protein in the execution of phagocytosis (Chepelev et al., 2009). Yet we have to 
consider several technical and conceptual limitations of the use of RNA-Seq and our 
subsequent filtering strategy to identify candidate confounding genes involved in 
phagocytosis (Fig. 15). For instance, it is highly unlikely, but not formally excluded that 
genes silent in macrophages – and therefore missed by RNA-Seq – could indirectly 
affect isolated, cultured macrophages, and ultimately account for the observed 
differences in phagocytic activity. Also, by using RNA-Seq, we did not consider variations 
in noncoding regions, which might potentially alter functional cis-regulatory elements that 
control transcription and possibly alter abundance of the transcripts.  Furtehrmore, we 
did not include differentially expressed genes into our candidate gene search strategy - 
yet differentially expressed genes could also influence the phagocytic phenotype. 
Interestingly, we found a significant proportion of differentially expressed genes mapping 
on Chr2. This finding could reflect the presence of DNA polymorphisms that regulate 
gene expression (cis-acting regulatory SNPs) in this region (Noyes et al., 2010). Also, 50 
of the 304 differentially expressed genes were found to be associated with phagocytosis, 
possibly influencing phagocytosis of apoptotic cells. To further examine whether the 
expression of these genes is influenced by Prnp, and to exclude the influence of different 
genetic backgounds on gene expression (Cowles et al., 2002), we will analyze the 
transcriptome of pMΦ derived from coisogenic 129-PrnpEdbg/Edbg and 129-Prnpwt/wt mice.  
In addition to Sirpa, B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt macrophages harbored 
sequence variations of several other genes of interest. In particular, we found that Mertk, 
Tyro3 and Thbs1, genes also implicated in phagocytosis, are linked to Prnp on Chr2, and 
polymorphic between the two strains. The segregation pattern of the B6 and 129 alleles 
of Tyro3 and Thbs1 in various hyperphagocytic Prnp-/- lines allowed us to dismiss these 
two genes as candidates. This was not possible for Mertk, since the allelotypes always 
followed the Sirpa allelotypes in all our experimental mice. The only non-synonymous 
coding SNP found between B6.129-PrnpZrchI/ZrchI and B6.129-Prnpwt/wt codes for a 
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conservative AA substitution within the transmembrane region of MER (I516V), and is 
predicted not to alter the function of this protein. The corresponding AA substitution is 
also present in humans and was classified as a non-disease causing normal variant. For 
these reasons, we excluded Mertk as a candidate gene. Yet we have to take into 
consideration that Mertk encodes a receptor protein tyrosine kinase (PTK), whose 
activation involves receptor dimerization (Lemke and Rothlin, 2008). Therefore, the 
transmembrane regions of these proteins are considered an important part of the 
signaling process and pathogenic mutations involving the transmembrane region of PTK 
have been identified in different cancers (Li and Hristova, 2010). To discriminate the 
effect of polymorphisms of Sirpa and Mertk, we would need to screen mouse breedings 
for the occurrence of transallelic meiotic recombination between Sirpa and Mertk, or 
alternatively, perform phagocytosis assays testing different Sirpa polymorphisms using 
compounds blocking MER signaling.  
Finally, we cannot rule out that additional polymorphic genes not yet implicated in 
phagocytosis, and thereby missed by our filtering strategy, may contribute to the 
phagocytic phenotype. Irrespective of potential contributions by these other genes, our 
data exclude a role for PrPC in the modulation of phagocytosis and strongly suggest 
polymorphisms of Sirpa as the cause of the previously reported phagocytic phenotype of 
Prnp knockout mice. 
 
4.3.2 Modulation of EAE development by Prnp and its polymorphic 
flanking genes – a blurry picture 
Encouraged by our findings that polymorphic flanking genes and not Prnp status, in 
particular Sirpa polymorphisms, explained the reported role of PrPC in phagocytosis, we 
strived to determine the influence of different Sirpa polymorphisms in combination with 
presence or absence of Prnp in the development of mouse EAE. When inducing EAE in 
PrnpZrchI/ZrchI mice on a B6129 background with all possible combinations of Sirpa129 and 
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SirpaB6 alleles, we found that B6129-PrnpZrchI/ZrchISirpa129/129 mice showed a more severe 
disease course, whereas SirpaB6/B6 homozygosity rescued the Prnp-/- phenotype, 
suggesting a role of the Sirpa B6/129 polymorphism in EAE development. The influence 
of Prnp was not detectable when comparing B6129-PrnpZrchI/ZrchI SirpaB6/129 with mice 
derived from a B6x129 crossing (B6129-Prnpwt/wt SirpaB6/129). As assessed by STR-
analysis, the background of each of the two groups was not well matched, since the F1 
wild type animals were heterozygous for all genes and the Prnp knockout group 
contained more B6-derived homozygous genes. Hence the lack of EAE exacerbation in 
Prnp-/- could be attributed to genetic background differences. Finally, we tested the effect 
of Sirpa polymorphisms and Prnp gene dosage using congenic Prnp-/- mice with all 
Prnp/Sirpa combinations. These experiments revealed the lack of influence of the Sirpa 
B6/129 polymorphism; however, a more severe EAE disease course in Prnp wild type 
mice was observed, in contrast to previously published findings. In summary, we found a 
potential influence of Sirpa and/or flanking genes in the absence of Prnp, and could not 
reproduce previous findings showing a protective role of PrPC in neuroinflammation 
(Gourdain et al., 2012; Hu et al., 2010; Ingram et al., 2009; Tsutsui et al., 2008; Williams 
et al., 2011). These findings raise the question whether one or several additional genes 
flanking Prnp and Sirpa might exert a stronger effect on disease course, and play a role 
in the outcomes observed in our experiments (Fig. 38). 
 
 
Figure 38. A polymorphic gene other than Prnp and Sirpa might influence EAE disease 
course. EAE severity was not influenced by Prnp, nor by the B6/129 polymorphism of Sirpa. Red 
and yellow boxes depict alleles of an unknown polymorphic flanking gene, which might be 
responsible for the observed differences in EAE disease course.  
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Are there any indications for the effect of such confounding effects in the previously 
published studies? In contrast to the phagocytosis phenotype found in congenic Prnp 
mice carrying confounding ESC-derived flanking genes, exacerbation of EAE also 
occurred in coisogenic Prnp mice, where knockout and wildtype mice differed only in 
Prnp. In this study, the use of siRNA to block Prnp provided additional support for a role 
of Prnp in EAE development. However, in comparison to studies performed in congenic 
Prnp-/- mice, the effect of Prnp ablation seemed rather low. In addition, EAE studies 
using of PrPC overexpression yielded inconsistent results, along with discrepant findings 
about a causative Prnp-dependent alteration in T cell activation. Possible explanations 
for these findings are variations in protocols and the use of mice with different genetic 
backgrounds. EAE is a highly complex model, and the susceptibility to EAE is known to 
be influenced by many genes, pathways and induction protocols (Baxter, 2007; 
Constantinescu et al., 2011; Gold et al., 2006). Another possible explanation might be 
the influence of another flanking locus that could alter EAE susceptibility to a greater 
extent than Prnp alone (Fig. 38), or in combination with Prnp.  
A similar complex situation was recently described in a model of kainate-induced 
seizures. Using congenic and coisogenic Prnp-/- strains, in combination with genetic 
complementation studies with a Prnp transgenic line, the authors disproved a previously 
attributed role of PrPC in alteration of synaptic and electrophysiological activities, and 
attributed this effect to unknown 129-derived flanking genes (Striebel et al., 2013). 
Hence, careful examination of the role of polymorphic genes flanking Prnp and their 
interactions is necessary to clarify their impact in such complex models as EAE or 
kainate-induced seizures. 
 
4.3.3 Concluding remarks  
The linkage of Sirpa129 to Prnp- in all analyzed Prnp-/- lines may contribute to processes 
beyond the control of phagocytosis. The Sirpa sequence of mouse strains typically 
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employed for backcrossing of Prnp-/- mice (e.g. C57BL/6, BALB/c, and FVB) differs from 
that of 129 mice (Sano et al., 1999; Takenaka et al., 2007), hence rendering Sirpa a 
potential confounder in most studies of Prnp-/- mice.  The expression pattern of Sirpa 
mirrors that of Prnp, and includes myeloid cells, hematopoietic stem cells, neurons and 
pancreatic β cells (Linden et al., 2008; Matozaki et al., 2009). Also, PrPC-deficient mice 
share numerous subtle phenotypes with mice lacking functional Sirpa, including 
behavioral (Gadotti et al., 2012; Nico et al., 2005; Ohnishi et al., 2010) and metabolic 
phenotypes (Kobayashi et al., 2008; Strom et al., 2011). These observations suggest 
that additional and also non-immunological phenotypes attributed to Prnp may reflect the 
effects of polymorphic Sirpa.  
The confounding effects of ESC-derived genes flanking the targeted locus are known 
(Gerlai, 1996; Smithies and Maeda, 1995), and there are recommendations regarding 
breeding schemes and genetic quality control of mouse colonies (Crusio et al., 2009; 
Ridgway et al., 2007; Wolfer et al., 2002) – but they are rarely implemented (Holmdahl 
and Malissen, 2012). Consequently, reports of flanking gene problems are rare and 
mostly rely on the observation that a certain phenotype of knockout mouse can be 
rescued via extensive backcrossing to a specific background after reduction of the 129-
derived region flanking the targeted locus (de Ledesma et al., 2006; Eisener-Dorman et 
al., 2010; Kanagawa et al., 2000; Schalkwyk et al., 2007), and rarely demonstrate the 
effect of flanking genes using a coisogenic line (Striebel et al., 2013). Accordingly, a 
solution to this problem is the use of coisogenic knockout animals, such as the 
Edinburgh-Prnp-/- line in the prion field – yet they are rarely available. Today’s possibility 
to use B6-derived ESC for the generation of knockout animals (Pettitt et al., 2009; Seong 
et al., 2004), and new efficient genome editing technologies (Horvath and Barrangou, 
2013; Joung and Sander, 2013) will hopefully advance the generation of coisogenic 
knockout lines. However, it is important to keep in mind that also these lines are subject 
to spontaneous mutations and must therefore be regularly screened for genetic stability. 
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Finally, these new tools may also help to resolve unanswered questions regarding the 
function of the prion protein - in the immune system and beyond. 
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4.4 MICE, MATERIAL AND METHODS 
 
4.4.1 Mice 
The following mice were analysed: PrnpZrchI/ZrchI mice (Büeler et al., 1992), on a mixed 
B6129 background or backcrossed to B6 for >12 generations or to C for >17 generations 
and congenic wild-type B6 and C mice purchased from Harlan or Charles River or bred 
in house; PrnpNgsk/Ngsk (Sakaguchi et al., 1995) extensively backcrossed to B6; 
PrnpEdbg/Edbg mice on a pure 129/Ola background (Manson et al., 1994) and coisogenic 
wild-type 129/Ola mice; PrnpZrchII/ZrchII mice (Rossi et al., 2001) on a mixed B6129 
background; PrnpGFP/GFP mice (Heikenwalder et al., 2008) backcrossed to B6 for 10 
generations; tga20 mice (Fischer et al., 1996) on a mixed B6129 PrnpZrchI/ZrchI 
background; SHPS-1 (Inagaki et al., 2000) backcrossed to B6 for >5 generations. Mice 
were genotyped as indicated in the original description of each line. To introduce SirpaB6 
into B6129-PrnpZrchI/ZrchI mice, B6129-PrnpZrchI/ZrchI SirpaB6/B6 tga20tg/tg mice were crossed 
with B6129-PrnpZrchI/ZrchI Sirpa129/129 mice (Fig. 18). To generate congenic B6.129-
PrnpZrchI/ZrchI and Prnpwt/wt mice with all possible combinations of SirpaB6 and Sirpa129 
alleles, B6.129-Prnpwt/ZrchI SirpaB6/129 mice were intercrossed and meiotic recombination 
events between Prnp and Sirpa were identified by Prnp genotyping and RFLP analysis of 
Sirpa exon 2 in the offspring (Fig. 21). Mice with a recombinant haplotype (referred to as 
obligate carriers) were further crossed as shown in Fig. 21. The same approach was 
followed to generate congenic C.129-PrnpZrchI/ZrchI and Prnpwt/wt mice with all possible 
combinations of SirpaC and Sirpa129 alleles (Fig. 26). All animal experiments were 
performed in compliance with the Swiss Animal Protection Law, with the approval of the 
Veterinary office of the Canton Zurich. 
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4.4.2 RNA-Seq 
All steps of RNA-Seq were performed at the FGCZ. All bioinformatics analyses were 
performed by Giancarlo Russo, FGCZ. 
 
Library preparation 
Total RNA was isolated from cultured pMΦ using the RNeasy mini Kit (QIAGEN), snap 
frozen and kept at -80°C until further analysis. RNA quality was determined with a Qubit 
(1.0) fluorometer (Life Technologies) and a Bioanalyzer 2100 (Agilent). Only samples 
with a 260 nm/280 nm ratio between 1.8–2.1 and a 28S/18S ratio between 1.5–2 were 
further processed. The TruSeq RNA Sample Prep Kit v2 (Illumina) was used in the 
subsequent steps. Briefly, total RNA samples (1 μg) were poly A-enriched and reverse-
transcribed into double-stranded cDNA. TruSeq adapters were ligated to double-
stranded cDNA. Fragments containing TruSeq adapters on both ends were selectively 
enriched with PCR. The quality and quantity of the enriched libraries were validated 
using Qubit (1.0) Fluorometer and Caliper GX LabChip GX (Caliper Life Sciences). The 
product is a smear with an average fragment size of approximately 260 bp. Libraries 
were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% (v/v) Tween-20. 
 
Cluster generation and sequencing 
The TruSeq PE Cluster Kit v3-cBot-HS (Illumina) was used for cluster generation using 2 
pM of pooled normalized libraries on the cBOT. Sequencing was performed on the 
Illumina HiSeq 2000 paired end at 2 X101 bp using TruSeq PE Cluster Kit v3-cBot-HS 
(Illumina). 
 
Data analysis 
Reads were quality-checked with fastqc. Low quality ends were clipped (3 bases from 
the start, 10 bases from the end). Trimmed reads were aligned to the reference genome 
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and transcriptome (fasta and gff files, respectively, UCSC mm10 database) with tophat v 
2.0.6. Tophat was run with the following options: mate inner distance set to 30, the 
corresponding standard deviation to 100, maximum 10 multi-hits were allowed in the 
alignment. Reads that did not align at the first attempt were split into 25-bases long 
sections on which a second attempt of alignment was performed. In B6.129-PrnpZrchI/ZrchI 
pMΦ, all reads mapping to Prnp between BstEII and EcoRI restriction sites in exon 3 and 
in the 3’UTR, respectively, were excluded from the analysis because they might have 
represented fused mRNA containing neo and residual Prnp, as reported in the brain of 
these mice (Büeler et al., 1992). Polymorphisms were detected using GATK v 2.1.8 
using following options: baq Gap open penalty (whole-genome analysis) set to 30; 
minimum consensus coverage to genotype indels set to 8 (default: 5); minimum base 
quality score and minimum variants phred score set to 15. Variants were annotated 
using snpEFF v 3.0 and distribution of the reads across genomic isoform expression was 
quantified using http://www.biomedcentral.com/1471-2105/12/323 cufflinks v 2.0.2 and 
differentially expressed genes listed with its utility Cuffdiff using default options. All 
remaining data and statistical analyses, formatting and pictures-generating was 
produced via in-house R-scripts (R v 2.15.2). 
 
4.4.3 RFLP and sequencing analysis of candidate genes 
To distinguish Sirpa129 vs SirpaB6 or SirpaC, Tyro3129 vs Tyro3B6, or Thbs1129 vs Thbs1B6 or 
Thbs1C alleles, gDNA was PCR-amplified using the primers listed below and amplicons 
were digested with the restriction enzymes listed below. Digestion products were 
separated by electrophoresis on an agarose gel. To distinguish Mertk129 vs MertkB6, 
gDNA was was PCR-amplified using the primers listed below and amplicons were 
sequenced. In the candidate recombinant mice identified in the screening for meiotic 
recombination between Prnp and Sirpa, recombinant haplotypes were confirmed by 
sequencing of Sirpa ORF and genotyping the resulting offspring. 
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For RFLP analysis of Sirpa (5’3’):  
Gene Forward primer Reverse primer Restriction 
enzyme 
RFLP 
Sirpa 
B6vs129 
CCGTTCTGAACTGCACTTTG  GGGGTGACATTACTGATACGG AvaI 
RFLP 
Sirpa 
Cvs129 
ACAGAGGAGTAGGGCAAAGC  TAGGTACCGGCATCTTCTGG XmnI 
 
For RFLP analysis of Tyro3 (5’3’):  
Gene Forward primer Reverse primer Restriction 
enzyme 
RFLP 
Tyro3 
B6vs129 
GGGATTAAAGGATCCGGCCC CACCTTCGACAGTGAGCCAT HpyCH4III 
 
For RFLP analysis of Thbs1 (5’3’):  
Gene Forward primer Reverse primer Restriction 
enzyme 
RFLP 
Thbs1 
B6vs129 
GGATAGCCAAGCGTCTGGAG TCGCATCTGTTGTTGAGGCT Cac8l 
 
For Mertk sequencing (5’3’): 
Gene Forward primer Reverse primer 
Mertk TGGTCTGCAGTAAGCCCTTG AAGGTAAGCTCGATGGCTCG 
 
For Sirpa ORF sequencing (5’3’): 
Gene Forward primer Reverse primer 
Sirpa
-1 
AGTCCACCTTAAGAGGACCAAGTAGC TGTACAGAAACAGGACGCGGA 
Sirpa
-2 
TCTCCCTCCTTGCTCTGCAG TACCTCGCAGATGACCTTAGAATTAA 
Sirpa
-3 
CCTAGTGGAAAGAATGTCTCCTACAAC
A 
CATATTCTGTGTGGTTGTTAGGCTCA 
Sirpa
-4 
CCAGGTACAGTCTTTGATCCAGGA CCAGGGAGTCTCTGCTGGTCTA 
Sirpa
-5 
ACCCCAGGTTGCGTCCTTGA GTGGGTGGTTTGCCCTGGCT 
Sirpa
-6 
CCAATGCTGACCTAATGTTGGC CATCTATACACCCGTGTGTGTATACAC
A 
Sirpa
-7 
AACTTGTCTTTGTCCGGGCC GGCACAGTTCATCCTCACCC 
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4.4.4 Genome-wide and Chr2 STR analysis 
Genome-wide STR analysis was performed as previously described (Bremer et al., 
2010). Briefly, purified gDNA was amplified using multiplex PCR with fluorescently 
labelled primers (FAM, NED, VIC; Applied Biosystem), diluted, denatured and subjected 
to capillary electrophoresis on a 3130xl Genetic Analyzer (Applied Biosystems). Various 
mouse strains were used for calibration. Peak detection, binning and allele calling were 
performed using the GeneMapper software in combination with an in-house–developed 
software.  
 
4.4.5 High-resolution microsatellite genotyping on Chr2 
This analysis was performed in collaboration with Jayne Danska and Steven Martin-Toth 
(Hospital for Sick Children, University of Toronto). Novel microsatellite markers were 
generated as previously described (Ivakine et al., 2006). DNA was amplified for 35 
cycles: 30s at 94°C, 30s at 55°C, 1min at 72°C using Multiplex Master Mix (Qiagen 
#206143) using the following microsatellite markers: 
For high resolution microsatellite genotyping on chromosome 2  (5’3’): 
Marker_ID primer1 primer2 
D2Jyh582 ACTAAGCCCAACACAGCCTT GCCTACCATATGCAAGACCC 
D2Jyh1192 TCTCTTTGACTTTCACACATGC CCCTGTGAGTGACAGAGGTATC 
D2Gul161 GTGGCTCTTTCTCCTGTTCC GTATGCATGTATGTTTATGTGTGGT 
D2Gul169 TGCCTGAAGCTAACTACAGTGTAC CATCATCATTATCAGAAGCATGTT 
D2Ngul154
3 
GATGTACAGAGGGCACTGCA AGTCACCTATGTTGGATGTACCAC 
D2Ngul158
6 
ATGGGCTGATGATGTCACA AGGTCCACATCCATACAGCA 
D2Gul289 GGGAACTGACTTAGATCCTAAAAG
T 
CTGGCACACAACCCCC 
D2Ngul167
7 
ACCTCCAAAGCAGAATCCTC TCCACACTCTAAAGGGATCAAG 
D2Ngul168
6 
CTCGAGAGTACATACGCATGC AGCAAGACACCTGATAGTACGTG 
D2Ngul176
1 
TGTGGAGCAGGTGACGTC AGCCTCACCTCATGAAAGCT 
D2Ngul179
7 
TTTCCCCAAAACCAGCAT GATTTCTTTCCATTCCCCAA 
D2Ngul181 ACTGTTGTGGCCAAAATGG CCTGCACAGTCTTTGTTGTTG 
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6 
D2Ngul184
9 
AGGTGAAGGGTTATTTCTGGAC CCAGGACAGCTTCTAGTAGTGTCT 
D2Ngul186
5 
TTAAACAGGAATTCTTTCAACATTT ATAAGCTGTGCTCTGGCCTT 
D2Ngul188
8 
ACCACTTCGATATCATTGGGA GCCCTGCAAACACTAAATCA 
D2Ngul193
7 
GCTCATGTCCTTCCAAGAATG GGGAAGAAGAGGAAGGAATTG 
D2Jyh2400 GCAATACCTCCAGCAATTTGT CCATCCTACCAAAAGTAATCCA 
D2Jyh2407 CAGTGAGACCCTGTCTCAAAA CTGCCTTCCTAGAGCTGTCTT 
D2Gul374 ATGACTTAAGCATTTTAAGCCAAA CCCCCCAACTTTAAACACA 
D2Gul399 CAGCAGGTAAGAGCCCTTG TGAAATTATTTTTGTCCTTTTTTGT 
D2Gul498 GACCCTGCAGATCTCAGCA CATTTTTCTAATCATTTATGTCTTATGT
G 
The PCR product was diluted 1/20, and 1 µl mixed with a 10 µl mixture containing 
formamide and a 500LIZ size standard. Samples were resolved on the 3730XL DNA 
Analyzer (Applied Biosystems). Alleles were sized, in comparison to standards, by 
viewing electropherograms in GeneMapper (Applied Biosystems) 
4.4.6 Phagocytosis assay with pMΦ 
On day 0, peritoneal cells were collected from age- and gender-matched adult mice 
according to standard methods (Fortier and Falk, 2001), resuspended to 2.2 x 106 in 5 ml 
of DMEM (GIBCO) with 10% foetal bovine serum (FBS, GIBCO), 1% Glutamax (GIBCO) 
and antibiotics, plated in one-well slide chambers (BD Falcon) and incubated at 37°C. 
After 2 hours, non-adhering cells were removed and the remaining cells (referred to as 
cultured pMΦ) were kept overnight in culture. On day 1, thymocytes were harvested from 
3 to 8 week-old mice of the same background as the genotypes under investigation, 
incubated for 3 hours at 37°C in the presence of dexamethasone 1 µM to induce 
apoptosis, washed and added to the cultured pMΦ at different ratios for 1 hour. For each 
experimental group, technical replicates (at least duplicates) were performed. Cells were 
washed, fixed with formalin and stained with May-Grünwald-Giemsa. Slides were 
randomized, scanned with Nanozoomer (Hamamatsu), random fields (50 fields/slide) 
were generated and phagocytosis rate was assessed using in-house developed 
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software. The same operator blinded to experimental groups validated all software-
analysed slides. For each technical replicate, >800 cells were evaluated (indicated as a 
dot in the graphs). Phagocytosis rate was defined as the percentage of macrophages 
having at least one apoptotic body. 
 
4.4.7 Phagocytosis assay with BMDM 
On day 0 femurs were collected from age and gender-matched adult mice and flushed 
with RPMI1640 medium (GIBCO) containing 10% FBS (GIBCO) 1% Glutamax (GIBCO) 
and antibiotics. Bone marrow cells were plated into 6 well plates at 2 x 106/well in 3 ml 
culture medium containing 10 ng/ml of M-CSF (Invitrogen) and cultured overnight at 
37°C. On day 1, cells were transferred to new 6 well plates to remove loosely adherent 
stroma-like cells. On day 6, cells were harvested, adjusted to 5 x 105 cells in 500 µl and 
plated into 24 well plates. Apoptotic thymocytes (see above) were suspended at 1 x 
106/ml in PBS and labeled with 20 ng/ml of the pH-sensitive dye pHrodo Red, SE 
(Invitrogen) for 30 minutes at room temperature, washed, and 500 µl of cell suspension 
were added to BMDM culture for 1 hour at 37°C. After washing, BMDM were harvested 
with Accutase (Invitrogen) and gentle scraping, stained with FITC-labeled anti-CD11b or 
isotype control antibody (BD Bioscience) and rate of phagocytosis was analyzed by flow 
cytometry as the percentage of pHrodo positivity among CD11b+ cells. At least 10000 
events were acquired in the living gate. 
 
4.4.8 Flow cytometric analysis 
Freshly isolated peritoneal cells were incubated with FITC-labelled anti-F4/80 or isotype 
control antibody (BD Pharmingen). Thymocyte apoptosis was assessed using the FITC 
Annexin V Apoptosis Detection Kit II (BD Pharmingen). Flow cytometry was performed 
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using a FACSCalibur or a FACSCanto (BD Bioscience), data were acquired with 
CellQuestPro or FACS Diva software, respectively, and analysed with FlowJo software. 
 
4.4.9 Immunofluorescence 
After interaction with pHrodo-labeled apoptotic thymocytes, BMDM were washed, fixed 
with 4% paraformaldehyde for 10 min, and stained with FITC anti-mouse F4/80 
(Biolegend) and DAPI (Sigma). Images were acquired using FluoView FVi confocal 
microscope (Olympus) and analyzed using Imaris software (Bitplane). 
 
4.4.10 Induction of EAE and clinical evaluation 
On day 0, mice were immunized s.c. with 200 μg MOG35-55 peptide in CFA in the lateral 
abdomen. 200 ng pertussis toxin in PBS was administered i.p. on day 0 and day 2. Mice 
were scored daily as follows: 0, no detectable signs of EAE; 0.5, distal limp tail; 1.0, 
complete limp tail; 1.5, limp tail and hind-limb weakness; 2, unilateral partial hind-limb 
paralysis; 2.5, bilateral partial hind-limb paralysis; 3, complete bilateral hind-limb 
paralysis; 3.5, complete hind-limb paralysis and partial forelimb paralysis; 4, moribund 
(total paralysis of forelimb and hind limb); and 5, death. Statistical analysis was 
performed using an unpaired Student’s t test, and P values less than 0.05 were 
considered significant. 
 
4.4.11 Histology and immunohistochemistry 
Whole mouse brains and spinal cords were fixed in 4% paraformaldehyde in phosphate-
buffered saline, decalcified in (10%) ethylenediaminetetraacetic acid and paraffin-
embedded. Slides were stained with HE, LN, Iba-1 (Wako, #019-19741), CD3 (SP7, 
Dako), neurofilament (NE14, Sigma) and GFAP (Dako, #Z0334). 
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4.4.12 Statistical analysis 
Comparisons of phagocytic activity of macrophages of different genotypes were 
performed using One-way ANOVA and Bonferroni’s multiple comparison post-test (alpha 
level 0.05), or two-tailed unpaired t-test, using GraphPad Prism software. The statistical 
test, p-values and n for each statistical analysis are indicated in the corresponding figure 
legends. For EAE experiments, data are presented as mean EAE clinical score ± 
standard error of the mean (SEM). Groups were compared at single timepoints using 2-
sided unpaired Student’s t-test using an alpha of 0.05. All analyses were performed 
using GraphPad Prism software.  
 
  
                                                                                                                                                    87 | 
 
 
 
4.5 SUPPLEMENTARY TABLES 
 
4.5.1 Supplementary Table 1. List of differentially expressed genes in pMΦ 
of B6.129-PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt identified by RNA-Seq. 
 
The table below lists 304 differentially expressed identified by RNA-Seq (p<0.05), sorted 
by Log2–fold change (Fig. 12). Chr2 contains significantly more differentially expressed 
genes (genes on Chr2 in yellow). This clustering is even more pronounced when 
considering the highly differentially expressed genes (absolute Log2-fold change > 1) and 
correcting for chromosome size. 
 
Gene Locus FPKM 
WT 
FPKM 
KO 
Log2-fold 
change 
p-value q-value Phag. * SNPs
§ 
Spint1 chr2:119237359-
119249513 
55.71 0.56 -6.63 0.00E+00 0.00E+00 - - 
Jmjd7 chr2:120027482-
120032604 
1.15 0.03 -5.31 4.13E-06 4.37E-04 - - 
Bub1b chr2:118598210-
118641592 
2.15 0.1 -4.47 0.00E+00 0.00E+00 - - 
Gpr176 chr2:118277097-
118373419 
0.9 0.05 -4.31 2.55E-13 1.35E-10 - - 
Prnp chr2:131909927-
131938431 
7.96 0.42 -4.24 0.00E+00 0.00E+00 + - 
Slc15a2 chr16:36750163-
36784962 
1.11 0.22 -2.33 6.35E-07 8.25E-05 - - 
Hpgds chr6:65117292-
65144730 
0.78 0.18 -2.13 1.17E-06 1.39E-04 - - 
Mamdc2 chr19:23302608-
23448322 
0.7 0.17 -2.06 5.10E-06 5.25E-04 - - 
Cdo1 chr18:46713204-
46728342 
4.44 1.2 -1.89 1.34E-08 3.01E-06 - - 
Rhov chr2:119269200-
119271226 
11.06 3.01 -1.88 3.11E-15 2.78E-12 - - 
Hpgd chr8:56294551-
56321046 
4.1 1.27 -1.69 7.18E-08 1.19E-05 - - 
AA467197,Mir14
7 
chr2:122637886-
122641076 
7.7 2.4 -1.68 8.17E-06 7.66E-04 - - 
Gcnt1 chr19:17326140-
17372844 
10.23 3.57 -1.52 1.78E-15 1.72E-12 - - 
Arhgap22 chr14:33216822-
33369936 
1.81 0.64 -1.5 1.25E-05 1.11E-03 - - 
8430406I07Rik chr2:144271034-
144281229 
6.07 2.23 -1.45 1.95E-10 6.29E-08 - + 
Arhgap19 chr19:41766587-
41802084 
4.69 1.75 -1.42 1.02E-11 3.85E-09 - - 
Dkk2 chr3:132085291-
132180304 
3.76 1.44 -1.38 4.51E-09 1.12E-06 - - 
C1qc chr4:136889801-
136892914 
286.23 114.96 -1.32 0.00E+00 0.00E+00 + - 
LOC100038947 chr3:15795146-
15848487 
8.92 3.65 -1.29 1.19E-07 1.89E-05 - + 
Gas6 chr8:13465373-
13494535 
2.37 0.98 -1.27 3.01E-05 2.27E-03 + - 
E2f2 chr4:136172393- 0.74 0.31 -1.26 5.50E-04 2.61E-02 - - 
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136196056 
Rab3il1 chr19:10018227-
10035586 
4.85 2.05 -1.25 5.25E-07 7.11E-05 - - 
Cadm1 chr9:47530351-
47853385 
6.32 2.67 -1.24 2.05E-10 6.43E-08 - - 
Sirpb1b chr3:15495753-
15575065 
3.26 1.4 -1.22 2.37E-04 1.29E-02 - - 
Ophn1 chrX:98557514-
98890985 
3.2 1.37 -1.22 2.14E-07 3.23E-05 - - 
Slc46a3 chr5:147878440-
147894802 
7.81 3.46 -1.17 3.12E-08 6.38E-06 - - 
Slc27a6 chr18:58556239-
58612869 
1.62 0.72 -1.17 5.82E-04 2.74E-02 - - 
C1qb chr4:136880144-
136886177 
405.41 181.39 -1.16 1.53E-14 1.19E-11 + - 
Olfml3 chr3:103735393-
103738001 
14 6.3 -1.15 8.99E-09 2.14E-06 - - 
Apoc1 chr7:19689480-
19692658 
30.41 14.03 -1.12 4.29E-05 3.10E-03 - - 
Man2a2 chr7:80349096-
80371375 
14.1 6.5 -1.12 4.22E-14 3.07E-11 - - 
Spg11 chr2:122028582-
122118386 
8.82 4.1 -1.1 2.39E-08 4.97E-06 - + 
Stard13 chr5:151037514-
151190193 
1.52 0.71 -1.1 4.01E-04 1.99E-02 - - 
Gm11710 chr11:115031485-
115037769 
23.93 11.13 -1.1 8.57E-07 1.07E-04 - - 
C1qa chr4:136895915-
136898844 
324.73 152.9 -1.09 2.27E-13 1.26E-10 + - 
Sepp1 chr15:3270766-
3280508 
139.37 66.18 -1.07 1.47E-12 6.60E-10 - - 
Aif1 chr17:35170991-
35176001 
20.99 10.02 -1.07 9.23E-07 1.13E-04 + - 
Enpp1 chr10:24641410-
24712102 
5.7 2.74 -1.06 3.17E-07 4.67E-05 - - 
Fcgr4 chr1:171018925-
171029761 
4.7 2.26 -1.05 8.21E-04 3.53E-02 + - 
Apcdd1 chr18:62922326-
62953195 
4.55 2.2 -1.05 7.79E-06 7.60E-04 - - 
Rnf150 chr8:82863355-
83091271 
2.58 1.27 -1.03 4.74E-08 8.36E-06 - - 
Gm11710 chr11:115020727-
115027012 
7.8 3.82 -1.03 6.09E-04 2.85E-02 - - 
Tmem37 chr1:120067376-
120073780 
54.21 27.01 -1.01 1.04E-09 2.95E-07 - - 
Apoc2 chr7:19671578-
19676864 
76.59 38.56 -0.99 1.20E-08 2.73E-06 - - 
Cd300lh chr11:115042130-
115048295 
24.25 12.33 -0.98 7.95E-06 7.64E-04 - - 
Ms4a7 chr19:11321405-
11336116 
60.5 30.74 -0.98 5.87E-08 9.91E-06 - - 
Siglec1 chr2:131069219-
131086765 
7.72 3.95 -0.97 2.03E-09 5.24E-07 - - 
Ccr5 chr9:124121542-
124127183 
31.57 16.11 -0.97 5.44E-11 1.86E-08 + - 
Arhgap15 chr2:43748823-
44387623 
4.98 2.57 -0.95 2.39E-05 1.92E-03 + - 
Lgals1 chr15:78926724-
78930465 
52.22 27.08 -0.95 3.51E-08 6.81E-06 + - 
Zfyve19 chr2:119172499-
119217050 
10.5 5.47 -0.94 8.84E-06 8.04E-04 - + 
Lgmn chr12:102394097-
102439697 
325.24 170.66 -0.93 8.13E-09 1.97E-06 - - 
Egr1 chr18:34861206-
34864956 
3.5 1.83 -0.93 1.28E-04 7.78E-03 + - 
Fos chr12:85473900-
85477270 
9.36 4.99 -0.91 6.93E-06 7.02E-04 + - 
Eif2ak4 chr2:118388616-
118475234 
7.03 3.86 -0.86 6.65E-07 8.50E-05 - + 
BC055004 chr5:138225903-
138251875 
5.34 2.96 -0.85 2.13E-04 1.19E-02 - - 
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C530028O21Rik chr6:124996719-
125003097 
9.76 5.46 -0.84 1.45E-04 8.60E-03 - - 
Sorl1 chr9:41968488-
42124289 
2.01 1.13 -0.83 1.24E-04 7.65E-03 - - 
Enc1 chr13:97241104-
97253040 
10.23 5.76 -0.83 1.82E-07 2.82E-05 - - 
Thbd chr2:148404470-
148408188 
12.48 7.05 -0.82 3.16E-07 4.67E-05 - - 
Fam125b chr2:33729955-
33887946 
10.54 6.07 -0.79 3.56E-07 5.05E-05 - - 
Igfbp4 chr11:99041259-
99052643 
9.82 5.7 -0.79 7.61E-05 4.97E-03 - - 
Fam105a chr15:27655070-
27681542 
11.69 6.77 -0.79 1.32E-05 1.14E-03 - - 
Fabp4 chr3:10204342-
10208576 
380.32 221.92 -0.78 4.69E-08 8.36E-06 - - 
Dock4 chr12:40446052-
40846488 
5.59 3.25 -0.78 9.36E-07 1.13E-04 - - 
Stab1 chr14:31134852-
31168641 
25.8 15.06 -0.78 1.10E-07 1.77E-05 + - 
Fcgr1 chr3:96282908-
96293969 
17.19 10.12 -0.76 2.15E-06 2.48E-04 + - 
Klra2 chr6:131219234-
131247362 
15.11 8.9 -0.76 3.31E-05 2.46E-03 - - 
Daglb chr5:143464492-
143504442 
23.16 13.85 -0.74 5.73E-07 7.66E-05 - - 
Rasgrp3 chr17:75435904-
75529053 
10.9 6.51 -0.74 2.65E-05 2.07E-03 + - 
Pld4 chr12:112760654-
112768986 
51.58 31.02 -0.73 3.41E-07 4.89E-05 + - 
Ms4a6c chr19:11469367-
11482196 
80.23 49.42 -0.7 2.63E-05 2.07E-03 - - 
Sh3bgrl2 chr9:83548337-
83600291 
9.41 5.81 -0.69 4.81E-05 3.40E-03 - - 
Malat1 chr19:5795689-
5802671 
124.79 77.55 -0.69 9.25E-04 3.85E-02 - - 
Zfp395 chr14:65358675-
65398930 
6.12 3.82 -0.68 1.69E-04 9.85E-03 - - 
Mafb chr2:160363676-
160367065 
107.2 67.27 -0.67 6.93E-06 7.02E-04 + - 
Hgf chr5:16553549-
16619439 
7.8 4.88 -0.67 3.83E-04 1.92E-02 + - 
Mtus1 chr8:40990911-
41133726 
36.97 23.21 -0.67 3.81E-06 4.14E-04 - - 
Abcc3 chr11:94343294-
94392976 
13.59 8.55 -0.67 7.05E-06 7.08E-04 - - 
Gpcpd1 chr2:132529082-
132578248 
20.04 12.71 -0.66 3.63E-05 2.67E-03 - - 
Fabp5 chr3:10012605-
10016610 
329.2 207.78 -0.66 4.30E-06 4.47E-04 - - 
Engase chr11:118476959-
118489198 
23.36 14.74 -0.66 3.66E-06 4.01E-04 - - 
Arg1 chr10:24915206-
24927470 
321.13 204.41 -0.65 1.17E-04 7.34E-03 + - 
Zdhhc14 chr17:5492599-
5753891 
6.52 4.16 -0.65 8.07E-04 3.50E-02 - - 
Zranb3 chr1:127954185-
128102408 
5.04 3.24 -0.63 6.94E-04 3.13E-02 - - 
Fry chr5:150259929-
150497753 
4.46 2.88 -0.63 5.10E-05 3.57E-03 - - 
Iqgap2 chr13:95627176-
95891922 
28.48 18.37 -0.63 1.35E-05 1.16E-03 - - 
Cd244 chr1:171559192-
171585316 
5.69 3.7 -0.62 1.04E-03 4.17E-02 - - 
Frmd4b chr6:97286866-
97617657 
12.44 8.11 -0.62 3.18E-05 2.39E-03 - - 
Lair1 chr7:4007072-
4063204 
9.79 6.37 -0.62 3.00E-04 1.57E-02 - - 
Maf chr8:115703252-
115706894 
6.89 4.48 -0.62 6.60E-04 3.02E-02 + - 
Sgsh chr11:119314786-
119355510 
7.99 5.2 -0.62 2.03E-04 1.14E-02 - - 
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Rassf2 chr2:131992849-
132029988 
38.85 25.54 -0.61 1.84E-05 1.53E-03 - - 
Clec12a chr6:129350243-
129365303 
16.78 10.96 -0.61 2.03E-04 1.14E-02 - - 
Mr1 chr1:155127877-
155146780 
9.38 6.18 -0.6 1.04E-03 4.17E-02 - - 
Usp35 chr7:97309379-
97325964 
6.56 4.31 -0.6 7.55E-04 3.35E-02 - - 
Ssh2 chr11:77216424-
77460219 
20.58 13.61 -0.6 2.51E-05 2.00E-03 - - 
Epas1 chr17:86753863-
86833410 
10.55 6.95 -0.6 6.78E-05 4.49E-03 - - 
Kif13b chr14:64652530-
64806296 
11.4 7.58 -0.59 6.46E-05 4.32E-03 - - 
Dhrs3 chr4:144892826-
144927645 
90.01 60.34 -0.58 5.25E-05 3.66E-03 - - 
Per3 chr4:151003654-
151044622 
5.15 3.47 -0.57 8.23E-04 3.53E-02 - - 
Tmem176b chr6:48833811-
48841374 
104.29 70.41 -0.57 2.63E-04 1.40E-02 - - 
Ccl6 chr11:83582060-
83623693 
193.94 130.83 -0.57 1.15E-04 7.27E-03 - - 
Bcl6 chr16:23965051-
23988612 
9.79 6.6 -0.57 8.01E-04 3.49E-02 - - 
Dock10 chr1:80501072-
80758553 
10.38 7.08 -0.55 1.22E-04 7.63E-03 - - 
C3ar1 chr6:122847139-
122856157 
134.63 91.83 -0.55 6.86E-04 3.11E-02 - - 
Abca9 chr11:110100821-
110168153 
22.04 15.03 -0.55 8.29E-05 5.39E-03 - - 
Gpr65 chr12:98268656-
98276632 
24.49 16.72 -0.55 3.98E-04 1.99E-02 - - 
Abhd12 chr2:150832514-
150904731 
146.07 100.78 -0.54 2.21E-04 1.22E-02 - - 
Plxnc1 chr10:94790865-
94944578 
10.01 6.86 -0.54 1.84E-04 1.05E-02 - - 
Nav1 chr1:135434579-
135585355 
8.4 5.82 -0.53 1.72E-04 9.87E-03 + - 
Adam8 chr7:139978940-
139992488 
88.42 61.22 -0.53 2.67E-04 1.42E-02 - - 
Sesn1 chr10:41810573-
41908436 
30.62 21.26 -0.53 6.15E-04 2.86E-02 - - 
Mctp1 chr13:76384960-
77031810 
9.16 6.35 -0.53 1.04E-03 4.17E-02 - - 
Ldlrad3 chr2:101950200-
102186377 
15.15 10.6 -0.52 6.08E-04 2.85E-02 - - 
Ptplad2 chr4:88412929-
88438926 
23.24 16.17 -0.52 7.98E-04 3.49E-02 - - 
Tef chr15:81802672-
81826863 
32.45 22.67 -0.52 2.90E-04 1.53E-02 - - 
Slc37a2 chr9:37229148-
37255738 
16.55 11.59 -0.51 4.45E-04 2.18E-02 - - 
Fasn chr11:120805957-
120824547 
14.35 10.05 -0.51 2.59E-04 1.39E-02 - - 
Itgb5 chr16:33829664-
33949338 
76.42 53.67 -0.51 4.20E-04 2.06E-02 + - 
Nceh1 chr3:27183003-
27244911 
36.08 25.44 -0.5 3.35E-04 1.72E-02 - - 
Atp8a1 chr5:67618140-
67847431 
7.14 5.03 -0.5 8.69E-04 3.68E-02 - - 
Trpm2 chr10:77907721-
77969872 
6.93 4.9 -0.5 1.08E-03 4.27E-02 - - 
Chd3 chr11:69344350-
69369391 
15.37 10.84 -0.5 3.65E-04 1.85E-02 - - 
Vps13c chr9:67840395-
67995634 
18.84 13.42 -0.49 6.47E-04 3.00E-02 - - 
Nuak1 chr10:84371318-
84440471 
11.18 7.97 -0.49 1.14E-03 4.45E-02 - - 
Ttyh3 chr5:140620577-
140649031 
37.81 27.35 -0.47 9.03E-04 3.78E-02 - - 
Slc36a1 chr11:55204339-
55236330 
25.92 18.69 -0.47 7.67E-04 3.38E-02 - - 
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Abcd2 chr15:91145870-
91191807 
21.2 15.26 -0.47 7.23E-04 3.22E-02 - - 
Rftn1 chr17:49993306-
50190497 
44.91 32.69 -0.46 1.09E-03 4.30E-02 - - 
Zdhhc18 chr4:133606991-
133633429 
23.83 32.75 0.46 1.16E-03 4.52E-02 - - 
Zyx chr6:42349827-
42358395 
63.95 88.08 0.46 1.12E-03 4.41E-02 - - 
Met chr6:17463956-
17573980 
8.41 11.62 0.47 1.29E-03 4.96E-02 - - 
Slfn4 chr11:83175185-
83190216 
14.27 19.84 0.47 9.49E-04 3.91E-02 - - 
Gpr84 chr15:103308234-
103310438 
58.68 81.13 0.47 8.53E-04 3.64E-02 - - 
B430306N03Rik chr17:48316161-
48326511 
22.73 31.38 0.47 8.85E-04 3.72E-02 - - 
Slc2a6 chr2:27021364-
27027998 
32.1 44.68 0.48 8.51E-04 3.64E-02 - - 
Golim4 chr3:75876383-
75956831 
16.1 22.38 0.48 7.01E-04 3.15E-02 - - 
Oasl2 chr5:114896933-
114912245 
14.23 19.91 0.48 1.04E-03 4.17E-02 - - 
H2-Aa chr17:34282750-
34287771 
59.85 83.2 0.48 9.30E-04 3.85E-02 + - 
Filip1l chr16:57301999-
57606867 
13.4 18.78 0.49 1.05E-03 4.17E-02 - - 
Nfkb2 chr19:46304736-
46327156 
41.11 57.81 0.49 1.02E-03 4.14E-02 - - 
Sod2 chr17:13007838-
13018119 
100.16 143.55 0.52 8.78E-04 3.70E-02 + - 
Cd274 chr19:29367437-
29388094 
53.76 76.83 0.52 3.16E-04 1.64E-02 - - 
Vsig4 chrX:96247202-
96293438 
41.88 59.95 0.52 3.55E-04 1.80E-02 - - 
Smpdl3b chr4:132732965-
132757171 
33.27 48.05 0.53 1.88E-04 1.06E-02 - - 
Ampd3 chr7:110772603-
110812395 
66.32 95.89 0.53 3.54E-04 1.80E-02 - - 
Panx1 chr9:15005784-
15045478 
12.36 17.82 0.53 1.28E-03 4.95E-02 - - 
Prkar2b chr12:31958478-
32061279 
25.5 36.91 0.53 1.33E-04 7.98E-03 - - 
Ephx1 chr1:180989555-
181017495 
106.75 155.25 0.54 1.68E-04 9.83E-03 - - 
Spp1 chr5:104435110-
104441053 
154.37 224.33 0.54 6.76E-04 3.07E-02 + - 
Rpl23 chr11:97777525-
97782439 
36.59 53.03 0.54 5.67E-04 2.68E-02 - - 
Id2 chr12:25093798-
25096092 
61.57 89.63 0.54 1.11E-04 7.03E-03 - - 
H2-Q4 chr17:35379616-
35384674 
65.04 94.87 0.54 9.06E-05 5.82E-03 + - 
Fpr1 chr17:17876470-
17883939 
38.8 56.46 0.54 2.23E-04 1.22E-02 + - 
Ptgr1 chr4:58965589-
58987078 
51.38 75.38 0.55 8.56E-05 5.54E-03 - - 
Ppfibp2 chr7:107595050-
107758032 
16.67 24.39 0.55 5.15E-04 2.46E-02 - - 
Egr2 chr10:67537868-
67542188 
62.34 91.31 0.55 1.27E-04 7.77E-03 + - 
Gbp6 chr5:105270701-
105293699 
6.33 9.31 0.56 4.73E-04 2.28E-02 + - 
Tln2 chr9:67217084-
67559703 
2.63 3.88 0.56 2.60E-04 1.39E-02 - - 
Rai14 chr15:10568977-
10714631 
23.72 35.28 0.57 3.95E-05 2.89E-03 - - 
Rpl7a chr2:26910806-
26913311 
50.23 74.88 0.58 2.39E-04 1.29E-02 - - 
Dnajc10 chr2:80315465-
80354055 
74.19 110.68 0.58 1.42E-04 8.45E-03 - - 
Efnb2 chr8:8617438-
8660773 
15.15 22.58 0.58 4.48E-05 3.22E-03 - - 
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Phldb1 chr9:44686307-
44735198 
9.39 14.03 0.58 5.46E-05 3.76E-03 - - 
Serpinb9 chr13:33004540-
33017955 
16.73 25.02 0.58 4.66E-05 3.33E-03 - - 
Pfkp chr13:6548156-
6648724 
22.54 33.61 0.58 6.59E-04 3.02E-02 - - 
Slc23a2 chr2:132052495-
132145108 
23.19 34.9 0.59 2.71E-05 2.10E-03 - - 
5730494N06Rik chr2:132239491-
132247788 
19.39 29.1 0.59 9.23E-04 3.85E-02 - - 
Icam1 chr9:21015959-
21028796 
38.47 57.88 0.59 2.29E-05 1.87E-03 + - 
Procr chr2:155751216-
155755478 
127.52 192.71 0.6 2.99E-05 2.27E-03 - - 
Bcam chr7:19756137-
19770532 
6.68 10.15 0.6 1.01E-03 4.11E-02 - - 
Src chr2:157424292-
157471838 
6.92 10.58 0.61 1.23E-04 7.63E-03 + - 
Tnfaip3 chr10:19000909-
19015410 
21.69 33.39 0.62 1.68E-05 1.41E-03 - - 
Tpm4 chr8:72135291-
72153129 
171.12 264.81 0.63 5.57E-05 3.79E-03 - - 
Abcc4 chr14:118482691-
118706219 
14.28 22.09 0.63 7.83E-06 7.60E-04 - - 
Pcx chr19:4510471-
4621752 
7.35 11.37 0.63 6.41E-05 4.31E-03 - - 
Rpl36a chrX:134585653-
134588062 
43.1 66.61 0.63 1.08E-03 4.27E-02 - - 
Gpr35 chr1:92973118-
92986391 
17 26.56 0.64 4.82E-05 3.40E-03 - - 
1500003O03Rik chr2:119547706-
119587022 
51.69 80.75 0.64 4.05E-06 4.36E-04 - - 
Gss chr2:155563182-
155592706 
21.04 32.89 0.64 1.63E-05 1.38E-03 - - 
Car6 chr4:150187015-
150201135 
16.12 25.05 0.64 1.80E-04 1.03E-02 - - 
Rps12 chr10:23785182-
23787209 
60.69 94.26 0.64 2.42E-04 1.31E-02 - - 
Angptl2 chr2:33136972-
33371478 
11.27 17.67 0.65 2.63E-05 2.07E-03 - - 
Niacr1 chr5:123863569-
123865516 
6.17 9.7 0.65 1.02E-03 4.14E-02 - - 
Bcl2a1d chr9:88723287-
88731850 
23.6 37.06 0.65 3.32E-04 1.71E-02 - - 
Dcbld2 chr16:58408534-
58469745 
3.71 5.82 0.65 6.08E-05 4.12E-03 - - 
Vmn2r26 chr6:124024757-
124062035 
9.25 14.57 0.66 6.90E-05 4.54E-03 - - 
Adora2a chr10:75316942-
75334788 
9.36 14.79 0.66 6.65E-05 4.42E-03 + - 
Fpr2 chr17:17887823-
17893952 
31.46 49.64 0.66 1.24E-05 1.11E-03 + - 
Psma5 chr3:108256925-
108279952 
8.56 13.75 0.68 1.30E-03 4.96E-02 - - 
Rassf4 chr6:116633007-
116673836 
83.89 134.06 0.68 1.23E-04 7.63E-03 - - 
Dusp16 chr6:134715472-
134792628 
5.56 8.89 0.68 5.47E-05 3.76E-03 - - 
Chn2 chr6:54039931-
54430221 
7.18 11.69 0.7 4.97E-04 2.38E-02 - - 
Olr1 chr6:129485246-
129507165 
85.3 138.84 0.7 4.10E-06 4.37E-04 + - 
Slc7a2 chr8:40862366-
40922070 
86.04 140.17 0.7 1.46E-04 8.61E-03 - - 
Ahrr chr13:74211117-
74292309 
5.68 9.2 0.7 1.31E-05 1.14E-03 + - 
Alas1 chr9:106233454-
106247954 
194.52 317.73 0.71 4.12E-05 3.00E-03 - - 
Dnmt3l chr10:78030030-
78063615 
5.47 8.97 0.71 8.59E-04 3.65E-02 - - 
Slc22a23 chr13:34179157-
34345182 
1.53 2.49 0.71 6.62E-04 3.02E-02 - - 
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Ets2 chr16:95702406-
95721049 
15.25 24.99 0.71 6.11E-07 8.08E-05 - - 
H2-Ab1 chr17:34263226-
34269418 
69.92 114.49 0.71 4.33E-07 6.07E-05 + - 
Gstm2 chr3:107981701-
107986436 
10.48 17.3 0.72 4.56E-04 2.21E-02 - - 
Slc28a2 chr2:122426476-
122461130 
2.33 3.88 0.73 4.63E-04 2.24E-02 - + 
Srxn1 chr2:152105729-
152111353 
226.13 374.61 0.73 2.93E-05 2.24E-03 - - 
Akr1b8 chr6:34354163-
34368454 
18.03 29.95 0.73 8.60E-06 7.94E-04 - - 
Ppip5k1 chr2:121289601-
121351013 
3.88 6.49 0.74 2.35E-05 1.90E-03 - + 
F3 chr3:121723536-
121735052 
6.42 10.69 0.74 1.71E-04 9.86E-03 - - 
A530064D06Rik chr17:48151895-
48167257 
18.11 30.27 0.74 3.23E-06 3.58E-04 - - 
Cyp1b1 chr17:79706952-
79715041 
10.5 17.5 0.74 6.38E-07 8.25E-05 + - 
Nfkbie chr17:45555715-
45563168 
17.82 29.92 0.75 3.28E-07 4.77E-05 - - 
Ralgds chr2:28513166-
28553082 
8.69 14.72 0.76 8.47E-06 7.88E-04 + - 
Cxcl14 chr13:56288642-
56296551 
63.47 107.74 0.76 5.62E-08 9.62E-06 - - 
Rpl12 chr2:32961711-
32964045 
16.87 28.82 0.77 3.67E-04 1.85E-02 - - 
Ppap2b chr4:105157346-
105232767 
5.04 8.58 0.77 1.85E-05 1.53E-03 - - 
Ripk3 chr14:55784994-
55788857 
9.73 16.68 0.78 1.24E-05 1.11E-03 - - 
Rpl24 chr16:55966274-
55971437 
36.44 62.4 0.78 7.56E-06 7.46E-04 - - 
Plcb2 chr2:118707516-
118728438 
4.17 7.21 0.79 1.48E-06 1.74E-04 - + 
Cd53 chr3:106758860-
106790149 
233.15 402.03 0.79 1.48E-05 1.26E-03 - - 
Nqo1 chr8:107388224-
107403205 
71.95 124.92 0.8 1.48E-08 3.25E-06 - - 
Epha4 chr1:77367184-
77515088 
2.91 5.1 0.81 2.38E-06 2.69E-04 - - 
Dnm1 chr2:32308470-
32353304 
1.52 2.67 0.81 9.55E-04 3.93E-02 - + 
Vcan chr13:89655309-
89742512 
2.54 4.45 0.81 5.55E-05 3.79E-03 - - 
Slc6a9 chr4:117835257-
117872470 
13.95 24.71 0.82 1.51E-08 3.25E-06 - - 
Socs2 chr10:95411489-
95416857 
6.58 11.66 0.82 1.26E-05 1.11E-03 - - 
Ltc4s chr11:50236471-
50238471 
19.16 33.78 0.82 2.25E-04 1.23E-02 - - 
Pdgfb chr15:79995875-
80014808 
14.97 26.5 0.82 2.08E-08 4.40E-06 - - 
Rcan1 chr16:92391952-
92466146 
28.14 49.59 0.82 4.14E-08 7.77E-06 - - 
Ifi205 chr1:174011997-
174031755 
3.27 5.82 0.83 8.10E-04 3.51E-02 - - 
Ly6i chr15:74979811-
74983430 
11.27 20.06 0.83 1.30E-04 7.86E-03 - - 
Ass1 chr2:31470269-
31520670 
33.97 60.68 0.84 5.05E-07 6.91E-05 - - 
Rps27 chr3:90212666-
90213648 
54.11 96.93 0.84 2.19E-04 1.21E-02 - - 
1810029B16Rik chr8:66476345-
66486507 
33.27 59.54 0.84 3.21E-08 6.44E-06 - - 
H2-Q8 chr17:35394098-
35395632 
8.01 14.31 0.84 1.05E-04 6.68E-03 + - 
Ptges chr2:30889470-
30903297 
34.17 61.47 0.85 1.79E-09 4.74E-07 - - 
Bcl2a1a chr9:88956919-
88962416 
25.95 46.93 0.85 9.16E-07 1.13E-04 - - 
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Chst11 chr10:82985496-
83195891 
6.36 11.52 0.86 1.02E-08 2.36E-06 - - 
Gpr132 chr12:112850875-
112860916 
5.05 9.19 0.86 7.23E-06 7.19E-04 - - 
Susd2 chr10:75636618-
75644008 
1.43 2.61 0.87 1.15E-03 4.49E-02 - - 
Unc5b chr10:60762594-
60831581 
4.08 7.52 0.88 3.42E-08 6.75E-06 - - 
Maff chr15:79347677-
79359076 
2.77 5.11 0.88 7.08E-04 3.17E-02 - - 
Tmem119 chr5:113793728-
113800352 
6.4 11.84 0.89 2.34E-06 2.67E-04 - - 
Treml4 chr17:48264294-
48275358 
4.28 7.91 0.89 6.55E-04 3.02E-02 - - 
Malt1 chr18:65430996-
65478792 
13.06 24.17 0.89 5.32E-10 1.59E-07 + - 
Cxcl2 chr5:90903898-
90905938 
23.05 42.88 0.9 4.65E-08 8.36E-06 + - 
Igf2bp1,Mir3063 chr11:95957163-
96005944 
0.76 1.41 0.9 1.28E-04 7.78E-03 - - 
Tnfsf4 chr1:161395437-
161418206 
11.53 21.78 0.92 1.24E-07 1.94E-05 - - 
Cish chr9:107296688-
107301961 
4.15 7.87 0.92 1.30E-05 1.14E-03 - - 
Nckap1 chr2:80501294-
80580965 
1.31 2.49 0.93 4.03E-04 2.00E-02 - - 
Clec5a chr6:40529090-
40910666 
31.79 60.8 0.94 3.82E-11 1.35E-08 - - 
Hspa1a chr17:34969358-
34972156 
1.93 3.69 0.94 1.67E-04 9.81E-03 - - 
Pf4 chr5:90772434-
90773383 
600.2 1159.14 0.95 1.55E-09 4.18E-07 + - 
Gbp2 chr3:142620662-
142638008 
22.24 43.92 0.98 4.25E-12 1.70E-09 - - 
Dcstamp chr15:39745931-
39760934 
4.93 9.74 0.98 2.00E-06 2.33E-04 - - 
Chac1 chr2:119351241-
119354327 
4.96 9.88 0.99 8.08E-06 7.66E-04 - + 
H2-Q7 chr17:35439154-
35443773 
58.39 116.36 0.99 7.50E-10 2.18E-07 + - 
Gpr68 chr12:100876681-
100908198 
7.64 15.24 1 4.35E-08 8.03E-06 - - 
Il1a chr2:129297369-
129309972 
19.27 39.18 1.02 6.01E-12 2.33E-09 + - 
Layn chr9:51056779-
51077094 
10.93 22.12 1.02 1.37E-09 3.79E-07 - - 
Rasgrp1 chr2:117279992-
117342877 
0.46 0.94 1.04 1.23E-03 4.76E-02 - - 
Irg1 chr14:103047011-
103056573 
43.81 92.61 1.08 1.24E-14 1.03E-11 - - 
Il1b chr2:129364579-
129375733 
25.65 54.76 1.09 5.89E-13 2.86E-10 + - 
Nnt chr13:119334316-
119409138 
8.59 18.32 1.09 6.66E-13 3.10E-10 + - 
H2-Q6 chr17:35424876-
35428361 
32.54 69.21 1.09 2.29E-12 9.86E-10 + - 
A130040M12Rik chr13:68233964-
68450346 
0.85 1.82 1.1 3.28E-04 1.69E-02 - - 
Heph chrX:96455435-
96574484 
6.08 13.13 1.11 3.44E-11 1.25E-08 - - 
Csf1 chr3:107741047-
107760469 
21.98 48.32 1.14 1.75E-13 1.07E-10 + - 
Il20rb chr9:100457718-
100486473 
4.52 9.97 1.14 3.12E-09 7.89E-07 - - 
Clec4e chr6:123281788-
123289871 
224.77 506.54 1.17 9.20E-11 3.06E-08 - - 
Hspa1b chr17:34956428-
34959238 
1.85 4.15 1.17 2.55E-06 2.85E-04 - - 
Adora2b chr11:62248983-
62266452 
1.99 4.53 1.18 2.82E-05 2.17E-03 - - 
Serpinb1a chr13:32842091-
32851185 
10.6 24.52 1.21 3.18E-13 1.61E-10 - - 
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Plcb1 chr2:134786163-
135475258 
0.92 2.15 1.22 9.88E-08 1.62E-05 - - 
Traf1 chr2:34943257-
34961772 
2.41 5.65 1.23 1.99E-07 3.05E-05 - + 
Il1rn chr2:24336859-
24351491 
23.96 56.97 1.25 0.00E+00 0.00E+00 + - 
Amotl1 chr9:14541966-
14615000 
0.49 1.17 1.26 8.58E-07 1.07E-04 - - 
Cdc42ep2 chr19:5917555-
5924816 
2.45 5.86 1.26 8.14E-06 7.66E-04 - - 
Flrt3 chr2:140395429-
142390050 
4.36 10.49 1.27 2.38E-12 9.89E-10 - - 
Abcb4 chr5:8893720-
8959226 
0.84 2.05 1.28 4.30E-06 4.47E-04 - - 
Dynlt1a chr17:6310544-
6317474 
2.49 6.06 1.29 4.49E-04 2.19E-02 - - 
Nfatc4 chr14:55824794-
55833943 
0.91 2.31 1.34 3.31E-05 2.46E-03 - - 
Cxcl3 chr5:90786102-
90788090 
66.88 174.46 1.38 0.00E+00 0.00E+00 - - 
Mtap1a chr2:121289601-
121351013 
0.32 0.88 1.44 1.70E-04 9.86E-03 - + 
Six1 chr12:73041826-
73046712 
1.2 3.47 1.53 3.81E-08 7.27E-06 - - 
Col18a1 chr10:77052178-
77166530 
8.82 26.31 1.58 0.00E+00 0.00E+00 - - 
Gatm chr2:122594472-
122611277 
27.46 85.13 1.63 0.00E+00 0.00E+00 - - 
Ccl24 chr5:135569936-
135573043 
100.51 318.64 1.66 0.00E+00 0.00E+00 - - 
Tmc3 chr7:83584930-
83623709 
0.23 0.74 1.67 2.30E-05 1.87E-03 - - 
Osmr chr15:6813576-
6874313 
0.08 0.24 1.69 1.22E-03 4.72E-02 - - 
Artn chr4:117926161-
117929763 
1.51 5.18 1.78 2.28E-10 6.99E-08 - - 
Six4 chr12:73100258-
73113245 
0.08 0.28 1.78 3.07E-04 1.60E-02 - - 
Ccl22 chr8:94745683-
94751388 
0.57 2.17 1.94 1.10E-06 1.32E-04 + - 
Thy1 chr9:44043383-
44048579 
0.14 0.58 2.06 7.58E-04 3.35E-02 - - 
Atp8b1 chr18:64528978-
64661000 
0.09 0.41 2.27 4.60E-07 6.38E-05 - - 
Dynlt1b chr17:6430111-
6436295 
2.89 14.91 2.36 2.08E-13 1.21E-10 - - 
Clu chr14:65968482-
65981545 
0.05 0.42 3.14 4.10E-04 2.02E-02 - - 
Exd1 chr2:119519403-
119547627 
0.06 0.57 3.25 4.83E-08 8.38E-06 - + 
Gchfr chr2:119167787-
119172389 
0.13 1.33 3.37 7.97E-04 3.49E-02 - - 
Cd163l1 chr7:140218266-
140231145 
0.03 0.34 3.58 8.76E-06 8.03E-04 - - 
Tmem181b-ps chr17:6439001-
6450994 
0.39 5.6 3.84 0.00E+00 0.00E+00 - - 
Gm14085 chr2:122484940-
122528040 
0.05 1.04 4.48 1.63E-13 1.06E-10 - - 
Sfrp2 chr3:83766320-
83774314 
0 1.11 7.79 9.95E-04 4.08E-02 - - 
Erdr1 chrY:90785441-
90816465 
0.07 21.69 8.32 1.57E-13 1.06E-10 - - 
Rpl31-ps12 chr16:16753015-
16829363 
0.37 146.86 8.64 0.00E+00 0.00E+00 - - 
Supplementary Table 1. List of 304 differentially expressed genes in pMΦ of B6.129-
PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt identified by RNA-Seq. 
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4.5.2 Supplementary Table 2. Genes containing non-synonymous SNPs 
between B6.129-PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt 
 
The table below lists 132 genes containing non-synonymous SNPs between B6.129- 
Prnpwt/wt and B6.129-PrnpZrchI/ZrchI pMΦ identified by RNA-Seq. The genes are sorted by 
chromosome location. 62 of these genes (47%) are located on Chr2 and 4 thereof have 
been implicated in phagocytosis (Fig. 15). 
 
Gene Locus FPKM 
WT 
FPKM 
KO 
Log2-fold 
change 
p-value q-value Diff. 
expr.§ 
Phag.* 
Ppfia4 chr1:134296782-
134332928 
4.27 3.46 -0.30 0.08 0.83 no no 
Cacna1s chr1:136052900-
136119822 
0.01 0.01 0.03 0.99 1.00 no no 
Atp1a4 chr1:172223507-
172258424 
0.00 0.00 0.00 1.00 1.00 no no 
Mgat4a chr1:37439339-
37536259 
43.39 42.94 -0.01 0.92 1.00 no no 
A530032D15Rik chr1:85088138-
85109853 
0.49 0.45 -0.10 0.83 1.00 no no 
Heatr7b1 chr1:88227019-
88277579 
0.11 0.08 -0.51 0.67 1.00 no no 
Traf1 chr2:34943257-
34961772 
2.41 5.65 1.23 1.99E-07 3.05E-05 yes no 
B230118H07Rik chr2:101560780-
101632528 
3.39 3.73 0.14 0.57 1.00 no no 
Hipk3, Mir1902 chr2:104426481-
104494489 
26.64 26.82 0.01 0.94 1.00 no no 
Qser1 chr2:104754796-
104816696 
4.17 3.73 -0.16 0.30 1.00 no no 
Thbs1 chr2:118111921-
118127133 
707.41 365.26 -0.95 0.00 0.10 no yes 
Eif2ak4 chr2:118388616-
118475234 
7.03 3.86 -0.86 6.65E-07 8.50E-05 yes no 
Plcb2 chr2:118707516-
118728438 
4.17 7.21 0.79 1.48E-06 1.74E-04 yes no 
Bahd1 chr2:118901614-
118924524 
10.46 10.71 0.03 0.82 1.00 no no 
Chst14 chr2:118926496-
118928583 
7.12 7.03 -0.02 0.93 1.00 no no 
Rpusd2 chr2:119034789-
119042197 
1.15 1.09 -0.07 0.78 1.00 no no 
Fam82a2 chr2:119136997-
119157034 
10.50 12.22 0.22 0.20 1.00 no no 
Zfyve19 chr2:119172499-
119217050 
10.50 5.47 -0.94 8.84E-06 8.04E-04 yes no 
Chac1 chr2:119351241-
119354327 
4.96 9.88 0.99 8.08E-06 7.66E-04 yes no 
Exd1 chr2:119519403-
119547627 
0.06 0.57 3.25 4.83E-08 8.38E-06 yes no 
Ndufaf1 chr2:119655450-
119662798 
5.66 5.75 0.02 0.93 1.00 no no 
Rtf1 chr2:119675067-
119735407 
9.52 10.03 0.08 0.61 1.00 no no 
Rpap1 chr2:119763958-
119787537 
4.26 3.87 -0.14 0.51 1.00 no no 
Tyro3 chr2:119799513-
119818103 
0.26 0.36 0.46 0.28 1.00 no yes 
Mga chr2:119897227- 7.33 7.19 -0.03 0.85 1.00 no no 
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119969581 
Mapkbp1 chr2:119972698-
120027403 
2.70 2.28 -0.24 0.19 1.00 no no 
Ganc chr2:120355308-
120504919 
2.61 3.00 0.20 0.50 1.00 no no 
Tmem87a chr2:120355309-
120404116 
12.40 17.40 0.49 0.00 0.09 no no 
Zfp106 chr2:120506829-
120563831 
30.17 29.02 -0.06 0.70 1.00 no no 
Cdan1 chr2:120716153-
120731517 
3.37 2.83 -0.25 0.16 1.00 no no 
Ttbk2 chr2:120732816-
120850584 
1.95 2.07 0.09 0.63 1.00 no no 
Ubr1 chr2:120850655-
120970715 
7.22 6.91 -0.06 0.66 1.00 no no 
Tmem62 chr2:120977061-
121007842 
9.92 9.71 -0.03 0.85 1.00 no no 
Lcmt2 chr2:121137291-
121140698 
4.63 3.57 -0.37 0.06 0.72 no no 
Adal chr2:121142140-
121156678 
4.12 5.20 0.34 0.12 1.00 no no 
Zscan29 chr2:121157426-
121171149 
7.73 8.38 0.12 0.42 1.00 no no 
Trp53bp1 chr2:121196727-
121271386 
6.43 6.16 -0.06 0.76 1.00 no no 
Mtap1a chr2:121289601-
121351013 
0.32 0.88 1.44 0.00 0.01 yes no 
Ppip5k1 chr2:121310561-
121351013 
3.88 6.49 0.74 2.35E-05 1.90E-03 yes no 
Wdr76 chr2:121506722-
121544859 
1.23 1.56 0.35 0.19 1.00 no no 
Spg11 chr2:122053526-
122118386 
8.82 4.10 -1.10 2.39E-08 4.97E-06 yes no 
B2m chr2:122120107-
122186189 
3019.43 2916.05 -0.05 0.84 1.00 no no 
Slc28a2 chr2:122426476-
122461130 
2.33 3.88 0.73 0.00 0.02 yes no 
Slc30a4 chr2:122681238-
122702663 
4.89 4.35 -0.17 0.32 1.00 no no 
Pldn chr2:122738504-
122749487 
9.33 11.75 0.33 0.03 0.49 no no 
Sqrdl chr2:122765358-
122809551 
94.96 122.34 0.37 0.01 0.24 no no 
Usp8 chr2:126707327-
126759314 
38.70 36.02 -0.10 0.47 1.00 no no 
2010106G01Rik chr2:126890394-
126933235 
60.17 68.69 0.19 0.21 1.00 no no 
Stard7 chr2:127270228-
127298934 
15.21 14.40 -0.08 0.60 1.00 no no 
Mertk chr2:128698996-
128802188 
45.87 44.28 -0.05 0.72 1.00 no yes 
Polr1b chr2:129100995-
129126595 
4.97 4.75 -0.06 0.72 1.00 no no 
Ckap2l chr2:129268209-
129297212 
0.35 0.37 0.06 0.88 1.00 no no 
Sirpa chr2:129592838-
129632228 
356.34 375.60 0.08 0.73 1.00 no yes 
Vps16 chr2:130417683-
130444269 
14.78 13.95 -0.08 0.63 1.00 no no 
Fam113a chr2:130417684-
130424641 
5.37 7.02 0.39 0.14 1.00 no no 
1110034G24Rik chr2:132690282-
132751055 
7.69 6.97 -0.14 0.52 1.00 no no 
Trmt6 chr2:132804214-
132816054 
9.42 8.63 -0.13 0.45 1.00 no no 
Mkks chr2:136873781-
136891406 
8.87 8.21 -0.11 0.55 1.00 no no 
Rrbp1 chr2:143947394-
144011263 
68.09 60.61 -0.17 0.29 1.00 no no 
8430406I07Rik chr2:144271034-
144281229 
6.07 2.23 -1.45 1.95E-10 6.29E-08 yes no 
Rin2 chr2:145786115-
145887616 
62.96 49.07 -0.36 0.01 0.29 no no 
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Fam110a chr2:151969397-
151980219 
6.05 5.31 -0.19 0.41 1.00 no no 
Slc52a3 chr2:151996510-
152009258 
0.60 0.87 0.54 0.17 1.00 no no 
Zcchc3 chr2:152411955-
152415044 
1.78 1.65 -0.11 0.70 1.00 no no 
Rem1 chr2:152627007-
152635191 
0.69 0.99 0.52 0.23 1.00 no no 
H13 chr2:152669460-
152708668 
20.03 19.08 -0.07 0.72 1.00 no no 
Prex1 chr2:166566344-
166713832 
32.51 31.06 -0.07 0.64 1.00 no no 
Gm14393 chr2:175061548-
175067763 
0.30 0.56 0.89 0.25 1.00 no no 
LOC100038947 chr3:15795146-
15848487 
8.92 3.65 -1.29 1.19E-07 1.89E-05 yes no 
Srsf11 chr3:158010492-
158036639 
24.25 24.62 0.02 0.88 1.00 no no 
Pip5k1a chr3:95059595-
95106858 
12.33 13.67 0.15 0.35 1.00 no no 
2010305A19Rik chr4:108328151-
108340718 
4.13 4.13 0.00 1.00 1.00 no no 
Aldoart1 chr4:72850582-
72852634 
13.44 14.33 0.09 0.58 1.00 no no 
Gbp11 chr5:105323025-
105346472 
0.14 0.15 0.10 0.87 1.00 no no 
Fam20c chr5:138755080-
138810063 
171.49 194.08 0.18 0.28 1.00 no no 
Smurf1 chr5:144876494-
144965830 
17.12 18.87 0.14 0.33 1.00 no no 
Fam193a chr5:34369932-
34486458 
7.19 7.21 0.00 0.98 1.00 no no 
Igbp1b chr6:138657091-
138658444 
0.00 0.00 0.00 1.00 1.00 no no 
4930544G11Rik chr6:65952570-
65954014 
0.00 0.00 0.00 1.00 1.00 no no 
4931417E11Rik chr6:73468572-
73469667 
0.00 0.00 0.00 1.00 1.00 no no 
Plxna1 chr6:89316313-
89362613 
38.42 36.78 -0.06 0.68 1.00 no no 
Iqsec1 chr6:90659597-
90810123 
18.34 16.96 -0.11 0.42 1.00 no yes 
Atp2a1 chr7:126428766-
126463073 
0.03 0.05 0.88 0.69 1.00 no no 
Btbd1 chr7:81792073-
81829431 
11.13 12.06 0.12 0.46 1.00 no no 
Fut10 chr8:31187331-
31261483 
5.00 4.68 -0.10 0.68 1.00 no no 
Sugp1 chr8:70042812-
70071953 
12.57 11.95 -0.07 0.66 1.00 no no 
Pde4c chr8:70724063-
70751176 
0.00 0.01 1.80e+308 0.16 1.00 no no 
Mast1 chr8:84911852-
84937353 
1.75 1.55 -0.18 0.45 1.00 no no 
Gnat1 chr9:107674473-
107679592 
0.02 0.02 0.11 0.95 1.00 no no 
Mre11a chr9:14784706-
14834417 
4.67 4.49 -0.06 0.77 1.00 no no 
Zfp26 chr9:20428317-
20460160 
2.42 2.68 0.15 0.36 1.00 no no 
Abcg4 chr9:44273189-
44288244 
0.03 0.05 0.96 0.30 1.00 no no 
Dmxl2 chr9:54365157-
54501626 
22.39 23.62 0.08 0.59 1.00 no no 
Gm5136 chr10:108497649-
109010975 
0.00 0.00 0.00 1.00 1.00 no no 
Ikzf4 chr10:128632414-
128645993 
0.00 0.00 -0.14 0.95 1.00 no no 
Tcf3 chr10:80409164-
80433653 
14.79 14.93 0.01 0.93 1.00 no no 
Map2k2 chr10:81105946-
81124697 
28.87 29.66 0.04 0.79 1.00 no no 
Tubg2 chr11:101155883-
101161787 
0.03 0.03 0.15 0.92 1.00 no no 
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Unk chr11:116030321-
116061194 
6.87 6.71 -0.03 0.84 1.00 no no 
Pycr1 chr11:120635711-
120643670 
0.11 0.08 -0.45 0.49 1.00 no no 
Zrsr1 chr11:22899727-
22982284 
3.76 3.76 0.00 1.00 1.00 no no 
Cyfip2 chr11:46193848-
46312859 
1.65 1.69 0.03 0.88 1.00 no no 
Pmp22 chr11:63131509-
63159546 
104.67 120.81 0.21 0.14 1.00 no no 
Myo1g chr11:6506547-
6520958 
28.34 28.85 0.03 0.85 1.00 no yes 
Zkscan6 chr11:65807243-
65829239 
6.13 6.10 -0.01 0.98 1.00 no no 
Myh13 chr11:67327102-
67371502 
0.00 0.00 -1.8e+308 0.49 1.00 no no 
Tnfaip1 chr11:78522849-
78536260 
14.98 14.79 -0.02 0.91 1.00 no no 
Aatf chr11:84422855-
84513501 
8.33 8.91 0.10 0.62 1.00 no no 
Prps1l3 chr12:57230411-
57457241 
9.47 9.91 0.07 0.69 1.00 no no 
Rhob chr12:8497758-
8499985 
81.65 79.56 -0.04 0.79 1.00 no yes 
Naip2 chr13:100144062-
100202092 
80.63 87.08 0.11 0.48 1.00 no no 
Ctsm chr13:61536443-
61541839 
0.00 0.00 0.00 1.00 1.00 no no 
Slc12a7 chr13:73763696-
73816742 
5.93 4.32 -0.46 0.01 0.18 no no 
Nr2f1 chr13:78188972-
78236564 
0.00 0.00 0.00 1.00 1.00 no no 
Mapk8 chr14:33377898-
33447158 
2.63 2.92 0.15 0.42 1.00 no no 
Ctsb chr14:63122461-
63177793 
1245.17 1117.34 -0.16 0.71 1.00 no no 
Akap11 chr14:78492245-
78536860 
5.72 5.33 -0.10 0.49 1.00 no no 
Fbxo32 chr15:58175878-
58214892 
5.90 5.97 0.02 0.91 1.00 no no 
Dnm1l chr16:16312232-
16359030 
10.24 10.92 0.09 0.54 1.00 no no 
Senp5 chr16:31959669-
32003287 
10.18 9.99 -0.03 0.85 1.00 no no 
Tiam1 chr16:89787110-
89974699 
4.99 6.60 0.40 0.01 0.27 no yes 
Cbr1 chr16:93607836-
93610349 
22.49 20.07 -0.16 0.36 1.00 no no 
Itpr3 chr17:27057303-
27122223 
1.51 1.45 -0.06 0.77 1.00 no yes 
H2-T23 chr17:36029977-
36032701 
123.29 137.29 0.16 0.29 1.00 no no 
H2-Bl chr17:36080188-
36084249 
0.12 0.16 0.46 0.60 1.00 no no 
Pabpc6 chr17:9666496-
9669704 
0.00 0.00 0.00 1.00 1.00 no no 
Gnal chr18:67088335-
67245830 
1.09 1.07 -0.03 0.96 1.00 no no 
Cetn1 chr18:9618418-
9619469 
0.00 0.00 0.00 1.00 1.00 no no 
Tle4 chr19:14448071-
14597983 
8.14 7.82 -0.06 0.72 1.00 no no 
Pank1 chr19:34810893-
34879455 
1.47 1.43 -0.04 0.92 1.00 no no 
1700055N04Rik chr19:3958807-
3970438 
0.01 0.00 -5.55 0.71 1.00 no no 
Ddx3y chrY:1260714-
1286613 
0.00 0.00 0.00 1.00 1.00 no no 
 
Supplementary Table 2. Genes containing non-synonymous SNPs between B6.129-
PrnpZrchI/ZrchI vs. B6.129-Prnpwt/wt. FPKM, Fragments Per Kilobase of exon per Million fragments 
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mapped; §differentially expressed as in Supplementary Table 1; * involved in phagocytosis, if 
retrievable records on pubmed.gov using the search terms: “gene xy phagocytosis”, and/or 
associated terms on geneontology.org, using unfiltered search parameters and considering all 
recorded species. 
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5 TRANSPLANTED STROMAL-VASCULAR PDGFRβ+ CELLS 
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5.1 INTRODUCTION 
 
5.1.1 The stromal compartment of lymphoid tissues 
 
The immune system defends the organism against external and internal damage and is 
traditionally divided into innate and adaptive components. The innate system comprises 
all cells and molecules that act as a first line defense system. In contrast, the adaptive 
system counteracts invaders with sophisticated and targeted weapons, which are then 
stored as immunological memory. In fact, the individual components of these two 
systems are tightly intertwined and cells with dual characteristics fulfill crucial functions in 
host defense and lymphoid development (Lanier, 2013; Spits et al., 2013).  
A functional immune system is essential in all parts of the organism and therefore, 
wherever we look, we will find immune cells on duty. To develop an optimal adaptive 
immune response, the immune system contains specialized compartments known as 
lymphoid organs. Primary lymphoid organs consist of bone marrow and the thymus, 
where B cells and T cells, mature from their respective precursors. This maturation 
process involves complex genetic rearrangements by the recombinase activating gene 
(RAG) encoded enzymes that lead to the acquisition of functional T and B cell receptors, 
and negative selection of auto-reactive cells (Kindt et al., 2007; Nishana and Raghavan, 
2012). Once B and T cells have reached immunocompetence in the primary lymphoid 
organs, they migrate to SLO, where they encounter ideal conditions to meet antigen-
presenting cells, interact with antigens and mount an adaptive immune response. The 
heterogeneous SLO form a network throughout the whole body, which filters and 
monitors body fluids for the presence of pathogens. The main SLO are LNs, spleen, and 
the MALT. LN occupy strategic positions in the body where they filter lymph, interstitial 
fluid derived from blood plasma, from the tissue (Girard et al., 2012). The spleen, located 
intraperitoneally, is the main blood filter of the organism (Mebius and Kraal, 2005), 
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whereas the mucosal surfaces in respiratory and the digestive tract undergo surveillance 
by MALT (Kindt et al., 2007). The highly organized microarchitecture of SLO contains 
distinct areas where B and T cells are concentrated. Resting naïve B cells accumulate in 
primary follicles, which, upon antigen challenge, become secondary follicles containing 
germinal centers, where B cells proliferate and undergo affinity maturation (Kindt et al., 
2007).  
The non-hematopoietic stromal cells contribute to the elaborate choreography of mobile 
hematopoietic cells in SLO. They not only provide the physical scaffold for the 
morphology of SLO by creating a meshwork through the whole organ, but also play an 
active role by secreting a variety of chemokines and adhesion molecules that facilitate 
communication within SLO, thereby ensuring antigen-delivery to control the entrance and 
exit of lymphocytes and antigen-presenting cell and to regulate their paths and 
positioning (Girard et al., 2012; Malhotra et al., 2013; Mueller and Germain, 2009). 
Recent work has advanced our understanding of the heterogeneity of stromal cells within 
lymphoid organs and has permitted characterization of single subsets with the use of 
markers, their specific locations and functions (Katakai, 2012; Katakai et al., 2008; Link 
et al., 2007; Malhotra et al., 2012; Malhotra et al., 2013). The main characteristics of the 
different stromal subsets are summarized in Table 10, and Fig. 39 and Fig. 40 show their 
location within the LN and spleen, respectively. 
During embryogenesis, all stromal subsets are thought to derive from a common 
mesenchymal progenitor, which – upon retinoic acid-mediated activation from neuronal 
cells – becomes an LTo expressing CXCL13 and subsequently LTβR. Interaction with 
LTαβ2-expressing CD45+CD4+CD3- LTi cells leads to upregulation of chemokines and 
expression and adhesion molecules, which then permit more hematopoietic cells to 
accumulate (Fig. 41) (Cupedo et al., 2004b; van de Pavert and Mebius, 2010). Similar 
events can take place in the adult organism upon prolonged inflammatory stimulation in 
a process called lymphoid neogenesis leading to the development of ectopic TLO, and 
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the de novo formed lymphoid organs can acquire highly organized architecture and 
functions as seen in SLO (Aloisi and Pujol-Borrell, 2006; Drayton et al., 2006; Mueller 
and Germain, 2009; Neyt et al., 2012). TLO are found in various infectious and 
autoimmune diseases in almost any parts of the body, suggesting that these organs 
contain LTo-like cells (Cupedo et al., 2004a; Katakai, 2012), but the precise initiating 
steps are not known so far (Neyt et al., 2012). Treatment regiments used in autoimmune 
diseases with ectopic lymphoid neogenesis, such as rheumatoid arthritis, include 
immunomodulatory medicaments that block pathways involved in TLO formation (Manzo 
et al., 2010). A detailed understanding of TLO development will foster the development 
of strategies to prevent further de novo TLO formation. 
 
 
Stromal 
cell 
subset 
Selected markers Functions 
LEC gp38+CD31+  
LYVE1, ICAM1, ICAM2, VCAM1, ER-TR7 
antigen, laminin, VE-cadherin, claudin 5, TLRs, 
CCL21, S1P 
Transport of lymph, antigens and cells; 
facilitation of entry of leukocytes into 
lymphatics; chemokine production and 
presentation 
FRC gp38+CD31- 
ER-TR7 antigen, laminin, desmin, fibrillin, 
fibronectin, α-SMA, LTβR, TNFR1, TNFR2, 
ICAM1, VCAM1, collagen I, collagen II, 
collagen IV, integrin α1, integrin α4, integrin 
β1, MHC class I, VEGF, PDGFRαβ, CCL21, 
CCL19, CXCL16 and IL-7 
Structural support; production of reticular 
fibers; formation of conduit network; 
chemokine production and presentation; 
substrate for lymphocyte migration; antigen-
presenting cell adhesion; T cell homeostasis; 
antigen presentation 
MRC gp38+CD31- 
Madcam1, CXCL13, LTβR, ER-TR7 antigen, 
ICAM1, VCAM1, RANKL, laminin, desmin, 
1BL-11 antigen  
Structural support; chemokine production; 
conduit function; possibly adult stromal 
organizer  
FDC gp38+/-CD31- 
CD16, CD21, CD23, CD32, CD35, C4, ICAM1, 
VCAM1, Madcam1, laminin, desmin, CXCL12, 
CXCL13, BAFF, Mfge8 
Antigen capture; presentation of immune 
complexes; chemokine production and 
presentation; B cell homeostasis 
BEC gp38-CD31+ 
PNAd (in lymph nodes), CD34, VE-cadherin, 
laminin, JAM-A, JAM-B, JAM-C, ZO1, ZO2, 
ESAM1, claudin 5, CCL21 (in mice) 
Transport of blood; entry of cells from the 
blood into tissues 
IAP gp38-CD31- 
integrin α7, calponin1, PDGFRαβ  
Contractile pericytes around vessels 
Table 10. Stromal cell subsets found in SLO. Location and surface expression of gp38 and 
CD31, as well as the expression of additional markers is used to divide stromal cells into 
subclasses. BAFF, B cell activating factor; C4, complement component 4; CCL, CC-chemokine 
ligand; ESAM1, endothelial cell-specific adhesion molecule 1; IL, interleukin; JAM, junctional 
adhesion molecule; LYVE1, lymphatic vessel endothelial hyaluronan receptor 1; PNAd, peripheral 
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node addressin; RANKL, receptor activator of NF-κB ligand; S1P, sphingosine 1-phosphate; TLR, 
Toll-like receptor; VEGF, vascular endothelial growth factor; ZO, zonula occludens protein. The 
table is reused from (Mueller and Germain, 2009) with permission from Nature Publishing Group 
(Rightslink license number: 3125970196683) and adapted using information found in (Katakai, 
2012; Katakai et al., 2008; Link et al., 2007; Malhotra et al., 2012; Malhotra et al., 2013).  
 
 
Figure 39. Anatomy of the LN and its stromal cellular subsets. (a) The LN is surrounded by a 
fibrous capsule and is compartmentalized into cortex (B cell zone with B cell follicles), paracortex 
(T cell zone) and medulla (plasma cells). (b) Blood vessels enter the LN at the hilus and end in 
the paracortex and cortex as specialized HEV composed of BEC, which express molecules 
permitting lymphocytes to enter the LN. Most HEV are surrounded by FRC, few also by contractile 
IAP. FRC form dense networks, on which lymphocytes and dendritic cells can crawl through the 
LN and interact. (c) Lymph enters the LN via afferent lymphatic vessels (3 upper endings) into the 
subscapular sinus that is lined by LEC and contains IAP and MRC, and is filled with macrophages 
and dendritic cells that capture antigens. Small antigens are also transported via special tubes in 
FRC conduits inside the LN. In the neighboring cortex, FDC networks embrace B cells in follicles 
and display antigens. (d) Many antibody secreting plasma cells and macrophages populate the 
LN medulla and LEC form a dense network, where they control the exit to efferent lymphatic 
vessels. Figure reprinted from (Malhotra et al., 2013) with permission from John Wiley & Sons 
A/S. Published by Blackwell Publishing Ltd; Rightslink license number: 3125500373268. 
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Figure 40. Stromal cell subsets in the 
spleen. The largest secondary lymphoid 
organ is specialized in filtering blood-
borne antigens. Splenic arteries end in 
sinusoids in the red pulp, where 
macrophages phagocytose old 
erythrocytes. Reticular fibroblasts form 
the splenic cords within the red pulp and 
direct blood flow. The splenic white pulp 
surrounds the arterioles and contains a 
T cell zone held together by a FRC 
network (periarteriolar lymphoid sheath) 
and B cell follicles, which are enmeshed by FDC. The arterioles end in the marginal sinus, which 
surrounds the white pulp and contains a MRC network, where macrophages and dendritic cells 
receive blood-borne antigens. Figure adapted and reprinted from (Mueller and Germain, 2009) 
with permission from Nature Publishing Group, Rightslink license number: 3125950277378. 
 
Figure 41. The TNF family: ligands and receptors of 
the TNF and LT pathways. Secreted LTα3 and TNF or 
membrane bound bind TNFR1 and TNFR2 and activate 
the canonical NFκB pathway. Membrane bound LTαβ2 
binds LTβR and activates both canonical and non-
canonical NF-κB signaling (Wolf et al., 2010). LTβR and 
TNFR signaling is essential for lymphoid organ 
development. Figure reused and adapted from 
(Gommerman and Browning, 2003) with permission from 
Nature Publishing Group; Rightslink license number: 
3126480151360. 
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5.1.2 FDC in physiological and pathological conditions 
 
Almost 50 years ago, several researchers published electron microscopic studies of 
lymphoid follicles, which revealed the presence of highly arborizing cells, whose 
dendrites were coated with trapped antigens (Mitchell and Abbot, 1965; Szakal and 
Hanna, 1968). Later, these cells were termed FDC (Klaus et al., 1980; Mandel et al., 
1980; Tew et al., 1982), and many subsequent studies have characterized the 
morphological and functional nature of these elegant cells (Fig. 42) (Aguzzi and Krautler, 
2010; Allen and Cyster, 2008; El Shikh and Pitzalis, 2012).  
 
Figure 42. FDC heterogeneity in primary and secondary lymphoid follicles. FDC and 
follicular stromal cells (FSC, presumably consisting of MRC and IAP, see Table 10) are the 
stromal cells found in B cell follicles. In primary follicles, FDC stain for FDC-M1 antigen (Mfge8 
(Kranich et al., 2008)), FDC-M2, CXCL13, BP3, ICAM1, VCAM1; FDC express CD21/35 and 
show moderate IC trapping. Upon immune activation, FDC in the light zone (LZ) of secondary B 
cell follicles change morphology and marker profile, and express high amounts of CD21/35 and in 
addition FcgR2b, which permits them to efficiently trap IC. Dark zone (DZ) FDC show only 
moderate IC trapping via CD21/35, express SDF1, but not CXCL13, FDC-M2 and Madcam1. 
Figure reused and adapted from (Allen and Cyster, 2008) with permission from Elsevier Limited, 
Oxford; Rightslink license number: 3126410594701. 
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What sets FDC apart from other stromal cells in SLO (Table 10) is their capability to 
capture and retain antigen-antibody complexes (IC) for prolonged periods of time 
(Donaldson et al., 1986). The native antigens are presented to naïve B cells in primary 
follicles, and to B cells in secondary follicles undergoing affinity maturation in GC (Allen 
and Cyster, 2008). In a process of negative selection, only B cells with high affinity 
receptors for the displayed antigens are thought to receive survival signals, whereas 
most B cells undergo apoptosis (McHeyzer-Williams et al., 2012). The apoptotic B cells 
in GC are then labeled with Mfge8 secreted by FDC, which serves as a bridging 
molecule for phagocytic TBM (Kranich et al., 2008). The role of the long-lasting IC 
retention and importance of antigen presentation by FDC in the GC reaction are under 
debate (Haberman and Shlomchik, 2003; Kosco-Vilbois, 2003). Affinity maturation has 
been shown to occur also in mice that lack FDC, yet high amounts of antigens or antigen 
supplied in depots are needed to obtain still suboptimal responses (Allen and Cyster, 
2008; Matsumoto et al., 1996; Wu et al., 2000).  
FDC capture IC via CR1 (CD35) and CR2 (CD21), and in a complement-independent 
mechanism via FcγRIIβ (Fig. 42). FDC do not consist of a homogeneous population, 
since during the transition from a primary to a secondary follicle, they dramatically 
change morphology, expression profile and IC trapping capability (Fig. 42) (Allen and 
Cyster, 2008; Yoshida et al., 1993). Two-photon live microscopy has facilitated the 
detailed investigation of how FDC acquire IC. In LN, IC are formed in the subcapsular 
sinus and bind to CR3 on subcapsular sinus macrophages, which then pass the IC into 
naïve B cells. The naïve B cells transport their prey to FDC and transfer the IC onto the 
CR2 on FDC dendrites (Gonzalez et al., 2011; Phan et al., 2007). A similar relay race 
takes place in the spleen, where IC-laden marginal zone B cells inexorably shuttle from 
marginal zone to the follicle, then pass their baton to FDC (Arnon et al., 2013). 
As mentioned above, FDC can be found in TLO in various chronic infectious and 
autoimmune diseases (Stranford and Ruddle, 2012). Besides contributing to the 
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anatomical scaffold of ectopic follicles, FDC can act as deleterious enhancer of the 
pathology (El Shikh and Pitzalis, 2012; Neyt et al., 2012). In autoimmune diseases such 
as rheumatoid arthritis, FDC continuously present auto-antigen to B cells and thereby 
sustain autoantibody formation. Hence the presence of FDC in ectopic TLO can lead to 
disease progression and is associated with bad outcome (El Shikh and Pitzalis, 2012; 
Manzo et al., 2010). 
Several pathogens have chosen FDC as their hiding place. In HIV infection, FDC retain 
virus particles on their surface and thereby act as the major reservoir for the virus (Smith 
et al., 2001). FDC mediate up-regulation of the HIV co-receptor CXCR4 on CD4+ cells 
and their continuous presentation of virus IC to CD4+ T cells leads to their infection and 
to an increase of the viral load (El Shikh and Pitzalis, 2012; Estes et al., 2002; Thacker et 
al., 2009). Also in the course of prion infection, FDC play a fatal role. Upon peripheral 
infection with prions, prions accumulate in SLO, long before they continue their journey 
to the central nervous system (Aguzzi and Zhu, 2012; Fraser and Dickinson, 1970; 
Glatzel et al., 2003). FDC express high levels of PrP, a prerequisite for disease 
propagation (Brown et al., 1999; Büeler et al., 1993; Klein et al., 1998). A recent study 
demonstrated that FDC-specific expression of PrP is sufficient to sustain prion 
propagation, suggesting that FDC not only serve as prion accumulating cells, but can 
also actively replicate prions (McCulloch et al., 2011). 
 
 
5.1.3 Scientific aims  
 
During embryonic lymphoid organ development, all stromal cells of future SLO derive 
from a mesenchymal precursor (van de Pavert and Mebius, 2010). In adulthood, ectopic 
lymphoid follicles containing mature FDC can occur almost anywhere in organism (Aloisi 
and Pujol-Borrell, 2006), suggesting the presence of a ubiquitous precursor. It is well 
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established that FDC are radiation-resistant stromal cells (Endres et al., 1999); however, 
the nature of the FDC precursor and the precise steps leading to FDC development in 
the adult organism remained incompletely understood.  
In her PhD thesis, Nike Kräutler substantially expanded our knowledge about the 
characteristics of putative FDC precursors. In a series of meticulous experiments around 
the FDC marker Mfge8 (Kranich et al., 2008), she was able to nail down the expression 
patterns of FDC precursor cells and added a crucial missing piece to the puzzle to clarify 
the origin of FDC. Specifically, she found the perivascular location of FDC precursors 
and their expression of PDGFRβ (Kräutler, 2010). In a subsequent Master thesis, 
Dushan Pereira established the isolation protocol for stromal-vascular derived PDGFRβ+ 
cells from adipose tissue. He showed that these cells possess FDC-precursor-like 
properties and that they respond to FDC differentiation factors in vitro (Perera, 2010). 
Several questions about the perivascular origin of FDC remained unanswered. 
Experiments using lineage tracing mouse strains could not unequivocally show that 
mature FDC expressed PDGFRβ+ during development. It was not clear whether the 
isolation of stromal-vascular derived PDGFRβ+ cells from adipose tissue yield pure cell 
populations. And most importantly, if PDGFRβ+ cells are transplanted into an 
environment without mature FDC, but with the presence of differentiation factors, would 
these cells indeed develop into mature FDC? 
Here, I will describe the experiments that led to the proof that mature FDC derive from 
stromal, perivascular PDGFRβ+ precursors. 
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5.2 RESULTS 
 
5.2.1 FDC are derived from PDGFRβ+ precursors 
 
Previous experiments have shown that FDC precursors are located perivascularly and 
that they express the mural cell marker PDGFRβ, a marker undetectable on mature FDC 
(Kräutler, 2010). Lineage tracing experiments using Pdgfrb-Cre mice, crossed to lacZ 
(R26R) Cre-reporter mice expressing beta galactosidase (β-Gal) as a result of Cre-
activity ((Foo et al., 2006), showed that indeed β-Gal activity was found in germinal 
centers containing mature FDC networks (Kräutler, 2010), suggesting that mature FDC 
express PDGFRβ during their development.  
However, the technical process to detect β-Gal activity does not permit additional 
immunhistochemical stainings and therefore the co-localisation of β-Gal staining with 
mature FDC markers on consecutive sections was unable to provide sufficient proof. In 
order to permit immunofluorescent costainings and high-resolution imaging, we crossed 
Pdgfrb-Cre mice with a Cre-inducible fluorescent reporter line (CAG-tdTomato [Ai14]) 
(Madisen et al., 2010). Using confocal microscopy, we observed strong expression of 
tdTomato in spleen sections from Cre+ animals (Fig. 43a), but not in spleens from their 
Cre- littermates (Fig. 43b). In fact, tdTomato was mainly localized in the vascularized 
parts of the spleen (red pulp, marginal sinus and central arteriole) (Fig. 43a). Importantly, 
we found tdTomato positive cells also in the white pulp, especially in areas of Mfge8-
positive mature FDC-networks (Fig. 43c). 
Ai14 mice show homogeneous cytoplasmatic tdTomato expression (Madisen et al., 
2010). In contrast, Mfge8 is a secreted molecule that is detected on the surface of 
Mfge8-expressing cells and on opsonized apoptotic cells, such as apoptotic B cells in the 
germinal center of lymphoid follicles. The two signals differ in their localization within 
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cellular compartments, hence we did not expect to find a precise co-localisation using 
high-resolution imaging. Accordingly, we found that the cell bodies of Mfge8+ cells show 
a strong signal surrounded by weak Mfge8-staining. In contrast, the long filiform 
processes of these cells were strongly Mfge8+ and – due to their sparse cytoplasm – less 
tdTomato+ (Fig. 43). Also, we expected dissociation of the Mfge8 and tdTomato signals 
in areas with densely Mfge8-labeled apoptotic B cells, which would be taken up by TBM, 
suggesting that a small proportion of Mfge8+ cells would be tdTomato-. 
 
 
Figure 43. Immunofluorescent staining for Mfge8 on sections of Pdgfrb-Cre+ Ai14+ spleens. 
(a) Bright expression of the fluorescent reporter tdTomato in the vascular compartment of a 
lymphoid follicle containing Mfge8-positive FDC network. (b) No tdTomato signal was detected in 
Pdgfrb-Cre – Ai14+ mice. (c) Higher magnifications of box in panel a shows bright cytoplasmatic 
tdTomato in Mfge8+ cell bodies (arrowheads) and dendrites (arrows). # central artery. Asterisks 
designate FDC networks in B cell follicles. Scale bar 20 µm. 
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To verify that the majority of Mfge8+ cells were tdTomato+, we performed a quantification 
of the confocal images using the Surpass-spots function of Imaris software (Fig. 44 and 
Table 11). We found that 86.6 ± 8.2% of the Mfge8+ areas in the spleen were also 
tdTomato+. Hence we concluded that (most) Mfge8+ cells (appeared to) have expressed 
PDGFRβ during their ontogeny. 
 
 
 
Figure 44. Morphometric analysis of splenic sections of Pdgfrb-Cre+ Ai14+ spleens stained 
with Mfge8. Four ROI in three confocal images were used for quantification using Imaris 
software. A ROI constituted of the right or left, upper or lower quadrant of a follicle (a). We first 
marked Mfge8+ areas by blue spots in the far-red channel (b). We then assessed in the red 
channel, whether the blue spots were localized on or next to a tdTomato+ area and marked this by 
a yellow dot (c). As shown in the overlay (d) most of the blue spots (Mfge8+) are associated with 
a yellow spot (tdTomato+) (small arrow). Arrowheads point to Mfge8+ spots not associated with 
tdTomato. 86.6 ± 8.2% of spots marking tdTdomato-positivity co-localized with spots marking 
Mfge8-positivity. Detailed numbers are listed in Table 11. Scale bar 20 µm. 
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Image ROI Number of spots in far 
red channel (Mfge8) 
Number of spots in 
red channel 
(tdTomato) 
% tdTomato+ spots co-
localizing with Mfge8+ 
spots 
1 1 56 52 92.86 
 2 67 63 94.03 
 3 46 45 97.83 
 4 85 80 94.12 
2 1 32 27 84.38 
 2 48 42 87.50 
 3 23 16 69.57 
 4 51 38 74.51 
3 1 161 144 89.44 
 2 285 222 86.05 
 3 90 77 85.56 
 4 36 30 83.33 
Sum  953 836  
Average±SD    86.60±8.2 
 
Table 11. Details of quantification of proportion of tdTomato+ in Mfge8+ areas in confocal 
images of Pdgfrb-Cre+ Ai14+ spleens stained for Mfge8 as shown in Fig. 44. Four ROI in 3 
confocal images were quantified using the Surpass-spot function in Imaris software. A total of 953 
spots were analyzed in the far-red channel. Thereof, 836 co-localized with tdTomato signal (86.6 
± 8.2%). 
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5.2.2 Characterization of isolated stromal-vascular PDGFRβ+ cells 
 
To analyze if PDGFRβ+ mural cells represent FDC-precursors, previous experiments 
were performed in our lab to establish the successful isolation of PDGFRβ+ cells from the 
stromal-vascular fraction of perigonadal WAT (Perera, 2010; Tang et al., 2008). 
Intraperitoneal white adipose fat deposits in mice are composed of mesenteric fat, the 
omental depot surrounding the stomach and spleen and bilateral perigonadal fat pads 
located around ovaries and testes (Cinti, 2005). Of those, the perigonadal fat constitutes 
the largest and most easily accessible intraabdominal fat mass in mice and is therefore 
commonly used to isolate the stromal-vascular fraction of adipose tissue. Mesenteric fat 
is known to contain mesenteric fat-associated lymphocytic clusters (FALC) (Moro et al., 
2010). FALC contain B cells required for the differentiation of FDC in secondary 
lymphoid organs and tertiary lymphoid tissues.  
We wanted to ensure that the perigonadal fat pads, which we used for PDGFRβ+ cell 
isolation, did not contain lymphocytic structures, which might contaminate our isolation 
and possibly skew our interpretations. We therefore performed serial sections through 
perigonadal fat pads of wild type animals and searched for the presence of lymphocytic 
clusters, in particular B cells. We did not detect lymphocytic infiltrates in the perigonadal 
fat by systematic histological analysis of perigonadal fat depots of two different mice. The 
fat contained abundant vasculature structures (Fig. 45a) and only scattered CD45+ cells, 
most of which were CD68+ macrophages (Fig. 45b). These results were confirmed by 
FACS analysis of perigonadal fat pads. Consistent with the histological analysis, CD45+ 
cells in fat consisted mainly of CD68+ macrophages (89%). Importantly, less than 0.05% 
of cells were B-cells and we did not find any follicular (CD23highCD21/35low) or marginal 
zone (CD23lowCD21/35high) B cells, which are cells essential for FDC maturation (Krautler 
et al., 2012). We concluded that the perigonadal white adipose fat used for isolation of 
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the stromal-vascular fraction does not contain lymphocytic structures, in particular no 
follicular or marginal zone B cells. 
 
Figure 45. Histological analysis of white adipose perigonadal fat and spleen sections from 
B6 mice. Serial sections taken every 100 µm were analyzed by HE (a) and immunofluorescent 
staining of CD45, CD68 (b) and B220 (not shown). The perigonadal fat contained many blood 
vessels (black arrows), but no lymphocytic. In comparison to spleen (c), the fat tissue contained 
only few scattered hematopoietic cells, the majority being macrophages (white arrows). Scale bar 
100 µm. 
 
 
Next, we wanted to further analyze the purity and characteristics of the cell fraction 
obtained by sorting stromal-vascular cells for PDGFRβ+ CD45- (Fig. 46). We extracted 
RNA from freshly sorted stromal-vascular PDGFRβ+ cells and total fat tissue and 
determined the expression of Perilipin-1 (Plin1) as a marker for adipocytes (Fig. 47a) and 
Cd45 for hematopoietic cells by RT-PCR (Fig. 47b). Compared to the serially diluted fat 
cDNA (102 to 108 dilutions), the sorted PDGFRβ+ cells showed 100-1000x less Plin and 
Cd45 expression. We concluded that sorted stromal-vascular PDGFRβ+ cells did not 
have relevant contamination by fat (Plin) or hematopoietic cells (Cd45). 
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Figure 46. Gating strategy for obtaining the PDGFRβ+CD45- cell fraction from collagenase-
digested stromal-vascular component of perigonadal WAT from a representative 
experiment (middle panel). Isotype staining confirmed the specificity of the staining (left panel) 
and the reanalysis determined the purity of the yielded cell population (right panel): 98.7% 
PDGFRβ+CD45- compared to 0.6% in isotype-stained sample (left panel). 
 
 
Figure 47. Purity of freshly sorted stromal-vascular PDGFRβ+ cells analyzed by RT-PCR. (a) 
Plin1 was used as adipose marker and (b) Cd45 as hematopoietic marker. Total fat cDNA was 
serially diluted from 102-108, of PDGFRβ+ stromal-vascular cell cDNA was used in 102 dilutions, 
H2O served as negative and Gapdh amplification as endogenous control. 35 PCR cycles were 
performed. In PDGFRβ+ stromal-vascular cells, both Plin1 and Cd45 expressions were 100-1000 
times reduced.  
 
To further characterize the expression profile of freshly sorted stromal-vascular 
PDGFRβ+ cells, we assessed PDGFRβ+ cell expression of markers for mural cells 
(Pdgfrb, Ng2), FDC-receptors (Ltbr and Tnfr1) and FDC-associated markers (Bp3, Cd21, 
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Fcgr2b, Madcam1, Clusterin, Cxcl13, Vcam1, Icam1, Periostin (Postn)), Sdf1) by qPCR 
and compared it to the expression of spleens (Fig. 48). Compared to spleen (set as 
100% expression level), mural cells markers were highly upregulated (Ng2 (1210%), 
Pdgfrb (737%)), confirming the identity of the isolated cells. Transcripts enconding LTβR 
and TNFR1, which are required for FDC differentiation, were both highly abundant (Ltbr 
(508%) and Tnfr1 (1639%)), as well as Periostin (Postn (12,055%), Icam1 (235%), 
Enpp2 (240%), Sdf1 (254%), and Prnp (576%, not included in Fig. 48). Some transcripts 
were reduced (Mfge8 (37%), Cxcl13 (21%), Vcam1 (64%), Igfbp3 (96%)), and others 
were strongly downregulated (Clusterin (4%), Madcam1 (2%), Bp3 (0.3%)), importantly 
also the transcripts characteristic of mature FDC, Cd21 (0.6%), and Fcgr2b (0.6%). 
Thus, isolated stromal-vascular PDGFRβ+ cells exhibited similar characteristics of 
putative immature FDC located in the marginal zone of splenic follicles (“preFDC”, 
(Kräutler, 2010)). 
 
 
Figure 48. Characterization of PDGFRβ+ 
cells isolated from the adipose stromal-
vascular compartment. FDC-associated 
markers (in black), receptors essential for 
FDC differentiation (in orange) and mural 
cell markers (in blue) were analyzed by 
qPCR from stromal-vascular PDGFRβ+ cells 
after sorting from perigonadal WAT and 
compared to their expression in spleens with 
Gapdh as endogenous control. Values are 
presented in a log2 scale (blue: 
downregulated, red: upregulated, white: no 
change in expression). Columns indicate 
individual spleens and each square 
represents the median expression of a 
particular gene (3 technical replicates) normalized to its mean expression in WT spleens (n=3). 
The heatmap was produced by Ulrich Wagner, Ludwig Institute for Cancer Research, University 
of California, San Diego. 
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The above measurements confirmed the purity and mural phenotype of the sorted 
PDGFRβ+ cells. The strong upregulation of transcripts coding for the FDC differentiation 
receptors LTβR and TNFR1 suggested that these cells might respond to their ligands 
and possibly differentiate into FDC. Previous experiments already showed that PDGFRβ+ 
cells, when cultured for 24 hours in the presence of agonistic anti-LTβR antibody and 
TNF (Katakai et al., 2008), responded by inducing FDC-associated markers Vcam1, 
Icam1 and Igfbp3, and downregulating the mural marker Pdgfrb, as assessed by qPCR 
(Perera, 2010). These experiments suggested that treated PDGFRβ+ cells indeed 
developed into FDC-like cells and at the same time lost their mural cell characteristics.  
In order to confirm these findings and to include additional markers, we repeated this 
analysis (Fig. 49). We compared mRNA levels of stromal-vascular PDGFRβ+ cells 
isolated from perigonadal WAT, which were treated with agonistic anti-LTβR antibody or 
its isotype control, both in the presence of TNF. Again, we found upregulation of Vcam1 
and Icam1, together with an increased expression of the additional FDC-associated 
markers Madcam1, Enpp2, and Sdf1, while Igfbp3 was not changed. The mural marker 
Pdgfrb was again downregulated, whereas Ng2 was not significantly changed. We found 
Mfge8 to be slightly downregulated, which is in contrast to previous experiments, where 
Mfge8 was not significantly changed, but showed variable expression between the 
replicates (Perera, 2010). Interestingly, Postn, which was highly expressed in freshly 
isolated and sorted stromal-vascular PDGFRβ+ cells, was not found in marginal zone 
preFDC (Kräutler 2012), whereas mature FDC again express Postn, possibly pointing to 
a transient downregulation of this marker during FDC maturation. To conclude, 
PDGFRβ+ cells tended to respond by expressing FDC-associated markers and to lose 
their mural cell phenotype when stimulated with FDC maturation factors in vitro. Hence, 
the in vitro conditions permitted the cells to make first steps towards FDC differentiation. 
However, the lack of detection of Bp3, Cd21 and Fcgr2b suggests that in vitro conditions 
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do not suffice to provide all requirements and signals needed for the differentiation of 
stromal-vascular PDGFRβ+ cells to mature FDC.  
 
 
 
Figure 49. Analysis of mural cell (in blue) and FDC-associated (in black) markers of 
stromal-vascular PDGFRβ+ cells. After FACS-sorting, cells were cultured for 24h, subsequently 
stimulated for 24h with agonistic anti-LTβR antibody and TNF or isotype control antibody. 
Expression of the following transcripts in agonist-, and isotype treated samples were assessed by 
qPCR and compared by unpaired t-test: Mfge8 (p=0.0136), Madcam1 (p=0.0324), Vcam1 
(p=0.0123), Igfbp3 (p=0.3328), Icam1 (p=0.026), Enpp2 (p=0.0088), Sdf1 (p=0.0195), Pdgfrb 
(p=0.0005), Ng2 (p=0.1604), and Periostin (p=0.0195). The graph shows relative expression 
compared to isotype-treated PDGFRβ+ cells and normalized over Gapdh mRNA levels (n=3 x 3). 
Error bars: SEM. 
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5.2.3 Transplanted PDGFRβ+ stromal-vascular cells develop into mature 
FDC 
 
We confirmed that mature FDC express PDGFRβ during their development, reinforcing 
the hypothesis that FDC stem from perivascular mural PDGFRβ+ precursors. We also 
confirmed that PDGFRβ+ cells can readily be isolated from the stromal-vascular fraction 
of perigonadal WAT into pure cells populations, and found that they expressed mural cell 
markers, receptors required for FDC differentiation, but lacked markers found on mature 
FDC. These cells also responded to FDC maturation factors in vitro by acquiring FDC-
like properties. However so far, we could not show that PDGFRβ+ cells can truly develop 
into mature FDC.  
To prove their bona fide identity as FDC precursors and to provide all requirements for 
differentiation, we decided to transplant stromal-vascular PDGFRβ+ cells under the renal 
capsule of recipient mice without FDC (Ltbr-/-) or lacking a mature FDC marker (CD21/35-
/-). Ltbr-/- mice cannot develop mature FDC (Fütterer et al., 1998), and they show dense 
perivascular lymphocytic infiltrates in lung, kidney, pancreas and liver due to aberrant 
homing of B and T cells to non-lymphoid organs (Chin et al., 2003). CD21/35-/- mice do 
have FDC, however they show an impaired humoral immune response due to an 
impaired IC trapping capability of FDC (Ahearn et al., 1996; Fang et al., 1998). Renal 
capsule grafting is a method broadly used in various research fields, such as cancer 
research (Wang et al., 2005), developmental research (Kurita et al., 2005; Ohazama et 
al., 2004), diabetes research (Zmuda et al., 2011) or immunology (Suematsu and 
Watanabe, 2004). The highly vascularized kidney not only ensures favorable outcomes 
of graft survival, but also permits to study the interaction of the graft with the host tissue 
in an in vivo setting. 
We again isolated the stromal-vascular fraction of perigonadal WAT from B6 donors and 
FACS-sorted PDGFRβ+ cells (Fig. 46). We then soaked those cells into collagen 
122 |  
 
 
 
sponges (Suematsu and Watanabe, 2004) and immediately transplanted them under the 
renal capsule of Ltbr-/- hosts in a first transplantation round, and of CD21/35-/- hosts in a 
second round of experiments. At day 7 and 15 post transplantation, we immunized and 
boosted, the animals i.v with sRBC to stimulate the development of lymphocytic tissues. 
After four weeks, we found clearly visible subcapsular renal transplants (Fig. 50). In two 
Ltbr-/- mice, the kidneys showed signs of acute inflammation (Fig. 50b). We then 
performed serial cryosections through the whole transplants. Each transplant yielded 20-
30 slides containing collagen sponge material and when stained by HE, lymphocytic 
aggregates were seen. Per transplant, we typically detected ≥10 distinct lymphocytic 
aggregates. When analyzed by immunohistochemistry, the transplants exhibited 
lymphocytic foci (Fig. 51a) containing B220+CD21/35+ B and CD3+ T lymphocytes, as 
well as putative CD21/35+ and FDC-M1+ FDC (Fig. 51b). We further analyzed the 
transplants by immunofluorescence and found Mfge8+ cells that co-expressed the 
mature FDC marker CD35 and formed a network among B220+ B cell lymphoid 
aggregates (Fig. 52a). These Mfge8+ cell networks also co-expressed other FDC-
associated markers, such as FcγRIIβ and PrP (Fig. 52b, c) In some lymphocytic foci, we 
found Mfge8+CD68+ macrophages that had engulfed apoptotic cells, reminiscent of TBM 
found in germinal centers close to FDC (Fig. 52c) (Kranich et al., 2008). Since the Ltbr-/- 
hosts cannot generate FDC, we concluded that mature FDC in the collagen sponges 
must have developed from the transplanted donor-derived stromal-vascular PDGFRβ+ 
cells. 
 
Figure 50. Macroscopic aspect of kidneys containing PDGFRβ+-transplants four weeks 
after surgery. (a) Kidney containing subcapsular renal graft in situ. (b) Examples of macroscopic 
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aspect of Ltbr-/- kidneys containing sponges. Arrows point to subcapsular renal graft containing 
sorted stromal vascular PDGFRβ+ cells in collagen sponges. Some kidneys showed a distinct 
roundish graft, some large flat grafts. The lower right kidney shows signs of inflammation. (c) 
Macroscopic aspects of CD21/35-/- kidneys containing subcapsular renal grafts (arrows). Scale 
bar 5 mm. 
 
 
Figure 51. Analysis of subcapsular renal transplant of Ltbr-/- and CD21/35-/- recipients four 
weeks after transplantation of collagen sponges containing PDGFRβ+ cells. (a) HE sections 
through the transplanted collagen sponge and kidney of Ltbr-/- (left panel) and C21/35-/- (right 
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panel) hosts stained with HE. Sponges contained dense lymphocytic aggregates (arrows). 
Dashed line indicates the border of collagen sponge and renal cortex. (b) Consecutive sections of 
lymphocytic aggregate of Ltbr-/- transplant showing CD3+ T cells, B220+/CD21/35+ B cells and 
putative CD21/35+ and FDC-M1+ FDC. Small arrows in upper middle panel designate collagen 
fiber. Scale bars: 100 µm. 
 
 
Figure 52. Immunofluorescent staining on collagen sponges containing PDGFRβ+ cells 
transplanted into Ltbr-/- host. (a) Mfge8+ CD35+ FDC enmesh B220+ B cell aggregate. Mfge8+ 
cells co-express FcγRIIβ (b) and PrP (c). Arrowheads point to Mfge8+ CD68+ TBM. Asterisks 
designate FDC-like network. Scale bars: 100 µm. 
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To ensure that the observed effect was dependent on the presence of PDGFRβ+ cells, 
we performed control transplantations with collagen sponges without stromal-vascular 
PDGFRβ+ cells into Ltbr-/- recipients (Fig. 53). These transplants contained scattered 
CD3+ T cells, few scattered B220+CD21/35+ B cells and many macrophages (not shown). 
Apart from Mfge8+ mesangial cells in the glomeruli of the renal cortex (Brunskill and 
Potter, 2012; Kräutler, 2010), we were unable to detect Mfge8+ cells within densely 
packed lymphocytic aggregates in the collagen transplants, as seen in sponges 
containing PDGFRβ+ cells (Fig. 53). Also extensive immunofluorescent studies failed to 
locate cells within the collagen sponges with network-like morphology and co-expressing 
Mfge8 with other FDC-associated markers (CD21/35, CD35, FcγRIIβ and PrP). We 
therefore concluded that the successful development of mature FDC in Ltbr-/- recipients 
depended on the addition of wild type adipose-derived stromal-vascular PDGFRβ+ cells. 
 
 
Figure 53. Analysis of subcapsular renal transplant of Ltbr-/- recipient without transplanted 
PDGFRβ+ cells. Four weeks after surgery, HE shows transplant containing collagen fibres, dense 
extra cellular matrix and scattered cells, but no dense lymphocytic infiltrates. Instead, the collagen 
sponge contains scattered CD3-positive T cells, few scattered CD21/35 cells, and no FDC-M1 
positive cells associated to lymphocytic infiltrates. Dashed line indicates the border of collagen 
sponge and renal cortex. Arrows point to glomeruli with FDC-M1 expressing mesangial cells. 
Scale bar 200 µm.  
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5.2.4 FDC derived from transplanted PDGFRβ+ stromal-vascular cells trap 
IC 
 
So far we have found that four weeks after renal subcapsular transplantation of collagen 
sponges containing stromal-vascular PDGFRβ+ cells, these transplants showed 
inflammatory foci containing cells that expressed markers found on mature FDC (Mfge8+ 
CD35+ FcγRIIβ+) and had the network-like morphology of FDC. Moreover, these FDC 
networks enmeshed B cell aggregates and some lymphoid foci contained TBM, features 
that can be found in germinal centers of lymphoid follicles. These findings suggest that 
stromal-vascular PDGFRβ+ cells may give rise to mature – and possibly functional - FDC.  
A defining feature of FDC is their capability to trap and retain IC for a long time, 
presenting them to developing B cells in germinal centers. FDC trap IC using the CR1 
(CD21) and CR2 (CD35) or FcγRIIβ (CD32), and their IC trapping capacity is highest in 
the light zone of GC in secondary follicles (Allen and Cyster, 2008; Yoshida et al., 1993). 
If the newly developed cells in the transplanted collagen sponges were indeed mature 
and functional FDC, they must be able to trap IC. We therefore wanted to test the IC 
trapping capability of the Mfge8+ networks in the sponges.  
IC trapping can be visualized in vitro, originally described by using anti-HRP-HRP 
complexes (Dijkstra et al., 1983). We used mouse PAP-IC and visualized peroxidase 
activity with a fluorescent dye in combination with Mfge8 or CD35 staining either in the 
presence of mouse serum (CR-mediated IC trapping requiring complement) or in 
absence of mouse serum (FcγRIIβ-mediated IC trapping) (Yoshida et al., 1993). We 
analyzed sections of subcapsular renal transplants of Ltbr-/- recipients four weeks after 
transplantation of collagen sponges containing PDGFRβ+ cells (Fig. 54). Both in 
presence and absence of mouse serum, we failed to detect PAP-IC in collagen sponges, 
despite the presence of Mfge8+ or CD35+ cell networks (Fig. 54). PAP-IC were largely 
bound on the abundant CD68+ macrophages in the collagen sponges (not shown). In 
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contrast, we found both CD35+ IC-PAP+ and Mfge8+ IC-PAP+ cells in B6 spleens (Fig. 
54). Interestingly, we detected many small primary follicles with CD35+ IC-PAP- and 
Mfge8+ IC-PAP- cell networks, alike in the transplants. This suggests that the lymphocytic 
aggregates found in transplanted collagen sponges resemble primary splenic follicles, 
which show a limited IC trapping capability, although their FDC already express the 
necessary receptors (Allen and Cyster, 2008; Yoshida et al., 1993) . 
IC trapping can also be visualized in vivo, for instance using fluorescent PE-anti-PE-IC 
(IC-PE) (Phan et al., 2007). To test this approach, we first injected B6 animals i.p. with 
anti-PE antibodies and 12h later with PE and analyzed spleen and lymph nodes (Fig. 
55). After 24h, we detected IC-PE bound to FDC networks in splenic lymphoid follicles 
and large amounts of non-FDC bound IC-PE both in the red and white pulp, 
documenting that cells other than FDC capture large amounts of IC and deliver them to 
FDC (Arnon et al., 2013; Mebius and Kraal, 2005). After 72h, most of the IC-PE signal 
was confined to FDC networks in the white pulp and co-stained with Mfge8 and CD35 
(Fig. 55).  
Next, we tested the IC trapping capability of newly developed FDC in collagen sponges 
containing PDGFRβ+ cells transplanted into CD21/35-/- hosts (Fig. 50, Fig. 51), which had 
been immunized and boosted with sRBC at day 7 and 14 after surgery, respectively. At 
day 28, we injected the mice i.p. with anti-PE, 12h later with PE, and sacrificed the mice 
three days later. The use of CD21/35-/- hosts permitted us to track potential newly 
developed mature FDC by the expression of CD21/35 as a genetic marker. In one of four 
operated animals, we detected IC-trapping cell clusters expressing CD21/35 displaying a 
network-like appearance (Fig. 56). Since any CD21/35 expressing cell must have been 
derived from the transplanted donor cells, we concluded that stromal-vascular PDGFRβ+ 
cells were indeed able to develop into mature and functional FDC. 
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Figure 54. In vitro PAP IC trapping in B6 spleen and subcapsular kindey transplants 
containing PDGFRβ+ cells four weeks after surgery. Cryosections of Ltbr-/- kidneys with 
collagen sponges or B6 spleens were incubated with PAP in the presence or absence of normal 
mouse serum, and co-stained with CD35 (a) or Mfge8 (b). No detection of CD35+PAP+ or 
Mfge8+PAP+ cells in transplants containing networks of CD35+ or Mfge8+. PAP trapping cells 
consisted largely of macrophages (not shown). CD35+PAP- or Mfge8+PAP- cell networks were 
also seen in small primary follicles in spleens, whereas secondary follicles exhibited high amounts 
of PAP trapping CD35+ or Mfge8+ co-expressing cells. Scale bar 50 µm 
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Figure 55. In vivo PE anti-PE IC trapping in B6 spleen (a) and inguinal lymph nodes (b,c). 
Mice were injected i.p. with anti-PE antibody and after 12h i.p. with PE to target the spleen or s.c. 
to target inguinal lymph nodes. 24h later, IC-PE could be detected both on FDC and on scattered 
cells in the red and white pulp (a, left and middle panel). After 72h, IC-PE retention was largely 
confined to FDC (a, right panel), and co-stained with Mfge8 and CD35, as shown in inguinal LN 
(b,c). Dashed line indicates border of lymphoid follicle. Asterisk marks FDC-network. Scale bar 50 
µm. 
 
Figure 56. In vivo PE anti-PE IC trapping in CD21/35-/- mice four weeks after renal 
subcapsular grafting of collagen sponge containing stromal-vascular PDGFRβ+ cells. Mice 
were injected i.p. with anti-PE antibody and with PE 12h later. After 72h, mice were sacrificed. 
Sponges contained donor-derived CD21/35+ with network-like morphology, capable of trapping IC 
(upper panels). Isotype control staining (lower panels) was performed on a consecutive section 
and confirmed specificity of the CD21/35 staining. Arrows point to CD21/35+ IC-PE+ cells. Scale 
bar: 50 µm.   
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5.2.5 Factors influencing outcome of stromal-derived PDGFRβ+ cells 
transplantations 
 
Not all transplantations of stromal-derived PDGFRβ+ cells showed a successful outcome. 
Of total 20 transplantations into Ltbr-/- or CD21/35-/- recipients, seven proved to be 
successful, as determined by the presence of lymphocytic infiltrates containing CD3+, 
B220+, CD21/35+, and FDC-M1+ cells (35%, Table 12). We wondered which factors 
might influence the successful development of a transplanted stromal-derived PDGFRβ+ 
cell into a mature and IC-trapping FDC.  
To support and stimulate the development of FDC networks, we immunized animals with 
sRBC i.v. Of 18 sRBC-immunized animals, six showed a successful outcome (33.3%). 
However, one non-immunized animal showed development of lymphocytic aggregates 
containing FDC (one of two non-immunized mice), hence immunization did not seem to 
be the main factor influencing outcome of the transplantations. 
Since we treated some of the animals post-operatively with antibiotics, we also assessed 
the effect of antibiotic treatment on transplantation outcome (Table 12). Of eight Ltbr-/-, 
which were kept under SPF conditions, none developed inflammatory foci with FDC, 
when treated with antibiotics right after surgery (0%). In contrast, six out of eight mice 
(75%), which did not receive post-operative antibiotic treatment, developed lymphoid 
aggregates in the transplants. Of four CD21/35-/- mice, which were housed under non-
SPF conditions, one animal showed a successful outcome, when treated with antibiotics 
post-operatively. This suggested that post-operative treatment with antibiotics acted as a 
negative factor affecting outcome of the transplantations and that an inflammatory 
environment might be favorable. We concluded that the successful formation of 
lymphocytic aggregates and differentiation of stromal-derived PDGFRβ+ cells to FDC in 
the transplanted collagen sponges appears to be mainly modulated by the immune 
status of the recipient mice. 
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 Recipient (n) Successful (n) Successful (%) 
All transplantations Ltbr-/- 16 6  
 Cd21/35-/- 4 1  
 total 20 7 35.0 
Effect of immunization     
Immunized Ltbr-/- 14 5  
 Cd21/35-/- 4 1  
 total 18 6 33.3 
Non-immunized Ltbr-/- 2 1  
 Cd21/35-/- 0 0  
 total 2 1 50.0 
Effect of antibiotic treatment    
Treated day 0-14 Ltbr-/- 8 0  
 Cd21/35-/- 4 1  
 total 12 1 8.3 
Non-treated day 0-14 Ltbr-/- 8 6  
 Cd21/35-/- 0 0  
 total 8 6 75.0 
 
Table 12. Overview of animals transplanted with adipose-derived stromal-vascular 
PDGFRβ+ cells and determination of the successful formation of lymphocytic aggregates 
containing CD3+, B220+, CD21/35+, FDC-M1+ cells. Assessment of the effect of sRBC 
immunization and post-operative antibiotic treatment on the successful outcome of the 
transplantations. 
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5.3 DISCUSSION 
 
5.3.1 PDGFRβ as a marker for FDC precursors  
A vast amount of experimental evidence pointed to a mesenchymal origin of FDC, but 
the identity of the direct precursor cells is not known. Using Mfge8 as a guiding molecule, 
previous work of our lab identified earliest Mfge8+ cells in the perivascular space, which 
co-expressed PDGFRβ. Here, using lineage tracing with Pdgfrb-Cre crossed to 
fluorescent reporter mice, we identified cells that co-expressed the fluorescent reporter 
and Mfge8 within FDC networks in B cell follicles, hence proving that these mature FDC 
expressed PDGFRβ+ during their development. To unambiguously show that 
perivascular PDGFRβ+ can develop to FDC, we isolated PDGFRβ+ cells from the 
stromal-vascular fraction of adipose tissue. After previously having made sure that our 
isolation protocol permitted us to obtain pure cell population not contaminated with 
mature FDC, we transplanted collagen sponges containing PDGFRβ+ cells under the 
renal capsule of mice, which cannot develop FDC. After four weeks, we identified 
lymphocytic aggregates containing mature and functional FDC within the sponges, 
thereby proving that FDC arise from PDGFRβ+ stromal-vascular cells. 
We transplanted 300,000-500,000 PDGFRβ+ cells, but detected only about 10-20 
conspicuous inflammatory foci in sponges of successful transplantations (Table 12). One 
possible reason for this apparently low yield might be a substantial loss of viable cells 
due to the stressful sorting and transplantation procedure. Another possibility might be 
that only a small fraction of the transplanted PDGFRβ+ cell population contained true 
FDC precursors. What are the reasons to believe that?  
In the adult stromal-vascular compartment, PDGFRβ+ is expressed by the two mural cell 
populations, vSMC and pericytes, which share also the expression of NG2, CD13 and 
under certain circumstances, α-SMA (Armulik et al., 2011; Gaengel et al., 2009). Both 
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vSMC and pericytes themselves do not represent a homogeneous population in terms of 
origin and their characteristics vary substantially depending on vessel type and size, and 
activation status (Adams and Alitalo, 2007; Armulik et al., 2011; Etchevers et al., 2001; 
Owens et al., 2004). Moreover, the lack of specific pericytes markers has often 
hampered the distinction of the two populations, which both ensheath the inner 
endothelial vessel wall. The difference is largely based on their morphology with 
pericytes sharing the basement membrane directly with endothelial cells and forming a 
single and discontinuous layer around them, while vSMC form continuous concentric 
layers around vessels (Armulik et al., 2011). 
Which of the cell types could represent or contain the putative FDC precursors? Both cell 
types have been reported to upregulate Mfge8 expression in states of stress and 
inflammation. In vSMC, Mfge8 has been linked to arterial wall inflammatory remodeling 
in hypertension, arteriosclerosis and diabetes mellitus, since Mfge8 expression is 
increased in activated and proliferating vSMC in an age-dependent manner (Fu et al., 
2009; Wang et al., 2012a; Wang et al., 2012b). Mfge8 is also expressed in retinal 
pericytes and in pericytes within melanomas, where it appeared to regulate pathologic 
angiogenesis partly via increased PDGFRβ signaling (Motegi et al., 2011a; Motegi et al., 
2011b). Hence, both vSMC and pericytes have a latent immunological potential (Olson 
and Soriano, 2011). In aortic arteriosclerotic lesions with TLO formation, activated vSMC 
expressed CXCL13 (Gräbner et al., 2009) and NG2+ pericytes were even shown to be 
able to sense inflammatory mediators and to actively allure innate leucocytes (Stark et 
al., 2013).  
Mural cells have also attracted attention in the stem cell field. While the existence of a 
vascular stem cell niche seems to be widely accepted (Bautch, 2011), the true stem cell 
potential and direct contribution to cell renewal of pericytes and vSMC is strongly 
debated (Armulik et al., 2011; Lin and Lue, 2013; Péault, 2012). Even so, mural cells 
seemed to gain stem cell properties when removed from their local vessel environment, 
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which led to the concept that pericytes might represent a stem cell reservoir (Bianco et 
al., 2008). Moreover, isolated mural cells carrying pericyte markers were reported to 
generate among others, adipocytes (Tang et al., 2008), osteoblasts and muscle fibres 
(Crisan et al., 2008; Dellavalle et al., 2011). Our finding that isolated mural cells can 
differentiate into FDC might therefore extend this list. 
Independent of the question of whether PDGFRβ+ cells that differentiated into mature 
FDC in our model should be called vSMC or pericytes or whether they represent cells in 
a continuum of differentiated mesenchymal stem cells within the vasculature, additional 
experiments are needed to better define their characteristics. Apart from PDGFRβ, 
additional markers such as Mfge8 might help to identify the immediate precursor cell 
likely to develop into FDC from the stromal-vascular compartment. In the more 
specialized environment of LN and spleen, gp38-CD31- IAPs and gp38+CD31-CXCL13+ 
MRC are the most promising cell populations for further investigation of immediate FDC 
precursors (Table 10) (Link et al., 2007; Malhotra et al., 2012; Malhotra et al., 2013; van 
de Pavert and Mebius, 2010). 
 
 
5.3.2 Recapitulation of FDC development in a collagen sponge 
Of 20 subcapsular kidney transplantations of PDGFRβ+ cells into 16 Ltbr-/- and four 
CD21/35-/- recipients, seven proved to be successful (35%; six Ltbr-/- recipients and one 
CD21/35-/- recipient), as determined by the presence of dense lymphocytic aggregates 
with CD3+, B220+, CD21/35+ and FDC-M1+ cells within the collagen sponges. We 
analyzed sRBC immunization and postoperative antibiotic treatment as factors that might 
influence the outcomes of the transplantations, and found that antibiotic treatment in the 
first 14 days after surgery seems to correlate with a negative outcome.  
What are the ideal circumstances that could enhance survival and lead to successful 
FDC maturation of transplanted PDGFRβ+ cells in the subcapsular renal space? A 
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prerequisite for cell survival is a sufficient supply of oxygen and nutrients. Before transfer 
to the recipient, the collagen sponge containing the sorted cells was soaked in cell 
culture medium and the procedure of placing the collagen sponge under the renal 
capsule inevitably led to a small damage of the highly vascularized renal cortex causing 
leakage of blood into the postoperative wound. Hence, it can be assumed that the 
transplanted cells have received all factors needed for survival. 
Transplanted PDGFRβ+ cells not only need to survive, but crucially depend on signals to 
differentiate into FDCs, the most important being LTαβ2 and TNF from LTi and B cells. As 
a consequence, and in parallel to “successful” TLO development, any factor that attracts 
LTi and B cells to the collagen sponge and triggers LTαβ2 and TNF secretion for a 
prolonged time would support maturation of PDGFRβ+ cell into FDC. Such initial trigger 
could be damage-associated molecular patterns (DAMPs) produced through mechanical 
damage introduced through the operation and placement of foreign biomaterial (Chen 
and Nuñez, 2010). In addition, the bacterial load introduced peri-operationally might have 
led to a chronic inflammatory stimulus needed for a sufficient and prolonged LTαβ2 and 
TNF supply for the PDGFRβ+ cell. Similar to helicobacter pylori eradication, where 
antibiotic treatment leads to the disappearance of lymphoid follicles located in the gastric 
mucosa and prevents the new formation thereof, our postoperative use of a broad-
spectrum antibiotic might have prevented chronic inflammatory stimuli and subsequent 
differentiation of PDGFRβ+ cells into mature FDC. Therefore, besides omitting antibiotic 
treatment, the addition of immunostimulatory molecules, such as CpG oligonucleotides 
or treatment with agonistic anti-CD40 antibody to stimulate B cells, might promote 
successful FDC development. On the side of the recipient, the presence of inflammatory 
cells at the site of operation might also be favorable. In this regard, Ltbr-/- mice represent 
a good model, since they show large perivascular lymphocytic infiltrates in peripheral 
organs including kidneys (Chin et al., 2003). Therefore, transplantations into Ltbr-/- hosts, 
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crossed to RIP-LTα mice (Sacca et al., 1997), which show chronic inflammation in 
kidneys, might even improve  transplantation outcomes. 
Besides searching for cells exhibiting the typical FDC network morphology and 
expressing typical FDC markers, we looked for evidence that our de novo FDC were 
functional. The ability to trap and retain IC for a long time is a functional hallmark of FDC, 
and we indeed identified CD21/35+ cells in CD21/35-/- recipients that had trapped PE-anti 
PE IC in vivo. Yet the development of IC trapping FDC seemed to represent a rare 
event, since only one of four treated CD21/35-/- mice exhibited such cells. Also, previous 
attempts to detect IC trapping FDC in vitro in Ltbr-/- transplants were not successful, 
despite the presence of Mfge8+CD21/35+FcγRII+ networks. These findings are in contrast 
to the notion that the appearance of CD21/35 on developing FDC coincides with IC 
trapping competence (Balogh et al., 2001; Horie et al., 1999). These results were 
obtained in developing murine spleens or in immunized LN, hence in SLO. However, to 
my knowledge, the dynamics of IC trapping in TLO has not been studied so far. In order 
to receive an IC, FDC depend on the well-organized delivery of B cells that have 
received the charge from subcapsular sinus macrophages in the LN (Phan et al., 2007), 
or marginal zone macrophages in the spleen (Arnon et al., 2013; Batista and Harwood, 
2009). Thus, in a rather disorganized environment as TLO or the transplanted collagen 
sponge, this process might not be as efficient as in SLO. In our transplantation setting, 
additional postoperative time and further stimulation of FDC development and TLO 
formation might have increased in vitro IC trapping ability of de novo generated FDC and 
the amount of IC trapped on their surface in vivo.  
 
 
5.3.3 A role for FDC precursors in prion diseases? 
Within lymphoid organs, PrPC-expressing FDC are thought to be the main cells of 
extraneuronal prion accumulation and the genetic or pharmacological ablation of LT and 
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TNF-signaling pathways required for FDC development abrogate or delay splenic prion 
accumulation (Klein et al., 1997; Mabbott et al., 2003; Montrasio et al., 2000). In LN, 
however, prion accumulation is TNFR-signaling independent, yet requires LTβR-
signaling, suggesting that cells other than mature FDC can accumulate prions (Prinz et 
al., 2002). These candidate prion accumulating cells have recently been more precisely 
characterized: in TNFR-/- LN, PrPSc was present in and around Madcam1+ HEV, and the 
prion deposition on these Madcam1+ cells was dependent on LT (O'Connor and Aguzzi, 
2013; O'Connor et al., 2012), in agreement with the LTβR-signaling dependence of HEV 
development and maintenance (Browning et al., 2005). Furthermore, FDC-independent 
accumulation was also observed in granulomas (Heikenwalder et al., 2008), which are 
small nodules consisting of epitheloid macrophages surrounded by a rim of fibroblasts 
and lymphocytes that can develop as a reaction to chronic inflammatory stimuli or foreign 
bodies. In granulomas, the putative prion-accumulating cell was characterized as a 
CD45-gp38-CD31-FDC-M1-VCAM-PrP+PDGFRαβ+LTβR+ stromal cell with mesenchymal 
stem cell characteristics (Heikenwalder et al., 2008; Nuvolone et al., 2009). 
Our finding that FDC arise from stromal perivascular PDGFRβ+ cells raises the 
interesting question whether cells that have been found to accumulate prions in the 
absence of mature FDC are in fact FDC precursors. Similar to the prion-accumulating 
cells in granulomas, FDC precursors express high levels of LTβR, PrP and PDGFRβ, 
and share markers and properties with FRC and IAP, which surround HEV (Link et al., 
2007; Malhotra et al., 2013; von Andrian and Mempel, 2003). Upon LTβR and TNFR 
stimulation, they upregulate Madcam1 expression and lose their mesenchymal stem cell 
like characteristics, in accordance with the concept that all stromal subsets of the 
secondary follicle derive from a common mesenchymal origin (Cupedo et al., 2004a; van 
de Pavert and Mebius, 2010), and that the stromal cells involved in ectopic 
lymphoneogenesis derive from perivascular pericytes-like mesenchymal cells.  
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In contrast to our findings that FDC precursors express Mfge8, granulomas did not 
contain FDC-M1+ staining, nor detectable Mfge8 transcripts as assessed by RT-PCR 
compared to Mfge8-/- and Ltbr-/- spleens (Heikenwalder et al., 2008). However, careful 
examination of Ltbr-/- organs reveals a distinct perivascular Mfge8 staining, indicating that 
very low levels of Mfge8 mRNA expressed by single putative FDC precursor cells could 
have been missed. 
Interestingly, vessel-associated PrPSc depositions have been found in patients suffering 
from sporadic and variant Creutzfeldt-Jakob disease, both within intracranial and 
peripheral vessel walls (Armstrong, 2010; Koperek et al., 2002). Whereas some of these 
deposits co-localized with CD68 staining indicating uptake by macrophages, other 
deposits were found on unidentified perivascular cells. Again, the presence of 
perivascular prion deposits poses the question whether these cells could be vessel-
associated FDC progenitors. Future experiments will assess whether FDC precursors 
are already capable of accumulating and/or replicating prions, or whether this capability 
is an exclusive feature peculiar to mature FDC.  
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5.4 MICE, MATERIAL AND METHODS 
 
5.4.1 Mice 
The following mice were used: Ltbr-/- (Fütterer et al., 1998), CD21/35-/- (Cr2-/-) (Ahearn et 
al., 1996) (obtained from Manfred Kopf), and C57BL/6 purchased from Harlan. Pdgfrb-
Cre mice (obtained from Ralf Adams) were crossed with Cre-inducible (CAG-tdTomato) 
Ai14 fluorescent reporter mice (Madisen et al., 2010). All animals were kept under SPF 
conditions, with the exception of CD21/35-/- (Cr2-/-) mice. All animal experiments were 
performed in compliance with the Swiss Animal Protection Law, under the approval of 
the Veterinary office of the Canton Zurich. 
 
5.4.2 Isolation of perigonadal white adipose stromal-vascular cell fraction  
Perivascular stromal cells were isolated as previously described (Perera, 2010; Tang et 
al., 2008). In brief, perigonadal white adipose depots were dissected, cut into little pieces 
and digested in stromal cell isolation buffer (DMEM with 2% fetal calf serum) containing 
1mg/mL collagenase D (Roche) at 37 ºC with constant shaking at 70 rpm for 2h. After 
approximately 1h, clumps were gently triturated using a blunt glass pipette to further 
dissociate the clumps. After digestion, the suspension was again gently triturated until all 
cells were dissociated and passed through a 210 µm nylon filter. The floating adipocyte 
layer was removed by aspiration. After red blood cells lysis in 5 ml of RBC lysis buffer 
(eBioscience), cells were filtered through a 50µm cell strainer and then subjected to 
sorting (FACS Aria, BD biosciences) to obtain a pure population of PDGFRβ+ stromal-
vascular cells. 
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5.4.3 Quantitative RT PCR 
Total RNA from fat, freshly sorted or treated (24h with 100ng/mL agonistic LTβR (AC.H6, 
Biogen) or hamster IgG (Ha4/8-3.1, Biogen) in the presence of 5ng/mL mTNF (R&D 
Systems)) PDGFRβ+ stromal-vascular cells was isolated using Trizol (Invitrogen) and 
subsequent chloroform extraction. cDNA synthesis was performed with QuantiTect, 
Reverse Transcription kit (Qiagen) using the manufacturer’s instructions. Samples were 
analyzed by quantitative real-time PCR using QuantiFast SYBR Green Master Mix 
(Qiagen) on a 7900HT (Fast Real-Time PCR systems; Applied Biosystems) using default 
cycling conditions. Expression levels were normalized to Gapdh expression levels. The 
following primers were used: 
 
Gene Forward primer Reverse primer 
Bp3 CTCCTCACCTCCAGAGCATC AATCGCCAACTTTGCCATAC 
Cxcl13 TCGTGCCAAATGGTTACAAA ACAAGGATGTGGGTTGGGTA 
Cd21 CCCATAGTACCAGGGGGATT AGACTGGCAGAGCTGTGGGT 
Cd45 AAACGATCGGTGACTTTTGG AGCTCTTCCCCTTTCCATGT 
Clusterin CCAGTTCCCAGACGTTGATT AGCAGGGATGAGGTGTGGAG 
Enpp2 TGGCTTACGTGACATTGAGG AAATCCAAACCGGTGAGATG 
Fcgr2b AATTGTGGCTGCTGTCACTG CAGTTTTGGCAGCTTCTTCC 
Gapdh CCACCCCAGCAAGGAGACT GAAATTGTGAGGGAGATGCT 
Icam1 ACTGCTTGGGGAACTGGAC AGGCATGGCACACGTATGTA 
Igfbp3 CGAGTCTAAGCGGGAGACAG TTGTTGGCAGTCTTTTGTGC 
Ltbr GCCGAGGTCACAGATGAAAT CAGGACACTGGTGAAGAGCA 
Madcam1 CCTCTGCTGAGCCCTACATC CTTGTGGTAGGTTGCCAGGT 
Mfge8 ATATGGGTTTCATGGGCTTG GAGGCTGTAAGCCACCTTGA 
Ng2 GATCCACCTCGCATCATCTT GTTCCCGACAGGAAAACTCA 
Pdgfrb CCGGAACAAACACACCTTCT TAGCTGGGGGACTCAATGTC 
Plin1 ACACTCTCCGGAACACCATC CCTCTGCTGAAGGGTTATCG 
Postn AGTGCTCTGAGGCCATCACT AGGTCGGTGAAAGTGGTTTG 
Prnp* GCTGGCCCTCTTTGTGACTA CTGGGCTTGTTCCACTGATT 
Sdf1 GCTCTGCATCAGTGACGGTA GGGCAGCCTTTCTCTTCTTC 
Tnfr1 ACCAAGTGCCACAAAGGAAC CACGCACTGGAAGTGTGTC 
Vcam1 GGCATCCTCACCTTAATTGC ACAGGTCTCCCATGCACAA 
 
* Prnp primers from (Huber et al., 2005)  
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5.4.4 Subcapsular renal transplantation of PDGFRβ++ stromal-vascular 
cells 
An isoflurane-anaesthetized Ltbr-/- or Cd21/35-/- mouse was laid on its side, shaved 
around the renal protrusion and the skin was sterilized. A skin incision of approximately 2 
cm was made, followed by a slightly shorter incision of the peritoneum. The kidney was 
externalized from the abdomen by gentle pressure and kept humid with sterile saline 
solution. Using a fine forceps, the kidney capsule was pinched, a small incision was 
made using the tip of a 21 gauge needle and a small pouch was gently formed with a 
fine straight iris spatula by blunt dissection. A collagen sponge (CS-35; KOKEN) of 
approximately 1mm3 size (Suematsu and Watanabe, 2004) soaked with 300-500’000 
FACS-sorted PDGFRβ+ cells was transferred to the kidney surface and gently pushed 
into the prepared subcapsular pouch using the spatula. The kidney was gently released 
into the abdomen, the peritoneum and skin were sutured and disinfected with Bethadine 
solution (Mundipharma). The animal was injected s.c. with 60 µl of 0.05 mg/ml Temgesic 
(Schering-Plough), transferred  into recovery and monitored daily. Some mice were 
immunized 1 week after surgery with 2x108 sRBC (ACILA AG) and boosted after 15 days 
with with 1x108 sRBC. Some mice were treated with 1:500 dilution 24% Borgal in 
drinking water (see Table 12 for details).  
 
5.4.5 In vitro IC trapping 
Protocol adapted from (Dijkstra et al., 1983). Cryosections were fixed with acetone and 
0.2% H2O2, air-dried, blocked with PBS with 1% goat serum and 0.5% BSA. Sections 
were incubated with 1:10 mouse PAP (Jackson Immuno) diluted 1:10 in PBS with 1% 
goat serum and 0.5% BSA and with or without 10% normal mouse serum (DAKO) for 1h 
at room temperature. Sections were washed and PAP-IC were detected using Alexa 
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647-Tyramide Signal Amplification (Molecular Probes, Invitrogen) according to 
manufacturer’s instructions. 
 
5.4.6 In vivo IC trapping 
Protocol adapted from (Balogh et al., 2001; Phan et al., 2007). On day one, mice were 
injected i.p. with 2mg/200µl polyclonal rabbit IgG anti-PE antibodies (Rocklands), and 
after 12h with 20µg/100 µl PE (Invitrogen) in PBS i.p. to target subcapsular kidney 
transplant or with 10µg/50µl PE in PBS s.c. into the flank to target inguinal lymph nodes. 
Mice were sacrificed after 24-72 hours. 
 
5.4.7 Immunohistochemistry and immunofluorescence 
Cryosections were stained with HE or with antibodies against CD3 (500A2), CD21/35 
(7G6), and FDC-M1 (BD biosciences) and detected using respective AP-coupled 
secondary and tertiary antibodies in combination with Fast Red staining kit (Sigma) or on 
the Leica Bond-III IHC stainer using the Leica Bond Polymer Refine Red detection kit. 
For immunofluorescent analysis, cryosections were stained using the following primary 
and secondary antibodies: anti-Mfge8 (2422, Alexis Corporation, sometimes used in 
biotinylated form), FDC-M1 (4C11, BD Biosciences), anti-CD68 (MAC1957, Serotec), 
anti-CD16/32 (FcgRIIb, 2.4G2, BD biosciences), anti-PrP (XN, made in our laboratory 
(Montrasio et al., 2000)), anti-CD21/35 FITC (7G6, BD biosciences), anti-CD35  (8C12, 
BD biosciences) and the secondary antibodies anti-rat Alexa488, anti-rabbit Alexa546, 
anti-rat Alexa594, anti-hamster Alexa647, streptavidin Alexa 647 (all Invitrogen). Tissues 
of Ai14 fluorescent protein reporter mice were pretreated as described (Madisen et al., 
2010). In short, animals were perfused with 4% PFA in PBS, organs were fixed overnight 
and subsequently cryoprotected in 20% (wt/vol) sucrose in PBS overnight. Sections were 
analyzed by fluorescence microscopy on a BX61 microscope (Olympus) or on a CLSM 
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Leica SP5, and images were processed using Imaris-Multicolor and 4D Image 
Processing and Analysis (Bitplane). 
 
5.4.8 Quantification of Mfge8 staining on Pdgfrb-Cre+ x CAG-tdTomato 
(Ai14) spleen sections 
Images of splenic follicles were acquired using a CLSM Leica SP5 and were processed 
using Imaris software. With the Surpass-spots function of Imaris software, the two 
channels containing Mfge8 signals (far-red channel) and tdTomato signals (red channel) 
were subsequently analyzed. First, Mfge8 signals were marked with spots. Then, 
tdTomato co-localization in the red channel was tested in relation to the previously set 
Mfge8+ spots. The cut-off for co-localization was set at the width of one spot. A co-
localizing tdTomato+ area was then marked with a second spot. No tdTomato+ area 
within the one spot range was scored as absence of co-localization. Three confocal 
images from four ROI containing Mfge8 signals from were quantified. 
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